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Summary 
 
Reactive oxygen species (ROS) are harmful species produced during metabolic 
processes, such as photosynthesis and respiration, of living organism. In both case, the 
substrate (oxygen/water) undergoes several multi electronic reaction, during which some 
electrons can “escape” from the catalytic cycle and produce ROS, such as superoxide 
radical anion, hydrogen peroxide, hydroxyl radical and other derivatives. These species are 
really dangerous, since they are able to oxidize almost all cellular  components. Indeed 
they can damage lipids, proteins, DNA, affecting cellular functions till cell death. 
Under oxidative stress condition, accumulation of damage due to ROS has been 
supposed to play a role in several pathologies, and in particular in age-related ones, 
such as Alzheimer’s disease (AD). This disease is characterized by an accumulation of 
neurotoxic senile plaques, mainly made of short peptide monomers, that tend to aggregate 
into fibrils, called amyloid β peptide (Aβ). Although the mechanism involved in the 
production of these peptides is still unknown, some hypothesis suggest that ROS are 
produced within the fibrils and are responsible for further Aβ production.  
Nature has developed different catalytic strategies to limit ROS production, and the most 
important is the enzymatic pathway: superoxide dismutases (SOD) and catalase (CAT) 
enzymes are able to dismutate, respectively, superoxide and hydrogen peroxide. 
Nevertheless, in case of unpaired ROS production it is of huge interest to find new 
artificial systems that are able to help natural enzymes in their task. In this thesis, 
four different classes of synthetic enzymes (synzymes) that mimic natural anti ROS 
systems have been investigated: 
I. Isostructural mononuclear manganese complexes, with general formula 
[Mn(L)X2], characterized by a pentadentate ligand L, containing  different 
heteroatoms (N, O or S) have been used for the dismutation of hydrogen peroxide 
and superoxide anion. Their activity, also depending on heteroatoms, and stability 
were studied, first in organic solvents to have a comparison with literature similar 
compounds, then in aqueous solution, where only few compounds were known to 
work. The sulfur-containing complex [Mn(L)(OTf)2] was found to exhibit high 
dual SOD/CAT-like activity with excellent stability, when used in the presence 
of a base. 
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II. Isostructural dinuclear manganese complexes, with general formula [Mn2L2X], 
were widely studied as artificial catalases. A comparison with other dimanganese 
complexes, in terms of Michealis-Menten parameter, KM and kcat, was performed. 
Superoxide dismutase activity was also evaluated, demonstrating the unique dual 
SOD/CAT behavior of [Mn2L2X] with respect to other dinuclear complexes. 
Finally, the ligands were modified with mitochondriotropic functionalities. In 
particular, two fluorescent rhodamine derivatives and a triphenylphosphonium salt, 
were taken into account.  
III. Some multimetallic manganese oxoclusters, containing 6-13 manganese atoms, 
were synthetized during a Short Term Scientific Mission in Dublin, in the group of 
Prof. Wolfgang Schmitt. The catalase-like activity of these compounds was 
tested for the first time. Their H2O2 dismutation capability was thus demonstrated 
and their stability in aqueous environment was checked. Preliminary test as SOD 
mimics were also performed. 
IV. In the end, a completely inorganic compound, a polyoxometalate  (POM) 
substituted with four ruthenium atoms, with formula [Ru4O4(OH)2(H2O)4(γ-
SiW10O36)2]10-, able to dismutate hydrogen peroxide was studied. Its activity in 
different biological buffers and media was initially optimized. Its capability of 
interaction with Aβ peptides, coupled with its catalase activity, were exploited 
to control these two major events involved in Alzheimer’s disease. Preliminary 
test on neuronal cells were then performed (with Dr.ssa de Bartolo (ITM-CNR, 
Rende, CS)), confirming the interesting properties of the compound in vitro 
and finding a very low toxicity.  Finally, encapsulation of POM was achieved in 
order to enables delivery and targeting in cells, using polymeric multilayer 
biocompatible microcapsules in which POM is deposited. The presence of POM 
and its catalytic activity were confirmed and analyzed. 
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Riassunto 
 
Le reazioni biochimiche che coinvolgono il trasferimento di elettroni dall’ossigeno per 
dare acqua, durante la respirazione cellulare, e dall’acqua per dare ossigeno, durante 
la fotosintesi, possono portare alla formazione di specie reattive dell’ossigeno (ROS, 
reactive oxygen species), dovute alla “perdita” di elettroni dal ciclo catalitico. Tra queste 
specie troviamo inizialmente il superossido O2-·, l’acqua ossigenata e il radicale ossidrile. 
Queste possono reagire con altre molecole per dare origine ad altre specie reattive, per 
esempio dell’azoto, ma soprattutto possono danneggiare peptidi, lipidi e DNA e causare 
ingenti danni alle funzioni cellulari fino a portare alla morte della cellula stessa. In  
condizioni di stress ossidativo, l’accumulo di queste specie sembra giocare un 
importante  ruolo nelle malattie degenerative, come ad esempio il morbo di 
Alzheimer (AD). In questo caso, la malattia è caratterizzata dalla presenza di aggregati 
proteici in forma di placche, che hanno un effetto neurotossico. Questi accumuli proteici 
sono costituiti principalmente da peptidi di 40-42 amminoacidi chiamati β-amiloidi (Aβ), 
che tendono ad aggregare, in forma di fibrille. Le cause della formazione e accumulo di 
questi peptidi non sono ancora del tutto chiare, ma si hanno evidenze sul coinvolgimento 
delle ROS nella fase di formazione dei peptidi, e sull’aumento della loro produzione, dopo 
la formazione delle fibre, a causa di reazioni mediate dai metalli intrappolate nelle fibre 
stesse.  
La natura ha sviluppato dei sistemi per proteggersi da queste specie reattive, tra questi 
citiamo gli enzimi superossido dismutasi (SOD) e catalasi (CAT), capaci rispettivamente di 
eliminare superossido e acqua ossigenata, che tuttavia in certe situazioni di elevato stress 
ossidativo possono risultare insufficienti per prevenire i danni. 
È quindi di estremo interesse lo studio di composti artificiali capaci di aiutare gli enzimi 
naturali nel loro compito di eliminare le ROS dall’ambiente biologico. Considerando ciò, 
in questa tesi sono state considerate le seguenti quattro classi di composti, utilizzati 
come enzimi sintetici (synzymes), per  imitare le funzioni dei sistemi anti ROS 
naturali: 
I. Complessi mononucleari ed isostrutturali di manganese, di formula generale 
[Mn(L)X2], caratterizzati da un legante pentadentato, L, contenente differenti 
eteroatomi (N, O, o S), sono stati studiati nella dismutazione dell’acqua ossigenata 
e del radicale anione superossido. L’attività è stata inizialmente analizzata in 
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solvente organico (acetonitrile) per aver dei termini di paragone con altri composti 
di letteratura. In seguito l’attività è stata studiata anche in acqua, dove solo pochi 
composti di letteratura sono risultati attivi. Se utilizzati in presenza di base, i 
complessi [Mn(L)(OTf)2] contenenti zolfo mostrano una duplice attività 
SOD/CAT ed un’elevata stabilità. 
II. Complessi dinucleari ed isostrutturali di manganese, di formula generale 
[Mn2L2X], sono stati studiati inizialmente per l’eliminazione dell’acqua ossigenata. 
Un confronto con simili composti di letteratura è stato effettuato tramite il calcolo 
dei parametri, derivati dall’ equazione di cinetica enzimatica di Michalis-Menten, 
KM e kcat. E’ stata anche analizzata la capacità di smaltire il superossido, 
dimostrando le caratteristiche uniche di [Mn2L2X] nella duplice attività 
CAT/SOD, in ambiente acquoso, rispetto ad altri complessi dinucleari. Infine, 
modificando i leganti, si è cercato di introdurre nuove funzionalità adatte alla 
veicolazione del composto in cellula. In particolare, sono stati utilizzati residui 
organici noti per la loro affinità verso i mitocondri, come i derivati della 
rodamina e i sali di trifenilfosfonio. 
III. Sono stati studiati oxoclusters multimetallici di manganese, contenti 6-13 atomi 
di metallo, sintetizzati durante un Short Term Scientific Mission (STSM, COST 
action CM1203) a Dublino, presso il laboratorio del Prof. Wolfgang Schmitt,  
analizzandone per la prima volta l’attività di dismutazione dell’ acqua ossigenata e 
del superossido, oltre che la stabilità in soluzioni acquose. 
IV. Un composto completamente inorganico, un poliossometallato (POM) contenete 
quattro atomi di rutenio, di formula [Ru4O4(OH)2(H2O)4(γ-SiW10O36)2]10-, è 
considerato per la sua solubilità in ambiente acquoso e la capacità di dismutare 
efficacemente l’acqua ossigenata. L’attività è stata analizzata in diversi tamponi e 
mezzi comunemente usati per analisi di sistemi biologici. In soluzione, il 
complesso è capace di ridurre la produzione di ROS e anche di interagire con 
peptidi amiloidei, evitandone l’aggregazione in fibrille, dimostrandosi quindi 
promettente nel contrastare due importanti eventi che si verificano durante la 
malattia di Alzheimer. In collaborazione con la Dr.ssa de Bartolo (ITM-CNR, 
Rende, CS)  sono state quindi effettuate prove preliminari in cellule neuronali, 
per verificare sia la tossicità del composto (che risulta essere nulla anche a 
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100µM di concentrazione) che l’effettiva attività anti-ROS e anti-
amiloidogenica in vitro.  
Infine si è studiato l’inserimento del POM all’interno della shell di 
microcapsule polimeriche multistrato, con la prospettiva di controllarne la 
veicolazione in cellula. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
 
Table of contents 
 
Summary                                                                                                                                I 
Table of contents                                                                                                               VII 
Abbreviations                                                                                                                      XI 
 
1. Introduction                                                                                                                    1 
1.1. Oxidative stress and related diseases                                                                        3 
1.2. Mitochondria, respiratory chain and reactive oxygen species (ROS)                       9 
1.3. Complexes and nanodimensional systems with CAT/SOD mimicking  
Activity                                                                                                                    12 
1.4. Amyloid peptides and Alzheimer’s disease                                                            16 
1.5. Aim of the thesis                                                                                                     19 
References                                                                                                                      21 
 
2. Antioxidant activity of Manganese complexes                                                           25 
2.1. Manganese complexes as artificial catalase (CAT) and superoxide  
dismutase (SOD): a general introduction                                                                27 
2.2. Mononuclear compounds [MnLX2] (1-3)                                                               34 
2.3. Dinuclear complex, [Mn2L2YClO4] (4) a catalytic screening                                 41 
2.4. Mitochondrial toxicity of 4                                                                                     47 
2.5. Modification of apical ligand of dinuclear complexes with  
mitochondriotropic substituent (5-7)                                                                       53 
2.6. Conclusions                                                                                                             65 
References                                                                                                                      67 
 
3. Manganese oxoclusters as artificial antioxidants                                                      71 
3.1. Oxoclusters, a brief overview and manganese compounds                                    73 
3.2. Stability and catalytic activity of multi-manganese complexes (8-16)                   74 
3.3. Conclusions                                                                                                             80 
References                                                                                                                      81 
 
 
VIII 
 
 
4. Polyoxometalates against degenerative diseases                                                        83 
4.1. Polyoxometalates: short description and applications in medicine                         85 
4.2. Catalytic activity and inhibition of  Tetranuclear Ruthenium (IV) polyoxometalate 
Na10[Ru4O4(OH)2(H2O)4(γ-SiW10O36)2] (17) in water solution                              90 
4.3. Interaction with amyloid peptides                                                                           95 
4.4. Toxicity in cell and protective effects in the presence of amyloids                      106 
4.5. Mitochondrial toxicity test                                                                                    111 
4.6. Encapsulation                                                                                                        115 
4.7. Conclusions                    121 
References                                                                                                                    122 
 
5. Conclusions                                                                                                                 125 
 
6. Experimental Part                              131 
6.1. Materials and methods                                                                                          133 
6.2. Instruments                    134 
6.3. Synthetic procedures                  135 
6.4. Catalytic measurements                  150 
6.5. Biological tests                   151 
References                    156 
 
Appendix                              I 
 
Acknowledgements  
 
 
 
 
 
 
 
 
 
IX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XI 
 
 
Abbreviations 
 
Aβ: Amyloid β or β-Amyloid 
ACN: Acetonitrile 
ADP: Adenosine diphosphate 
ATP: Adenosine triphosphate 
BBB: Blood Brain Barrier 
BBS. Borate Buffer Solution 
Cat: Catalyst 
CAT: Catalase 
CD: Circular dichroism 
DMAP: Dimethylaminopiperazine 
DMSO: Dimethylsulfoxide 
ESI: Electrospray ionization  
EtOH: Ethanol 
FCCP: Carbonyl cyanide-4-
(trifluoromethoxyphanylhydrazone) 
FT: Fourier Transform 
GC: Gas Chromatograph 
Hepes/HEPES: (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid ) 
HFIP: 1,1,13,3,3-Hexafluoro-2-propanol 
ICP-MS: inductive coupled plasma mass 
spectrometry 
IR: Infrared 
L: Ligand 
λ: Wavelength 
LC: Liquid chromatography 
 
 
M: Metal center (or Molecule in ESI) 
MALDI: Matrix-assisted laser desorption 
ionization 
MeOH: Methanol 
Mops/MOPS: 3-(N-morpholino) 
propansulfonic acid 
MS: Mass spectrometry 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
NAD: Nicotinamide adenine dinucleotide 
NMR: Nuclear Magnetic Resonance 
NP: Nanoparticle 
PBS: Phosphate Buffer Solution 
PEG: Polyethylenglycol 
POM: Polyoxometalate 
RNS: Reactive nitrogen species 
ROS: Reactive oxygen species 
SOD: Superoxide dismutase 
TEA: Triethylamine 
Tf: Triflate 
TOF: Time of flight 
TPP: Triphenylpohosphonium 
Tris: Tris(hydroxymethyl)aminomethane 
UQ:Ubiquinone 
UV-Vis: Ultraviolet-Visible 
 
 
 
 
 
XII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction 
3 
 
 
1.1 Oxidative stress and related diseases 
 
Aerobic eukaryotic organisms need oxygen for their bioenergetics activity. Reduction of 
molecular oxygen during electron transport chain, with production of water, allows ATP 
(Adenosine triphosphate) synthesis, the energetic fuel of cell. Instead, photosynthesis 
oxidize water to molecular oxygen using light to produce ATP, that is used to reduce 
carbon dioxide and produce glucose. Both systems involve a multi-electron transfer that 
allows these redox reactions. However, they are not perfect, sometimes electron transfer of 
respiratory chain fails and up to 4% of electrons can escape from the catalytic cycle and 
produce the so called Reactive Oxygen Species (ROS).1  
 
Figure 1: Source of cellular ROS and effects due to overproduction or deficiency of ROS. 
 
ROS is a generic terms used to group superoxide anion (O2-·), hydroxyl radical (∙OH) and 
hydrogen peroxide (H2O2),  but often it also includes reactive nitrogen species (RNS) such 
as peroxynitrite (ONOO-) and nitric oxide (∙NO2).2 Mitochondria are one of the main 
producer of ROS: since superoxide anion arises from  the first reduction  within the 
respiratory chain, it is called primary ROS. Subsequently, hydrogen peroxide is produced 
upon dismutation of superoxide, by superoxide dismutase (SOD) enzyme, which is also 
present in mitochondrial environment. Then hydroxyl radical can be generated from the 
reaction of H2O2 with metal ions, such as Fe3+ and Cu2+, through the so called Fenton 
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reaction. Hydroxyl radical is the most reactive species, the most dangerous oxygen species, 
with a life time of 10-9s (Scheme 1).3 
 
 
Scheme 1: Dismutation of superoxide radical: hydrogen peroxide/dioxygen production by SOD (1) and 
Fenton reaction with formation of hydroxyl radical (2). 
 
Under oxidative stress there is an imbalance between their production and removal that can 
produce damage to the cell.2,4,5 
While hydroxyl radical is dangerous for its reactivity, hydrogen peroxide is dangerous 
because of its diffusion capability, it can indeed damage not only mitochondria, but also 
other cell functionalities.1 If we consider that a human adult, at rest, breathes 3.5 ml 
O2/kg/min and if just 1% of this goes to superoxide radical (O2•-) this leads to 53.66 moles 
year or about 1.72 kg/year of O2•-. This number is going to increase up to 20-fold under 
aerobic exercise regime.6,7 
In particular ROS can damage important cellular component like membrane lipids, 
proteins, DNA, leading to secondary products which are still dangerous, and also cause cell 
death. Mitochondrial DNA mutation due to ROS has been implicated in cancer, cardiac 
disease and type II diabetes.8 ROS are implicated in several other physiological functions, 
including the cell signaling, which can be impaired at high concentration (Figure 1).  
Due to high oxygen consumption, central nervous system is particularly vulnerable to 
oxidative injury, also because antioxidant molecules and enzymes concentration is 
relatively low and there are much more molecule prone to oxidation (for example 
polyunsaturated lipids).9 Oxidative damage accumulates during life cycle, with related 
DNA, lipid, protein damage that have been proposed to play a key role in disease 
neurodegenerative disease.2,8,10,11 
ROS can be easily eliminated by the organism, using endogenous anti-oxidant, such as 
thiols and polyphenols. Glutathione, for example, is a simple molecule, that contain sulfur 
atoms that can be easily oxidized by ROS. In this way, they are able to limit damages to 
other molecules, however, once oxidized, they must be reduced again, to display high 
effectiveness. Enzymes, in particular glutathione peroxidase (GSP) and reductase (GSR), 
are thus needed to re-generate the reduced of glutathione.12 
Introduction 
5 
 
 
However, the most important antioxidant compounds are two enzymes whose substrate are 
ROS: superoxide dismutases (SOD) that are able to dismutate superoxide radical to 
hydrogen peroxide and oxygen and catalase (CAT) that can dismutate hydrogen peroxide 
into water and oxygen.13 These enzymes usually contain one or more metal center that 
catalyze multi electronic reactions. The most common superoxide dismutase are 
mononuclear, containing only one manganese atom, or dinuclear containing both copper 
and zinc (Figure 2). In both case there are many histidine residues and an acidic aminoacid, 
in this case aspartate, that coordinate the metal atoms, while a molecule of water completes 
the coordination sphere. 
 
 
Figure 2: Active site of a) Cu-Zn SOD and b) MnSOD. 
 
While Cu-ZnSOD is mostly located in the cytosol, MnSOD is mainly situated in 
mitochondria. Some eukaryotic species are known to produce an iron containing 
superoxide dismutase, also located in mitochondria. Both MnSOD and FeSOD contain one 
metal center and they seem to work through an alternate redox process involving both 
divalent and trivalent metal ions (Scheme 2).14 
 
O2 + H+ + SOD-M3+-OH- O2 + SOD-M2+-OH2
O2 + H+ + SOD-M2+-OH2 H2O2 + SOD-M3+-OH-  
Scheme 2: Alternate redox process for superoxide dismutation by MnSOD. 
 
There are also various species of catalases, the most frequent species contains a Fe-
protoporphyrin motif (Figure 3) and it is a tetramer of identical subunits, each bearing a 
metal center. Below the porphyrin plan there is a tyrosinate that coordinates to the metal 
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center and an arginine residues, while over it there are a histidine and an asparagine, that 
play a crucial role in hydrogen peroxide dismutation. There is also a channel, with 30 Å 
length and 15 Å width, for the access of active site.15 One defect of these type of catalases 
is that they are easily inhibited by cyanide and azide anion, like in hemoglobin. 
 
 
Figure 3: Active site of Fe-heme catalase 
 
On the contrary, dimanganese catalase is less sensitive to inhibitors. In Figure 4 is shown 
the active site of a MnCAT from L.plantarum: also in this case metals center are 
coordinated by histidines residues and acidic residues (glutamate), with two molecules of 
water and one hydroxyl, involved in the coordination of the two metal centers.16  
 
 
 
Figure 4: Structure of active site of MnCAT of L.plantarum, 
 
Due to high rate and efficiency of this enzyme, catalytic cycle it is not well known, but it 
has been supposed that during the catalytic cycle, manganese atoms change their oxidation 
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state from MnIII to MnII and vice versa, although a MnIV intermediate is not completely 
excluded. Furthermore, H2O2 binding is followed by a reduction of di manganese center 
with parallel oxidation of peroxide species and oxygen release. Then another H2O2 
molecule binds with a subsequent reduction to water and re-oxidation of the two 
manganese atoms (Scheme 3).17 
 
 
Scheme 3. Variation of Mn oxidation states, as supposed during catalytic cycle of catalase. 
 
SOD and CAT have a pivotal role in limiting ROS production in cells, SOD reduce 
dangerous superoxide radical  produced during electron transport chain of mitochondrial 
respiration (and, of course, superoxide formed during other cellular reactions, outside  the 
mitochondria). CAT, above all, has a very important role, indeed it intercept diffusible 
hydrogen peroxide, produced also by SOD enzyme, that could damage other organelles, 
and prevent the formation of very dangerous hydroxyl radical (Scheme 4).18 
 
 
 
Scheme 4: Reactive species produced in organisms and method of elimination by glutathione, SOD and CAT 
enzymes. 
 
It is known that the mutation of Cu-ZnSOD seems to be involved in amyotrophic lateral 
sclerosis, misfolding and aggregation of the enzyme, in which there is an alteration of 
metal binding site,  induce motor neuron toxicity, with inclusion of proteinaceous residues 
of the enzyme.19 
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SOD enzyme and its mimicking compounds have shown to have a protective and 
beneficial role in many disease, both in preclinical and clinical tests. Preclinical studies 
have confirmed a positive effect of the enzyme for ischemia-reperfusion injury, or against 
inflammations, Parkinson’s disease, cancer and many other pathologies, although in some 
situations native enzyme administration did not show very high efficiency, due to 
limitation of blood-brain barrier (BBB) penetration, cell permeability and half-life in 
circulating system. In addition, this is a very expensive method, so the use of artificial, low 
mass, superoxide dismutase mimicking systems is much more appealing.20  
Catalase is a very important enzyme, since it dismutates hydrogen peroxide and avoid its 
diffusion and the formation of hydroxyl radical that is one of the most dangerous oxygen 
species, capable of react very rapidly with every biomolecules. Recent research on 
inhibition of catalase has shown a neat increment of oxidative stress in peroxisomes with 
an increment of hydrogen peroxide and also a subsequent increment of mitochondrial ROS 
production.21 Considering Alzheimer’s disease, inhibition of catalase activity comport a 
more cytotoxic effect of amyloid peptides, that are involved in this pathologies.22  
Many degenerative pathologies can be linked to short/long term ROS overproduction, for 
example during aging. Among these, neurodegenerative disease are the most invalidating  
and with dramatic social consequences. Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Huntington’s disease (HD), amyloidosis, but also stroke, atherosclerosis, some forms 
of cancer, can be connected to oxidative stress. In the case of protein-based disease, such 
as AD, PD, HD and amyloidosis (but also Creutzfeldt-Jacob disease), production of 
harmful proteinaceous aggregates seems to be related to overproduction of ROS in the arch 
of life. Alzheimer’s disease is the most common age-related neurodegenerative disorders, 
probably one of the most devastating, both for the patients and the relatives.23 Many 
studies have been done on this pathology, however its causes are not really clear yet. 
Oxidative stress seems to be one of the cause of the disease, also because the typical 
plaque of AD, made mainly of amyloid peptide, are an important production site of 
reactive oxygen species. These reactive species can be involved in the production of more 
amyloid peptides, in a cycle that  lead in increased damages due to both oxidative stress 
and plaque formation.24 Amyloid peptides seems to be able to interact with mitochondria, 
disrupting their homeostasis, creating pores. In addition they affect the respiratory chain, in 
particular with complex I and complex IV, mitochondrial proteins involved in electron 
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transport chain during oxidative phosphorylation, causing a further increment in ROS 
production, especially of superoxide anion, affecting also ATP production.25 
As it will be shown in the next chapters, the use of catalytic antioxidant that mimic natural 
enzymes such as catalase and superoxide dismutase are of huge interest for the 
development of new drugs for cellular ROS scavenging.  
 
 
1.2 Mitochondria, respiratory chain and reactive oxygen species (ROS) 
 
Mitochondria play a central role in ROS production, since they are the energetic centrals of 
cell, producing ATP from ADP using generally glucose and oxygen. Mitochondria are also 
homeostasis regulators, in particular of calcium ions, and play a fundamental role in cell 
signaling and in the apoptotic process that lead to cell death, due to oxidative stress or 
aging (Figure 5).26  
 
 
Figure 5: Role of mitochondria in oxidative stress an apoptotic process. 
 
These organelles are usually 1-4µm in length and 1-0.2µm width and are made of an 
external membrane, an intermembrane space, an internal membrane folded in cristae and 
finally an inner matrix (Figure 6).  
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Figure 6: Schematic representation of a mitochondrion.27  
 
The outer membrane contains many transport proteins, integral proteins and porins, 
allowing free diffusion of small molecules, with less than 10kDa weight, but limiting 
heavier molecules crossing. Being freely permeable to ions and metabolites,  the 
intermembrane composition is equivalent to the cytosol. The inner membrane plays a 
crucial role in mitochondrial respiration, indeed  it contains all the proteins needed for the 
respiratory chain and many transport proteins. Its impermeability to charged species allows 
the production of the ionic gradients necessary for the ATP synthesis. The matrix is an 
highly concentrated solution of enzymes, that participate to the oxidative metabolism, 
substrates, nucleotides cofactors, ions and mitochondrial DNA/RNA, ribosomes that 
produce several mitochondrial proteins.28 The proteins involved in the oxidative 
phosphorylation are usually called “complexes”, there are four complexes, labeled I-IV, 
whose task is to create the protonic gradient used for the oxidative phosphorylation. The 
proton electrochemical gradient (ΔµH+, kJ·mol-1) is a thermodynamic measure of the 
removal of an ion gradient from equilibrium and has two components: difference in 
protons concentration, usually 0.5 pH units, and difference in electrochemical potential 
between the aqueous phases separated by the inner membrane, the membrane potential 
(Δψ). Complexes I, III and IV are called proton translocating complexes, they are directly 
involved in the gradient generation, while complex II  allows electron transport chain when 
complex I does not work because of damaging or substrate (NADH) deficiency. 
Ubiquinone (UQ) and cytochrome c (cyt c) are electrons carriers from complex to 
complex, in the case of ubiquinone two proton are also moved. Last, complex V, also 
known as ATPsynthase (ATPase), uses the proton gradient so formed to synthesize ATP 
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from ADP plus phosphate. All these components, together with  protons and electrons 
flows are shown in figure 7.27 
 
 
Figure 7: Mitochondrial respiratory chain and proton circuits during phosphorylation: a) classical circuit 
from complex I and b) when complex I is bypassed because environmental condition prevent it function. 
 
As said before, mitochondria are the major producers of reactive oxygen species, indeed 
ROS can be produced from ubiquinone, cytochromes or iron-sulfur clusters located in 
complexes I-II-III. In particular, complexes I and III have sufficiently negative potential to 
produce superoxide radical, however also complex II seems to be able to produce ROS.29 
Production of these species starts with superoxide radical production by a monoelectronic 
reduction of oxygen, although superoxide anion can dismutate spontaneously to oxygen 
and hydrogen peroxide, it is usually rapidly dismutated by MnSOD enzyme, that is present 
in the mitochondrial matrix. Superoxide anion could produce hydrogen peroxide that is 
less reactive but could easily diffuse out of mitochondrion or interact with active metal 
centers to give Fenton reaction and produce the dangerous hydroxyl radical, very reactive 
compound with an half-life time of nanoseconds (Figure 8). Others reactive species, for 
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example singlet oxygen and nitrogen reactive species (such as nitric oxide and 
peroxynitrite), can be  produced in different ways starting form superoxide anion.30 
It is known that ROS have a role in signaling of cells, indeed at low concentration they are 
essential for cell living and proliferation, however if their concentration is too high, 
growing of cells stops and at much higher concentration could lead to cell senescence, cell 
death and apoptosis.31  
 
Figure 8: Table of reduction potential, half-life time (T1/2) and concentration in vivo of common ROS. 
Effects of ROS concentration at cellular level. 
 
ROS are released into cytosol because of membrane potential and also through channel 
such as inner membrane anion channel (IMAC) and mitochondrial permeability transition 
pore (mPTP), but there are others ROS producer, for example mono amine oxidase 
(MAO), a flavoenzymes that is bound to the outer mitochondrial membrane, or protein 
p66Shc that plays a crucial role in the oxidative stress response.32  
 
 
1.3 Complexes and nanodimensional systems with CAT/SOD mimicking   
 activity 
 
One of the possible solution to limit damages by ROS is the use of antioxidants, natural 
molecules such as vitamins or polyphenols, but also artificial molecules like fullerene, 
peptide derivatives or metal complexes.33 One of the major problems is the high 
concentration needed of these molecules, indeed they eliminate ROS but usually working 
in stoichiometric ratio, meaning that one antioxidant molecule scavenges one reactive 
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specie. Another problem is that these molecules disperse and react in different sites before  
reaching the target: for this reason, there are many studies whose goal is the selective 
delivery of these molecules, for example using functional groups able to target 
mitochondria, also called mitochondriotropic.34 Among these latters we can found many 
rhodamine derivatives or phosphonium salts, usually positively charged and containing an 
hydrophobic domain (usually aromatic) that facilitate mitochondrial uptake (Figure 9).35   
 
 
Figure 9: Example of functionalized molecule for mitochondrial targeting a) rhodamine derivatives, b) 
triphenylphosphonium salt and c) peptide derivative containing natural and synthetic aminoacids.36 
 
The use of biomimetic catalysts, that try to imitate cellular enzymes as catalase or 
superoxide dismutase could in principle reduce the concentration needed, indeed they 
could work in catalytic concentrations and can be easily modified with targeting 
functionalization. These biomimetic compounds are usually metal complexes containing 
one or more (often two) metal centers, quite often manganese, iron or other essential 
metals trying to imitate natural systems.37   
Several metal ions  play a crucial role in biological systems, since they are involved in 
oxygen transport (copper and iron), multi electronic reactions such as respiratory chain or 
photosynthetic systems (manganese, iron), structural functions in some proteins for 
example in zinc-finger proteins (zinc, cobalt),  signaling and homeostasis (sodium, 
calcium, potassium).38 Many other heavy metals, such as mercury, platinum, ruthenium, 
cadmium, have toxic effects on biological systems, but some of their complexes are now 
under investigation as drugs. Indeed, changing the ligands of the metal center allows to 
modulate activity, toxicity and targeting, so to take advantage of their toxicity against 
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insane cells or to exploit some characteristics to bind specific proteins involved in diseases. 
For example copper is an essential elements, but over accumulation of copper, typical of 
Wilson’s disease, has a toxic effects. It has been demonstrated that reactive metals like iron 
and copper play a crucial role in Alzheimer’s diseases, since they accumulate in senile 
plaques and, upon coordination with peptide fragments of these plaques, enhance the 
production of reactive oxygen species.39  
Coordination metal complexes are widely studied as enzymes mimics for bioinspired 
reactions. In the literature, many examples of manganese complexes that are able to  mimic 
SOD and CAT activity were reported. However, not only manganese is active in the 
simulation of biological reactions, but also copper, iron and cobalt complexes. Among 
potentially toxic heavy metals, iridium and ruthenium compound are promising for their 
biomimetic activity and, like platinum or gold, are currently under investigation in 
medicinal chemistry.40 
In the last few years, new systems to fight oxidative stress, that differ from classical 
antioxidant molecules and also from coordination complexes, have appeared. Gold 
nanoparticles, silica nanoparticles, ceria nanoparticles, polyoxometalates and metal clusters 
have been studied as possible agents in medicine. Nanoparticles (NPs) of silica and gold 
are the most studied, and maybe the best known nanosystems used with medicinal aim, 
indeed there are several studies in which NPs, labelled with tracker molecule, were 
investigated to establish their toxicity, bioavailability and also their application in drug 
delivery.41 Interactions with cytochrome c of zinc oxide NPs have been studied, but also 
the interactions between amyloid peptides and CdTe NPs have demonstrated to reduce 
peptides aggregation in fibrils.42 Completely organic nanoparticles conjugated with 
fluorescent probe and organic drug, have been studied again against Alzheimer’s disease.43 
Recently, ceria nanoparticles have been used as protective agents against ischemic stroke, 
indeed it is known that cerium could be a good antioxidant, thanks to, redox switching 
between Ce3+ to Ce4+, CeNPs were used to eliminate ROS and apoptosis, demonstrating 
that they could reduce ischemic damages in brain (Figure 10).44 
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Figure 10: Example of phospholipidic-PEG CeNPs with anti ROS activity. 
 
Completely inorganic compound like polyoxometalates, that will be described better in 
chapter 4, have been used as therapeutic agents. Indeed they can interact with proteins, like 
albumin,45 if they are substituted with transition metals they can strongly interact with 
specific protein domains,  and also act anti-aggregating agents of amyloid peptides.46 Some 
of this polyoxometalates could act as peptide, hydrolyzer, some example involving 
proteolysis of human albumin serum have been recently reported.47 In this field, a 
polyoxometalate that can degrade amyloid peptide when irradiated with light, has been 
reported: the  POM is able to break oligomeric forms of these peptides, but also to cleave 
peptide bonds of amyloid leading to smaller fragments (Figure 11).48 
 
 
Figure 11: Schematic representation of photodegradation of amyloid peptides and oligomers catalyzed by a 
polyoxometalate (POM). 
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1.4 Amyloid peptides and Alzheimer’s disease 
 
Alzheimer’s disease (AD) is the most common cause of dementia (50-80%) of worldwide 
population, affecting about 18 millions of people, whose incidence increases with age. 
Maybe it is one of the most terrible among neurodegenerative diseases, both for the 
patients but also for their relatives, characterized by progressive cognitive decline, with 
impairment of daily living and progressive behavioral disturbance.49 Although some cases 
of genetic forms of AD exist, the most common AD is age related, meaning that, with the 
increase of the life expectancy, the number of people affected by AD is set to increase. 
Alzheimer’s disease was described for the first time in 1907 by Alois Alzheimer, a German 
psychiatrist and neuropathologist, that followed a 55 years patience affected by dementia. 
The autopsy revealed the hallmarks of the disease, the extracellular plaques and intraneural 
neurofibrillary tangles, that Alzheimer discovered to be formed by amyloid peptides.50  
Amyloid term, known in plant science, was used to describe lardaceous deposits in central 
nervous system, because of their reactivity to iodine staining, similar to cellulose-like 
material, in the middle of 1800. The true nature of amyloid was determined later, through a 
lot of hypothesis, till when X-rays diffraction of amyloid, dissolved every doubt about their 
structure and composition. Amyloid are proteinaceous deposit that gives Congo red 
birefringence, or a typical X-ray diffractive pattern of β-sheet pleated, with the chemical 
nature of fibrils with a diameter of 8-10nm.51 Other proteins are associated with fibrils and 
amyloid diseases and are involved in many pathologies such as Alzheimer’s, Parkinson’s, 
Huntington’s, type II diabetes, amyloidosis (Table 1).52 
 
Table 1: Proteins associated with fibrils and amyloid diseases.* 
Protein Disease Ref. 
α-Synuclein Parkinson’s (PD) 53 
Amyloid-β Alzheimer’s (AD) 54 
Huntingtin Huntington’s (HD) 53a,55 
IAPP Type II diabetes 56 
Lysozyme Hereditary systematic amyloidosis 57 
Tau AD, frontotemporal dementia 53a-b,58 
SAA Secondary systematic amyloidosis 57b 
ABri Familial British dementia 59 
Gelsolin Finish-type familial amyloidosis 60 
Medin Aortic medial amyloid 61 
*Term “amyloid” has been extended to intracellular protein deposit (Tau, α-Synuclein). The proteins listed are also 
considered “amyloid” on the basis of positive staining with amyloid-binding dyes and/or the presence of fibrillar 
morphology (adapted from ref. 52). 
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Concerning Alzheimer’s disease (almost all consideration are similar to other pathologies 
with their own protein involved in), it is characterized by the occurrence of a 40-42 AA 
peptides called β-Amyloids. They are generally produced by the cleavage of the Amyloid 
Precursor Protein (APP) by β/γ secretase enzymes, mainly into Aβ40, less toxic, while 
Aβ42 is predominant in senile plaque. They are characterized by an hydrophobic portion, 
whereby amino acids involved are lysine, leucine, valine and phenylalanine (KLVFF in 
one letter symbols†), that tends to form β-sheet secondary structures, these could lead to 
formation of oligomeric species and finally to fibrils. Both peptides can self-assemble into 
amyloid fibrils with facile conversion in physiological conditions and fibril seeds can 
incredibly increase further fibril formation. A typical fibrillation kinetics involves the 
formation of monomeric species that are able to produce oligomeric soluble forms, that can 
finally aggregate into fibrils (Figure 12).62  
 
 
Figure 12: a) Amino acidic sequences of Aβ42, with the hydrophobic region that tends to forms beta-sheet;     
   b) Kinetics of fibrillation of β-Amyloid from monomeric species to final mature fibrils. 
 
Usually Aβ42 are faster in nucleation and fibrillation than Aβ40, for this they are more 
toxic. The toxicity is due to many effects of beta amyloid oligomers and fibril: 
 Alteration of membranes, cellular and mitochondrial, resulting in alteration of their 
homeostasis; 
 Interaction with DNA and membrane receptors with consequent dysfunction; 63 
 Induction of oxidative stress due to accumulation of redox active metals, such as 
FeIII and CuII, but also accumulation of other important metal, for example AlIII and 
ZnII. 64 
                                                          
† For aminoacids nomenclature, three letter and one letter symbols, see the table in Appendix, pag. I. 
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Recent studies have thus focused on two sides: the first is to limit oligomers/fibril 
formation to avoid plaque deposition, the second is to reduce damages due to oxidative 
stress.  
Inhibition of fibrils formation is one of the goal of research, and many small molecules 
having this function have been studied, most of them are called beta-sheet breaker, because 
their interaction breaks secondary β-sheet structure.65 These molecules could be short 
peptides, complementary to KVLFF sequence, or hydrophobic molecule that are able to 
avoid fibrillation, like curcumin or resveratrol, that have also antioxidant properties.66 Also 
fullerene has been studied to inhibit fibrils formation thanks to hydrophobic interaction, 
while nanoparticles and inorganic compounds like polyoxometalates have been studied for 
their electrostatic interactions with positively charged domains of peptides.46,48 
The other important phenomenon that should be contrasted is the increase of oxidative 
stress due to accumulation of metals that can perform redox process with formation of 
reactive oxygen species (ROS). It was been noticed that antioxidant molecules can slow 
the course of the disease, probably because they slow down the damages due to high 
oxidative stress. Metal chelators, able to subtract metal ions, seemed to improve somehow 
the situation, indeed metals play a role also in fibrillation: the coordination of Aβ42 to 
metals can promote oligomerization and fibril formation, in addition to an increase in ROS 
production (Figure 13).64c,67  
 
 
Figure 13: Generation of Aβ species and the potential involvement of metal ions associated, in Alzheimer’s 
disease. Metal ions are shown to interact with Aβ species, facilitating aggregation and enhancing reactive 
oxygen species (ROS) generation, which can lead to oxidative stress and neuronal death. 
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As said before, Aβ can interact with mitochondria, with the membranes, disrupting their 
homeostasis, but also with electron transport chain complexes inducing an increasing in 
ROS production. These ROS increase the oxidative stress and could also induce an 
increase in amyloid production. It is not still well known if ROS production is a 
consequence of amyloid effects or if ROS accumulated during the life could generate the 
amyloid accumulation.68 It is however clear that a drug with dual anti ROS/anti 
amyloidogenic activity would be a powerful method to get better activity and better 
knowledge of such phenomena. 
 
 
 
 
1.5 Aim of the thesis 
 
The aim of this thesis is the study of organic or inorganic compounds, containing active 
metal center, able to fight against degenerative diseases. We have seen that reactive 
oxygen species are involved in many degenerative pathologies like Alzheimer’s or 
Parkinson’s diseases, but also in cancer, stroke, ischemia and other age-related syndromes. 
Natural defense sometimes are not enough, so it is important to help nature in the fight 
against oxidative stress. Coordination complexes able to eliminate superoxide anion or 
hydrogen peroxide have been considered in this thesis work, their catalytic activity has 
been tested and in some case also their toxicity. Tailored modification for targeting and 
delivery was also considered. A complete inorganic compound has been studied as 
artificial synzyme with high robustness in oxidative conditions and some peculiarity for 
protein interaction. Also in this case targeting and delivery methodologies was considered. 
Toxicity of this total inorganic compound has been investigated as its anti ROS efficiency. 
Finally some multimetallic oxoclusters were taken in account as ROS scavengers, these 
compounds were synthesized during a Short Term Scientific Mission (STSM) in Dublin, 
under supervision of Prof. Wolfgang Schmitt. Preliminary results about catalytic reactivity 
and stability in water will be presented with some perspective of application. 
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2.1 Manganese complexes as artificial superoxide dismutase (SOD) and  
       catalase (CAT) enzymes: a general introduction 
 
Many studies have been done to create mimicking systems of natural SOD and CAT 
enzymes. In particular, they describe the use of  mononuclear manganese compounds with 
one metal center able to dismutate superoxide anion, and dinuclear manganese complexes 
able to eliminate hydrogen peroxide. There are only few compounds reported in literature 
that are able to perform both reactions, and usually mononuclear compounds form dimeric 
structure to dismutate hydrogen peroxide. There are several parameters to evaluate SOD 
activity. The first analysis is the redox potential of the species, indeed optimal SOD 
activity requires a potential close to 0.36V vs. Normal Hydrogen Electrode (NHE), an 
intermediate value between superoxide reduction potential (0.89V) and oxygen reduction 
potential (-0.16V, pH 7). Natural SODs are in a range of potentials between 0.2-0.45V 
(Figure 14).1 
 
 
Figure 14: Redox potential of natural SODs at pH 7 (a2,b3,c4). 
 
Direct methods are available to estimate kinetic constant of superoxide dismutation, among 
these techniques we found pulse radiolysis and stopped flow analysis, in which superoxide 
anion is formed in situ and the kinetic of superoxide dismutation is followed by UV-Vis 
measurements. Considering indirect methods what is usually measured is the IC50, the 
concentration at which SOD mimic inhibits 50% of superoxide production, measured 
thanks to a sacrificial molecular probe (the absorbance of reduced specie is followed to 
evaluate superoxide production). For example, EPR spectroscopy exploits a spin-trap 
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sacrificial compound (usually DMPO). The most common method is known as McCord-
Friedovich (McCF), whereby superoxide is generated in buffer solution with a 
xanthine/xanthine oxidase system and the reduction of the sacrificial compound (nitro blue 
tetrazolium (NBT) or cytochrome c) is used to convert O2-· to dioxygen, while the 
formation of their reduced species is followed by UV-Vis  spectroscopy.5,6 From IC50, that 
depends on the molecular probe and its concentration, it is possible to calculate the 
catalytic rate constant, kMcCF (Figure 15) with which it is possible to have a good 
comparison between the SOD mimics. 
 
 
kMcCF = kindicator[Indicator]/IC 50  
Figure 15: Scheme of indirect method with xanthine/xanthine oxidase system, NBT as indicator and formula 
needed to calculate the kinetic constant of superoxide elimination. On the right, reduction of NBT and 
formation of blue formazan, followed at 550nm. 
 
Three other characteristic are needed to have a good SOD mimicking complex: it should be 
able to cycle from MnII to MnIII, the ligand should be stable in both oxidation states and 
there must be at least one coordination site for binding superoxide. There are many ligands 
systems for manganese atoms that match all these properties, starting from porphyrins, to 
macrocylic ligands, Salen/Shiff’s base ligands like and acyclic multidentate ligands (Figure 
16).1 
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Figure 16: Some example of macrocyclic, Salen type, porphyrins and multidentate acyclic manganese 
complexes with SOD activity. 
 
Many other factors should also be considered for a successful biological application, like 
lipophilicity, that should favors internalization in mitochondria, and maintenance of the  
activity in vitro and in vivo. To date, however, only few molecules, for example M4040X 
family have been tested in vivo.7 
 
Elimination of superoxide anion by dismutation is not enough, indeed hydrogen peroxide 
is formed during the reaction and, in the presence of iron or other reactive metals, it can 
undergoes Fenton reactions leading to formation of harmful hydroxyl radicals. For this 
reason, SOD mimics should be used together with CAT mimics or, even better, they 
should present a dual activity Many dinuclear manganese complexes have been synthetized 
in the last ten years, trying to imitate natural manganese catalase. Comparison among 
complexes is usually done considering second order kinetic constant of hydrogen peroxide 
dismutation. When the kinetic constants, calculated at increasing H2O2 concentrations, 
exhibits a saturation behavior,  Michaelis–Menten parameters can also be calculated. In the 
last case, a saturation behavior with a limiting maximum rate, and two constants, KM, the 
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affinity constant (it is the substrate concentration at which  the reaction rate is half of 
Vmax), and kcat, the unimolecular rate constant for ES dissociation into pristine enzyme and 
products (the higher is the value, the higher is the number of catalytic cycle performed by 
the catalyst), can be achieved (Scheme 5).8  
 
 
Scheme 5:  Michaelis-Menten equilibria, equation for the initial rates and kinetic constants kcat and KM. 
 
These two parameters allow to compare artificial catalases with the natural one, indeed 
Michaelis-Menten behavior is typical of enzymatic systems. In this system, the 
intermediate, ES, specie is considered to be in a steady state. It is possible to obtain an 
equation with a maximum rate value (Vmax) and the Michaelis constant (KM) , from which 
it is possible to calculate kcat, that depends on enzyme concentration. These parameters 
allow the comparison with other similar systems known in literature. Furthermore kcat/KM 
ratio gives an idea of catalyst efficiency, the higher is the ratio, the higher is the catalytic 
efficiency: for natural enzymes kcat is often very high while KM is very low. In table 2 are 
reported some values of kcat and KM of different literature compound able to dismutate 
hydrogen peroxide. 
 
Table 2: Artificial Mn systems with catalase-like activity compared in terms of efficiency parameters and 
reaction conditions. 
Entryref. Catalyst kcat(s-1) KM(mM) Solvent T(°C) 
DiMn catalysts that disproportionate H2O2 with saturation kineticsa 
19 [Mn2(-OAc)2(X1-hppnO)]+ 3.4-23 150-600 DMF, 25 
210 [Mn2(-OAc)(-OMe)(X2-hppentO)]+ 1.31-2.8 88-170 DMF, 10 
311 [Mn((X3-salpnO)2] 4.2-21.9 10-120 CH3CN, 25 
412 [Mn2(-O)(OAc)(OH)(benzimpnO)]+ 2.7 6 MeOH:H2O, 25 
513 [Mn2(-OAc)(-OMe)(X4-salpentO)S2]+ 0.75-7.9 16-78 DMF, 25 
614 [Mn2(-OAc)2(bphpmp)]+ 2.48 83 NR, 25 
715 [Mn2(X5-bphba)Cl2]+ 0.017-0.075 20-151 H2O, 25 
816 [Mn2(etsalim)4(Hetsalim)2]2++ 5 equiv. OH- 0.038 21 EtOH, 25 
917 [Mn(bpia)(-OAc)]22+ 0.237 45 DMF, 25 
1018 [Mn2(-O)2(-OAc)(Me3-tacn)(OAc)2] 5.5 - Ac. buffer, pH 4.6, 20 
1118 [Mn2(-O)2(-OAc)(Me3-tacn)(bipy)]2+ 13.2 - Ac. buffer, pH 4.6, 20 
1219 [Mn2(-Cl)2(tpa)2]2+ 107 3100 CH3CN, 25 
1320 [Mn(-O)(salpn)]2 250 250 Cl2CH2/CH3CN, 25 
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 Catalyst kcat(s-1) Solvent T(°C) 
DiMn catalysts that disproportionate H2O2 with second order kineticsb 
1421 [Mn2(bpmp)(-OAc)2]+ 0.29 DMF, 20 
1522 [Mn2(pmpemp)(-OAc)2]+ 14.5 CH3CN, 0 
1623 [Mn2(-O)2(tpa)2]3+ 0.065 CH3CN, 0 
1723 [Mn2(-O)2(bpg)2]+ 0.29 CH3CN, 0 
1823 [Mn2(-O)2(pda)2]- 1.6 CH3CN, 0 
1924 [Mn2(-O)2(X6-bispicMe2en)2]2+ 14-35 Phosphate buffer 7.5, 30 
a: saturation kinetics, rates described by Michaelis-Menten model;  
b: second order kinetics = kcat[cat][H2O2] 
S = solvent, X1= OMe, Cl; X2= OMe, H, Br; X3= 5-OCH3, H, 5-NO2; X4= OMe, Me, H, Cl Br, NO2;  
X5= OMe, Me, H, NO2; X6= H, OEt, Me, Cl, NO2. 
 
These kinetics are usually followed monitoring the oxygen evolution, measuring the 
volume of oxygen evolved, the pressure produced or by using a Clark electrode,  sensible 
to oxygen concentration.  
Mn complexes can be characterized by EPR, electrochemistry and IR spectroscopy. 
Although NMR analysis is not possible due to manganese paramagnetism, quite often 
crystal structures are available. While there is a huge number of ligands that coordinate 
two manganese atoms to give catalase mimics, only few mononuclear compounds have 
shown a dual activity. Noteworthy, the formation of dinuclear species, in particular for 
salen complexes, has been suggested also in in such cases. 
In the catalytic cycle, the two manganese atoms run from oxidation state +II to +III, 
sometimes also oxidation state +IV is involved (Scheme 6).25 
 
 
Scheme 6: Catalytic cycle of dimanganese core of catalase mimicking systems 
 
There are many example of catalase mimics in literature, containing alkoxo, phenoxo,oxo 
and carboxylate. Since the ligand change Mn environment and distance, the structure affect 
the reactivity behavior of Mn centers, which can go from Mn2II to Mn2III but could also 
reach Mn2IV, for example with salophen ligands. While MnIIIMnIV state is inactive towards 
hydrogen peroxide dismutation for natural enzymes (Scheme 7), artificial catalase usually 
are active at such  oxidation state with some exception that work in higher oxidation states. 
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MnIIMnIII oxidation state is also inactive in natural catalase, while Mn2II is very sensible to 
anionic inhibitors like azide (N3-), phosphate (HPO42-) and halides like chloride and 
fluoride (Cl-, F-).26 
 
Scheme 7: Scheme of interconversion between different oxidation states in Mn-catalase enzymes. 
Monoelectronic reactions lead to inactive form of catalase, with mixed oxidation states. 
 
The proposed catalytic cycle for artificial catalase is quite similar to the natural one, indeed 
the dimanganese core cycles from MnIIMnII to MnIIIMnIII oxidation state with respectively 
reduction of hydrogen peroxide to water and oxidation to oxygen. In the proposed cycle, a 
water molecule replace one coordination site of manganese left free by the bridging ligand. 
Water is then replaced by hydrogen peroxide and after two proton exchanges, water is 
released and manganese core oxidized to III-III; hydrogen peroxide coordinates again and 
oxygen is released with the reduction of manganese core to II-II, then the cycle starts again 
(Scheme 8).12  
 
Scheme 8: Proposed catalytic for artificial catalase systems with carboxylate apical ligands. 
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Ligands can also be divided in binucleating, in which one ligand coordinates two metal 
centers, and non-binucleating  in which two or more ligands coordinate the two manganese 
atoms (Figure 17).27 
 
 
Figure 17: Some common binucleating and non-binucleating ligands of artificial dinuclear catalase and their 
abbreviation. 
 
Obviously, all these complexes should have a labile position where coordinate hydrogen 
peroxide, very often this is occupied by a bridging carboxylate. It has been demonstrated 
that the presence of a carboxylate ligand could change drastically the reactivity of some 
complexes, indeed if the ligands stabilize the Mn2II form, catalase activity predominates, 
while if Mn2III state is stabilized, catalase activity disappears and the epoxidation of 
organic substrates is favored.26 
In the following chapters will be presented the results obtained with some mononuclear 
manganese complexes, with both CAT and SOD activity, and with a dinuclear manganese 
complex with high catalase activity, including its modification for mitochondrial targeting 
and preliminary toxicity tests on isolated mitochondria. 
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2.2 Mononuclear compounds [MnLX2] (1-3) 
 
Herein a series of seven-coordinate MnII complexes with linear pentadentate ligands 1-3 
(Figure 18) and their potential as catalytic antioxidants is presented. The series comprises 
isostructural ligands with both hard nitrogen and oxygen donors (NMe)2Py3 (1), 
(NTos)2Py3 (1’) and O2Py3 (2) as well as a soft sulfur-containing analogue S2Py3 (3).28 
 
 
Figure 18: Seven coordinate Mn(II) complexes containing linear pentadentate ligands with N, O and S 
donors (1-3). 
 
The synthesis and characterisation of the ligands and metal complexes, by the group of 
prof. George Britovsek (Imperial College London) are provided in the Experimental part. 
A seven-coordinate geometry was confirmed for complexes [Mn(1)Cl2] and [Mn(2)(OTf)2] 
in the solid state (see Figures 19) and is comparable to the structure of the macrocyclic 
MnII complex called M40403 (see page 29).29 In all cases, a distorted pentagonal 
bipyramidal coordination geometry is observed with the pentadentate ligand that chelate 
the manganese atoms and two apical ligands, chloride or triflate, that complete the 
coordination sphere of manganese. 
 
Antioxidant Activity of Mn Complexes 
35 
 
 
 
Figure 19: Molecular structure of [Mn(1)Cl2] (left) and molecular structure of [Mn(2)(OTf)2] (right). 
 
Triflate ligands are generally weakly coordinating and are easily displaced in acetonitrile 
or aqueous solutions to give complexes of the type [Mn(L)(S)2](OTf)2 with coordinated 
solvent ligands (S = acetonitrile or water) and uncoordinated triflate anions. The MnII 
complexes studied here are high spin over the temperature range from 233 and 343 K in 
acetonitrile solution, with magnetic moment values of 5.9-6.0 B. NMR spectroscopy is 
normally not useful for MnII complexes due to the extreme line-broadening caused by the 
paramagnetic MnII center. Cyclic voltammograms in acetonitrile are featureless between -
1.5 V and +1.5 V (vs. Ag/AgNO3), as was noted for related dicationic seven-coordinate 
MnII complexes.30 All complexes are essentially colourless and the UV-Vis spectra are 
featureless at wavelengths above 300 nm, indeed charge transfer and d-d transitions are not 
expected in the visible region for these MnII complexes and the only absorptions seen are 
due to -* transitions in the region of 260-280 nm (Figure 20).31  
 
 
Figure 20: UV-Vis spectra of 0.1mM manganese(II) complexes in CH3CN at 298 K. 
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Catalase-like activity of the complexes was initially evaluated in aqueous acetonitrile (in 
order to have a comparison with literature compounds), in the presence of excess H2O2 
(550 equivalents) by monitoring continuous oxygen evolution. The observed catalytic 
performances have been examined by determining the initial rate (R0), O2 yield and 
turnover number (TON, defined as mole of dioxygen evolved per mole of catalyst).  The 
results are collected in Table 3 and compared with literature data on salen-type complexes, 
which decompose irreversibly in water after several minutes.27,32  
 
Table 3: CAT-like activity of mononuclear Mn complexes‡. 
Compound R0a (M/min) % O2 yield (M) TON 
Salen-type 
complexesb,27,32 
260-29 
0.7-3.3 
(36-167) 
4-17 
[Mn(2)(OTf)2]c 18 6.3 (1038) 17 
[Mn(1)(OTf)2]c 29 8.7 (1426) 24 
[Mn(1)(Cl)2]c 5 0.6 (107) 2 
[Mn(1’)(OTf)2]c 8 2.4 (397) 7 
[Mn(3)(OTf)2]c 128 14 (2310) 39 
[Mn(3)(OTf)2]d 317 100(16500) 275 
[Mn(3)(OTf)2]e 25 12 (1950) 33 
a)Initial reaction rate calculated as MO2/min; b)[Mn]=10M, [H2O2]=10mM, 50mM phosphate buffer 
(pH 7-8), 3 min, 25 ˚C; c)[Mn]=60M, [H2O2]=33mM, CH3CN, 2 h, 25 ˚C; d) addition of NaOH sol. 
(10L 1M), CH3CN, 5h; e)[Mn]=60M, [H2O2]= 3mM, 50mM borate buffer (pH 9.2), addition of 
600M imidazole, 75 min, 25 ˚C. 
 
From Table 3, it can be observed that the activity is strongly affected by the nature of 
the ligands, increasing in the order (NTos)2Py3 (1’) < O2Py3 (2) < (NMe)2Py3 (1) < 
S2Py3 (3) for the bis(triflato) complexes, while the dichlorido complex [Mn(1)Cl2] is 
the least active. In comparison with previously reported results, these complexes 
display good catalyst stability as oxygen evolution is detected up to 2 hours of reaction 
and turnovers up to 39 can be obtained (Figure 21).  
                                                          
‡ A “health warning” has to be applied when comparing activities determined for different catalysts systems  
  by different groups of researchers in different labs. 
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Figure 21: H2O2 (33 mM) dismutation by [Mn(3)(OTf)2] (60M) in 12ml CH3CN at 25.0 °C. 
 
In all cases, the dismutation activities level off after approximately 20 minutes, but no 
precipitation or color change was observed at the end of the reaction. FTIR analysis of 
the recovered catalysts showed only little changes and no complex degradation (Figure 
22).33  
 
 
Figure 22: Comparison between FTIR spectra of [Mn(2)(OTf)2] before(red)/after(green) H2O2 dismutation 
reaction in CH3CN. 
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The kinetic profiles at different [Mn(3)(OTf)2] concentrations show a well-behaved 
first order dependence within the range of 30-90M (Figure 23). This observation is 
consistent with the involvement of a single-site catalyst in the rate-determining step of 
the process. The reaction mechanism is believed to involve the formation of a high 
valent Mn=O intermediate, followed by a rate limiting attack of H2O2, finally ending in 
O2 release.34  
 
Figure 23: Yield of oxygen evolution versus time at different [Mn(3)(OTf)2] concentrations (● 30µM, □ 
60µM, ▲ 78µM, ◊ 90µM) in CH3CN, 25 ˚C. Inset: initial rate of O2 evolution versus [Mn(3)(OTf)2] 
concentration. 
 
The progressive addition of water resulted in a decrease of the activity of 
[Mn(3)(OTf)2]. Since more water is produced from the dismutation reaction, this may 
explain the inhibition at longer reaction times. More importantly, the pH of the solution 
appears to have a major influence on the stability of the catalyst system.  The addition 
of small amounts of acid (HCl, 0.1M, 10L) resulted in an immediate loss of CAT 
activity, whereas the addition of a base (NaOH, 1M, 10L) generated a very active (R0 
= 317M/min) and remarkably stable catalyst performance (TON=275) and resulted in 
100% oxygen evolution within 5 hours (Figure 24). 
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Figure 24: Yield of oxygen evolution versus time using [Mn(3)(OTf)2] (60µM), H2O2 33mM  in CH3CN, 25 
˚C with the addition of 10µl NaOH 1M  ◊ and 10µl of HCl 0.1M ▲. 
 
Further investigations have shown that the reaction can also be carried out in an 
aqueous borate buffer solution at pH 9.2 with minimal catalyst deactivation, but only 
when an additional coordinating base such as imidazole is added (see Table 3).  On the 
contrary, the addiction of imidazole in acetonitrile did not increase the reactivity. The 
beneficial effect of added base in the H2O2 dismutation reaction was also noted by 
others authors.35,36,§, 
 
The novel seven-coordinate Mn(II) complexes of ligands 1-3 also show SOD-like 
activity in aqueous environment. The SOD reactivity of all complexes was evaluated 
using the NBT (nitro blue tetrazolium chloride) method, which allows monitoring of 
the catalytic removal of O2-· generated in a xanthine/xanthine oxidase system.37  
SOD activities were determined as IC50 (50% inhibition of NBT reduction) and the 
results are collected in Table 4. Overall, the MnII complexes with ligands 1-3 show 
similar or lower activity, if compared to the reference complexes EUK-113 and the 
salen complexes.33,38,39 The sulfur-containing complex [Mn(3)(OTf)2] provides the best 
SOD-like activity within the series with a kinetic constant close to that of M40403, 
known as the best only-SOD mimetic complex. The tosylated complex [Mn(1’)(OTf)2] 
was inactive under these conditions, probably due to the low solubility in water.  The 
                                                          
§ In phosphate buffer (pH 9) the catalyst is also active but less stable and performing with R0 18M/min  
   and final yield of 3%. In this case, the addiction of imidazole in acetonitrile did not increase the  
   reactivity. 
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sulfur donors in ligand 3 are believed to generate a stronger ligand field with increased 
complex stability under the experimental conditions.  
 
Table 4: SOD-like activity of mononuclear Mn complexes. 
Compound IC50 (M) kMcCF (M-1s-1) 
Mn-SOD of Thermus thermophilus40 ND 2 x 109 
M4040341 ND 2 x 107 
EUK-113a,33,39 0.13-0.7 ND 
Salen complexesa, 39 0.004-0.75 ND 
[Mn(3)(OTf)2]b 0.75 8 x 106 
[Mn(2)(OTf)2]b 1.41 4 x 106 
[Mn(1)(OTf)2]b 1.51 4 x 106 
[Mn(1)(Cl)2]b 2.57 2 x 106 
[Mn(1’)(OTf)2]b inactive / 
Ligand 3 c inactive / 
a) Cytochrome 1.0 mM, 1200 units/mL catalase, 50 mM xanthine and sufficient xanthine oxidase to produce 
a rate of reduction of cytochrome c of 0.025 absorbance unit (at 550nm) per minute; b) Xanthine 50M, NBT 
100M, Xanthine oxidase 0.005U/ml in phosphate buffer 50 mM pH 7.4, catalyst 0.6-1.8M. c) Various 
concentrations: 0.6-1.8M and 6M. 
 
As a remark, the mononuclear complexes reported have good SOD and CAT activity, in 
particular the sulfur containing complex 3 is the best of the series and it is able to 
dismutate hydrogen peroxide in water solution. This is particularly interesting if we 
consider that , in previous observations with a pentadentate SNNNS manganese complex, 
sulfur donors were found to inhibit antioxidant activity.42 In contrast, the [Mn(3)(OTf)2] 
complex with an alternating NSNSN binding motif, shows dual CAT and SOD activity, 
surpassing the nitrogen and oxygen-based complexes. 
Even if the condition are still not really near to physiological environment, this study  
opens new perspectives in the design of new manganese complexes as ROS scavengers. 
Future studies will be directed to identify the key intermediates involved in these 
dismutation reactions and establish structure-reactivity relationships. 
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2.3 Dinuclear complex [Mn2L2XClO4] (4): a catalytic screening  
 
Feringa et al., in 2005, presented a catalyst, able to dismutate hydrogen peroxide, which 
was proposed as a molecular propeller to move silica nanoparticles dispersed in organic 
solvents like acetonitrile, dichloromethane and glycerol.43 We have thus synthesized the 
same catalyst, [Mn2L2X], and deeply studied its potential as artificial catalase and SOD 
mimicking system.  
The ligand used is a dipyridylaminophenolate (L, Figure 25), characterized by two pyridyl 
rings, a tertiary amino group and a phenolate, so it is a tetradentate ligand, with three 
nitrogen atoms and an oxygen atom. This ligand is easily synthetized starting from 
dipyridylketone after five steps, that are described in the experimental part. 
 
 
Figure 25: Starting material and structure of the ligand L. 
 
It is a non-binucleating ligand, indeed two of them coordinate two manganese centers, 
while an apical bridging carboxylate complete the coordination sphere of the metals. 
Different catalyst [Mn2L2X] (4), were synthesized adding manganese perchlorate, a 
bridging ligand (benzoic acid (Bz) or 4-formyl benzoic acid (BzCHO), as in the original 
paper, acetate (Ac) and also chloride (Cl)) and trimethylamine to a methanol solution of L. 
The solution is left cool down after heating and a solid was recovered and washed with 
methanol and diethyl ether. The acetate complex was obtained in crystalline form (Figure 
26). 
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Figure 26: Synthesis and structure of [Mn2L2X] (4), with X=CH3(Ac), C6H5(Bz) or C6H4CHO (BzCHO), 
carbon atoms in green, nitrogen atoms in blue, oxygen atoms in red, manganese atoms in purple and 
hydrogen atoms in white. (Perchlorate anion can also be recognized in the crystal structure). 
 
Compared with other literature dinuclear compounds (Table 5), that have Mn-Mn distances 
higher than 3.4Å, in this case the distance is lower. Considering the acetate complex, it is 
characterized by a distance Mn-Mn of 3.123Å, a little bit higher than the benzoate 
complex, that has an Mn-Mn distance of 3.106Å. In natural compound the distances 
between manganese atoms are usually from 2.9 to 3.6Å, depending on the oxidation state 
of the metal centers and on the type of the ligands.44 
 
Table 5: Bond distances (in Å) obtained by X-Ray analysis. 
Complex Mn-Mn Mn-N(tertiary amine) Mn-N (aromatic ring) Mn-X 
[Mn2(-Cl)2(tpa)2]2+ 3.551945 2.285 2.250-2.231-2.238  
[Mn(bpia)(-OAc)]22+ 4.12846 2.402 2.330-2.305 2.213 
[Mn2(X5-bphba)Cl2]+ 3.41147 2.367 2.348-2.254 2.203 
[Mn2L2Bz]+ 3.10643 2.285 2.358-2.297 2.133 
[Mn2L2Ac]+ 3.123 2.351 2.377-2.277 2.129 
 
The reactivity of dinuclear Mn2L2Bz  was initially evaluated in CH3CN, as in the original 
literature report. Accordingly to the original study,  H2O2 decomposition to oxygen and 
water occurs at a fast rate (k  1.51·10-3 s-1), with no catalyst degradation, as confirmed by 
FTIR analysis. Then, the behavior of these complex in pure water and different buffers 
(phosphate buffer, MOPS/KOH and Hepes/HCl  buffers at pH 7.4, borate buffer at higher 
pH) was widely studied, in order to get the mechanistic insight, and to optimize their 
activity in biological buffers and to evaluate the activity in the presence of  typical CAT 
inhibitors. A first comparison was carried out measuring the evolved oxygen when using  
60µM of Mn2 complex and H2O2 33mM at 25.0 °C. Initial rate of dismutation and endpoint 
of reactions were compared to have an idea of the activity of the complex. As reported in 
table 6 below, in acetonitrile the initial rate is quite high but the reaction stops at about 
50%, the same happens in water, with a lower initial rate and a similar endpoint. In water, 
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catalytic H2O2 decomposition by Mn2L2Bz produces, within the first minutes (5 min), a 
drop of the solution pH, from an initial value of 7.0 to 5.5. The pH variation is likely 
responsible of the catalytic activity depletion in the long term. Indeed, the oxygen 
evolution activity can be restored at pH=6.2, upon addition of a base. Even if no H+ 
production is considered in the proposed mechanism,48 spontaneous acidification of the 
reaction mixture was observed in previous literature reports, where aggregation of Mn-
based complexes,  to form dimers and tetramers was described under catalytic regime.49 
The drop of activity under acidic conditions was proven by the observation, by positive 
ESI-MS, of the free ligand (m/z=306), while the expected peak (m/z=867) was no longer 
present in 5·10-4M  HCl. Due to such behavior,  buffer solutions were used in all the other 
experiments to avoid fall of the pH and of the reactivity. 
 
Table 6: Initial rate and H2O2 conversion of catalyst with benzoate as apical ligand (Cat 60µM, H2O2 33mM, 
25°C) in acetonitrile, water, borate buffer (BBS), phosphate buffer (PBS), HEPES and MOPS. 
 
 
 
 
 
 
 
a) Initial reaction rate; b) maximum O2 produced, when the reaction kinetic level off.  
 
The initial rate was higher in buffered solutions, especially in phosphate solution, however 
the endpoint of reactions was lowered, indeed in phosphate buffer only 40% of conversion 
was reached, while in Hepes and MOPS, only 10% or a little bit higher conversion was 
reached. Only borate buffer allowed a quantitative dismutation. Although buffer anions 
affected the reactivity, FTIR spectra confirmed the higher stability of the complex, in 
buffered solutions, after the reaction. In addition, while synthetic catalases are very 
sensitive to pH, and most of them are reported to work efficiently only at pH > 9,  the 
activity of Mn2L2X (60µM, H2O2 33mM) was maintained, in borate buffer, in the range 
7.8-8.9, a range which approaches that of natural MnCATs, which display high efficiency 
in the pH range 7-10.50 
 Compound Solvent R0 (µMO2/s)a Endpoint (O2 mM)b 
1 Mn2L2Bz CH3CN 37 7.6 (46%) 
2 Mn2L2Bz H2O 12 8.3 (50%) 
3 Mn2L2Bz BBS (pH7.8) 38 16.5 (100%) 
4 Mn2L2Bz PBS (pH7.4) 93 6.3 (39%) 
5 Mn2L2Bz HEPES 51 1.7 (10%) 
6 Mn2L2Bz MOPS 74 2.2 (14%) 
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Catalytic activity of the three complexes, and also chloride complex, in borate buffer at pH 
7.8 was screened to check how the nature of the ligands influences the dismutation (Figure 
27).  
 
Figure 27: Oxygen evolution versus time with different Mn2L2X complexes 60µM, H2O2 33mM, 50mM 
BBS at pH 7.8, 25 °C. 
 
Mn2L2Bz, Mn2L2BzCHO and Mn2L2Ac have, more or less, the same kinetic profile, and 
yield quantitative conversion of H2O2. However, the presence of the carboxylate bridge is 
not necessary for the catalase activity. Indeed, Mn2L2Cl has a slower initial rate but still 
good values and quantitative dismutation. The low sensitivity to the bridging motif may 
allow the synthesis of new multifunctional compounds, also taking advantage of the 
aldehydic function of Mn2L2BzCHO, without affecting the catalase activity.  
The dependence between initial reaction rate and [4] indicates a well-behaved first order 
kinetic dependence in the wide range of concentration explored (Figure 28). This is 
consistent  with the integrity of the dinuclear Mn core as the active site enabling H2O2 
decomposition, and rules out any aggregation/dissociation equilibria occurring before the 
rate determining step of the process. The same linear trend has been observed in both 
organic and aqueous solvents. The stability of the dinuclear structure was confirmed by the 
mass spectra collected after the reaction.  
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Figure 28: Graph of initial rate vs. 4 concentration, typical first order behavior. 
 
Stability was also checked by FTIR spectra of catalyst before and after reaction with 
hydrogen peroxide in aqueous solution, there are no changes in the spectrum after H2O2 
dismutation (Figure 29), confirming the stability and the robustness of the catalyst  in 
aqueous solution. 
 
 
Figure 29: FTIR spectra of Mn2L2BzCHO before (green) and after (red) reaction with H2O2. 
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The CAT-like activity of the Mn2L2Bz has been further investigated to allow a comparison 
with the natural enzyme and with synthetic analogs proposed in the literature up to now. 
The initial rates of oxygen evolution were determined in borate buffer (50mM) at pH 7.8 
and in CH3CN  at 25°C by setting up different H2O2 decomposition experiments in the 
presence of [Mn2L2X]= 7.5µM, and varying the initial H2O2 concentration in a wide range 
so that [H2O2]0=22-700mM. Data were analyzed collecting values of oxygen evolution 
rate, R0 (µMO2/s), for each [H2O2]0 conditions. Fitting of these experimental values, 
according to the Michaelis-Menten equation, results in well-behaved saturation curves 
from which the kinetic parameters as Vmax (µMO2/s), kcat (s-1), KM (mM) and kcat/KM (s-1M-
1) could be extracted. Table 7 collects Michaelis-Menten parameters of the different 
literature complexes. Several Mn-based systems have been proposed as artificial catalases. 
A large part of these are based on dinuclear MnII complexes, with close structural analogy 
to [Mn2L2Bz], and some representative examples are reported. 
 
Table 7: Summary of most active Mn complexes  with CAT-like activity. 
 
There are numerous catalase mimicking system that have quite high kcat and low KM, so 
they are really efficient, however they are hardly ever reported in aqueous environment 
(entry 2-3-5-6), indeed, the few compounds that are reported in water have low kcat and 
high KM, being their efficiency (kcat/KM) not so good (entry 4), and they may require high 
pH. Furthermore most of these compounds, when used in water, almost always works only 
few minutes than degrade. 
Considering the primary role of catalase enzymes against oxidative stress and degenerative 
diseases, it is important to transfer catalytic activity from lab conditions into aqueous 
biological environment.  
# Catalyst kcat  (s-1) KM(mM) kcat/KM (M-1s-1) Solvent T(°C) 
1 Mn2L2Bz 
37 470 80 BBS, pH 7.8, 25 
21 360 58 CH3CN, 25 
211 [Mn((X3-salpnO)2] 4.2-21.9 10-120 42-220 CH3CN, 25 
312 
[Mn2(µ-O)(OAc)-
(OH)(benzimpnO)]+ 
2.7 6 450 MeOH:H2O, 25 
415 [Mn2(X5-bphba)Cl2]+ 0.017-0.075 20-151 1-3 H2O, 25 
519 [Mn2(µ-Cl)2(tpa)2]2+ 107 3100 35 CH3CN, 25 
620 [Mn(µ-O)(salpn)]2 250 250 1000 Cl2CH2/CH3CN, 25 
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A central point of the research was the combined SOD/CAT mimicking activity enabled by 
a single synthetic catalyst. The interplay of both anti-oxidant mechanisms is not possible 
for a natural enzyme, due to its specificity properties, but it can be obtained with a 
synthetic catalysts. The SOD capacities of Mn2L2Bz under examination has been evaluated 
using the same method described above for the mononuclear compounds. The dinuclear 
complex shows a quite good activity, 2 orders of magnitude  (kMcFc 3.3·107 M-1s-1) lower 
than the best artificial SOD mimic (M40401, kMcFc 1.6·109 M-1s-1), that is the nearest to the 
natural SOD, but without catalase activity. However, the complex shows higher reactivity 
than a lot of reported mononuclear complexes with only SOD-activity. Up to date it is the 
best dinuclear complex known and the best one with double CAT/SOD activity. Compared 
with the compounds 1-3, it has higher reactivity as SOD mimic, and it has also higher CAT 
activity, working better also near physiological conditions (Table 8). 
 
Table 8: Summary of most active Mn complexes with SOD-like activity. 
 Compound kMcCF (M
-1s-1) 
11 MnSOD 8·108
21 M40401 1.6·109 
31 [MnCl4TE-2-PyP]5+ 4.08·108
41 Mn2L2Bz 3.3·107
528 [Mn(3)(OTf)2] 8·106
61 [Mn(TMIMA)2]2+ 3.6·106
71 EUK-8 6.0·105
Xanthine 50 mM, NBT100 µM, xanthine oxidase 0.005 U/ml in phosphate buffer 50 mM pH 7.8. 
 
 
2.4 Mitochondrial toxicity 
 
Focusing on dinuclear compound 4 structure, formed by two tetradentate ligands, made of  
3 aromatic rings, these hydrophobic portion could, in principle, easily cross mitochondrial 
membrane, also because the overall charge of the complex is slightly positive (+1). Having 
both SOD- and CAT-like activities, it is able to eliminate superoxide anion and also 
hydrogen peroxide, so it is really interesting as possible agent to reduce anomalous ROS 
production in mitochondria. Its activity was thus checked in some representative aqueous 
media, not only containing the buffer but also some salts like EGTA, used to chelate 
calcium, potassium chloride, needed to regulate the osmotic pressure of the solution, and 
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usually phosphate. In table 9 are reported some values of initial rate, endpoint and turnover 
number (TON) of the catalyst in different buffers, more or less complex, for example KH 
(Krebs-Henseleit) is a typical carbonate buffer containing many compounds, like 
magnesium sulfate, calcium chloride, glucose, sodium chloride, potassium chloride and 
potassium phosphate. The values of initial rate, as said before, depend on buffer type and 
pH, in particular the complex buffer containing EGTA, MOPS and phosphate was found to 
lower the initial rate and the TON. The same behavior was observed when the pH is 
lowered. In the last three lines of the table, some experiments in the presence of typical 
catalase inhibitors, cyanide, 3-amino-1,2,4-triazole and azide, have been performed in 
borate buffer, the best condition for [Mn2L2Bz] compound. It is possible to see that only 
cyanide anion has an inhibitory effect on the complex, with a reduced initial rate and 
halved production of oxygen. 
 
Table 9: Initial rate and oxygen production of [Mn2L2Bz] in different buffer at different pH and in the 
presence of catalase inhibitors. 
Compound Buffer R0 uMO2/s EndPoint µmolO2 Time TON 
[Mn2L2Bz] BBS pH 7.8 39 198 1h 275 
[Mn2L2Bz] PBS pH 7.8 95 77 1h 107 
[Mn2L2Bz] PBS pH 7.4 25 81 1h 113 
[Mn2L2Bz] KH pH 7.4 32 75 1h 104 
[Mn2L2Bz] MOPS Mito pH 7.4 17 26 1h 36 
In the presence of catalase inhibitors 
[Mn2L2Bz] BBS pH 7.8 NaN3 34 198 1h 275 
[Mn2L2Bz] BBS pH 7.8 ATZ 24 198 1h 275 
[Mn2L2Bz] BBS pH 7.8 KCN 11 95 1h 132 
 
The initial idea was to evaluate the effects of the complex on mitochondria, monitoring the 
different events: (i) during normal respiration, analyzing the basal respiration, (ii) during 
the phosphorylation process, when oxygen consumption increase and (iii) under uncoupled 
respiration, when the presence of an additive, carbonyl cyanide-4-
(trifluoromethoxyphanylhydrazone) (FCCP), induces increase of mitochondrial respiration 
due to disruption of the protonic gradient into mitochondria. Finally, we have monitored 
the effects on mitochondria in which the respiratory chain was interrupted by the addition 
of antimycin A, an antibiotic that also increase ROS production. However, the endogenous 
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catalase contribution was always much higher than the activity induced by 4. In addition, 
among common inhibitors, only cyanide was found to inhibit the enzymes, but also   
inhibited also our complex. Within such scenario it was impossible to appreciate any effect 
of the catalyst on the rate of oxygen evolution, in the presence of added H2O2, also using 
the oxygraph.  
Only the toxicity on the isolated mitochondria was thus evaluated, analyzing oxygen 
consumption rate, with a Clark electrode, during the different metabolic events i-iii.  
In a typical experiment, isolated mitochondria were injected in a reactor containing the a 
buffer solution at pH 7.4, where different concentration of complex were added. Oxygen 
consumption after the addition of mitochondria was registered, being the initial 
consumption due to basal respiration of the organelles (State2 or St2), from this rate it is 
possible to understand if the complex has had an uncoupling effects on respiration. 
Adenosine diphosphate (ADP) was then added and an increase of the respiratory rate was 
observed, indeed mitochondria started to produce ATP from ADP, since more oxygen was 
needed and an increase of oxygen consumption was observed, this was the rate during the 
phosphorylation (State3 or St3). After all ADP has been consumed, oxygen consumption 
returned on the level of basal respiration (State4 or St4). Finally after stabilization, FCCP 
was added, this compound leaded to the maximum oxygen consumption rate (StateUn or 
StUn). An example of these experiments is show in figure 30, there are many curves of 
oxygen consumption in the presence of different concentration of [Mn2L2Bz] (FerBz in the 
figure). 
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Figure 30: Mitochondrial oxygen consumption, mitochondria alone in black, and in the presence of 
[Mn2L2Bz] 100µM (red line), 50µM (blue line), 25µM (orange line), 10µM (green line), 5µM (cyan line) and 
2.5µM (yellow line). 
 
The complex showed a little uncoupling effect at about 50µM concentration, with an 
increase of basal respiration (St2), that can be easily seen also from the figure, probably it 
fostered the passage of some protons, leading to an increase of oxygen consumption to 
equilibrate again the protonic gradient. A toxic effect above 100µM is easily visible from 
the rate of oxygen consumption reported in table 10, where it is clear the lowering of 
phosphorylation rate (St3). It is possible that at high concentration (100µM) [Mn2L2Bz], 
interferes with ATPase, the protein involved in the ADP phosphorylation, leading to a 
decrease of the oxygen consumption. 
 
Table 10: Rate of oxygen consumption (nmolO2·mg protein-1·ml-1) with standard deviation (average of three 
measurement) at different states and with different concentration of complex [Mn2L2Bz]. 
[Mn2L2Bz], µM 0 2.5 5 10 25 50 100 
St 2 4.1±0.7 4.5±0.6 5.1±0.8 5.19±0.7 5.3±0.9 6.5±1.6 6.6±1.4 
St 3 12.8±3.0 15.3±5.1 15.6±3.8 15.37±4.0 14.6±3.0 13.2±2.3 8.1±1.8 
St 4 3.2±0.3 3.6±0.1 4.09±0.5 4.6±0.2 4.9±0.8 6.0±0.3 6.1±0.3 
St Un 13.0±2.2 15.7±3.3 19.7±6.9 21.9±7.3 19.3±6.4 16.2±4.9 15.7±5.2 
St 3/St 2 3.2±0.6 3.4±0.8 3.0±0.3 2.9±0.4 2.8±0.2 2.1±0.3 1.2±0.1 
St Un/St 2 3.2±0.5 3.5±0.9 3.8±0.9 4.1±0.9 3.6±0.8 2.5±0.7 2.4±0.7 
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Another parameter that can be considered is the ratio between rate of state3 and state2 (or 
state4), St3/St2, also called Respiratory Control Ratio (RCR) that gives an idea of the 
“health” of mitochondria, indeed if this ratio is equal or higher than 3, this means 
mitochondria are functioning well. What is possible to see is that the ratio in the presence 
of [Mn2L2Bz] is more or less near 3 until 25µM, while there is a neat decrease at 50µM or 
higher, so mitochondria are quite healthy under 50µM of our complex. 
Furthermore to better understand the effects of [Mn2L2Bz] on mitochondria a Calcium 
Retention Capacity (CRC) experiment was performed. Although mitochondria can 
accumulate calcium, it is not an infinite process, indeed the over-accumulation of calcium 
could induce the so called mitochondrial permeability transition, in which the formation of 
a pore (permeability transition pore or PTP), cause the catastrophic loss of integrity of the 
inner mitochondrial membrane. In CRC experiment several addition of calcium to isolated 
mitochondria in the presence of a florescence probe for calcium (Calcium Green™) 
detection were performed. When calcium was added there was an increase of fluorescence 
and a subsequent decrease because calcium is confiscated by mitochondria. This can 
happen several times until a certain concentration is reached, that is called calcium 
retention capacity, at which mitochondria release all the calcium accumulated with a clear 
increase of fluorescence, the release of the calcium is due to the formation of the 
permeability transition pore (PTP). These  events seems to be involved in many 
pathologies, apoptosis and also seem to be caused by oxidative stress. CRC was analyzed 
at different concentrations of [Mn2L2Bz] (Figure 31), and also in the presence of a 
protective agent, cyclosporin A, that postpones the pore opening (Figure 32), to evaluate 
the effects of our compound.  
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Figure 31: CRC graph of isolated mitochondria in the absence (black line) and in the presence of different 
concentration of [Mn2L2Bz]: 10µM (orange line), 5µM (red line), 2.5µM (blue line) and 1.25µM (green 
line).The arrows indicate the addition of calcium chloride and the total concentration added. 
 
 
 
Figure 32:CRC graph of isolated mitochondria in the presence of cyclosporin A and [Mn2L2Bz](blue and 
orange lines) compared  with blank experiment without cyclosporin A (red and black lines). 
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In the following table are resumed the concentration of calcium chloride added until there 
is the opening of the pores. 
 
Table 11: Calcium concentration at which there is pores opening in the presence of different [Mn2L2Bz] 
concentration and in the presence of cyclosporin A (on the right). 
 Without Cyclosporin A With Cyclosporin A (1µM) 
[Mn2L2Bz] 0 µM 1.25 µM 2.5 µM 5 µM 10 µM 0 µM  2.5 µM 
Opening, µM di Ca2+ 55 45 40 35 25 90 75 
 
The higher is the [Mn2L2Bz] concentration, the earlier is the pore opening Also in the 
presence of cyclosporin A, the opening of the pore is still earlier (75µM) than the control 
experiment (90µM). The complex interacts with the pore on the inner membrane, that is 
proved by the anticipation of the pore opening in the presence of the complex and this can 
be a confirm that it enters into mitochondria. Furthermore, it has been recently supposed 
that the transition pore could be formed by two ATP synthase (ATPase) proteins,51 this 
could be a further indication of the interaction with ATP synthase, that at higher 
concentration of complex (50µM) lead to an inhibition of phosphorylation rate. Further 
studied should be performed to understand if this anticipation of pore opening, and 
interaction with ATPase, at high complex concentration, could have a role in complex 
activity or  negative effects of toxicity.  
 
 
2.5 Modification of apical ligand of dinuclear complexes with    
      mitochondriotropic substituent (5-7) 
 
One of the biggest issue when  using drugs is their selective delivery/targeting to specific 
cell functionalities. Targeting and delivery systems are widely studied to improve the 
effects of the drugs, they are also important to implement the antioxidant efficiency of the 
catalyst. In our case, the aim is to target mitochondria, indeed most of ROS are produced 
into these organelles, so it is important to carry the catalyst near or, better, into 
mitochondria. Suitable functionalities were thus anchored on the antioxidant, in order to 
assist their penetration into cellular and mitochondrial membranes. In particular, since the 
latters  are usually negatively charged, almost all the targeting agents are positively 
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charged.52 Among literature examples, peptides represent one appealing possibility for 
building recognition motifs. Indeed, target peptides con be recognized by a certain 
sequences of aminoacids with a suitable secondary structure.53 Targeting peptides were 
also designed to incorporate  antioxidant moieties. The SS peptide is characterized by 
alternating aromatic residues such as dimethyltyrosine, that originates the antioxidant 
activity, and basic residues, like arginine and lysine, that provide the net positive charge to 
specifically target mitochondria (Figure 33 left).54 Another example of peptides are the 
XJB Gramicidin S analogs, based on a sequence of AA (usually hydrophobic, like leucine, 
valine, proline or phenylalanine), of membrane active gramicidin antibiotics, conjugated 
with TEMPO as radical scavengers (Figure 33 right).55 
 
 
Figure 33: SS peptide with antioxidant activity for targeting mitochondria (on the left), and Gramicidin S 
and an example of derivative containing TEMPO radical as ROS radical trap (on the right). 
 
Another kind of targeting molecule are the lipophilic cations, among containing a nonpolar 
framework and a positive charge, which are able to pass through  the membranes, 
exploiting the negative membrane potential (about -180mV) of mitochondria. Among these 
compounds, Rhodamine is widely used to target mitochondria, since it contains a positive 
charge and it can be easily modified, furthermore it is luminescent, and its optical 
properties could also be tuned and exploited for fluorescence imaging. Phthalocyanines 
were linked with two rhodamine residues to target mitochondria and used for 
photodynamic therapy and induce apoptosis.56 Conjugation of an anti-inflammatory 
compound, like dieckol, with rhodamine increases its activity thanks to rhodamine 
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trafficking.57 Although the precursors are cheap, some rhodamine derivatives are quite 
expensive, depending on their desired features, such as quantum yield of fluorescence, 
lipophilicity and charge (Figure 34). The cheapest is rhodamine B (Rho B, 0.45€/g), whose 
synthesis is easy and cheap. More complex rhodamine are more expensive, rhodamine123 
(Rho 123, 1650€/g) is the most expensive commercial one.58 
 
 
Figure 34:  General structure of rhodamines and some commercially available compounds. 
 
Another type of mitochondriotropic substituent are triphenylphosphonium salts (TPP), that 
are easily synthetized starting from a bromine compound and triphenylphosphine. With 
rhodamine, TPP compound represent the majority of non-peptidic mitochondrial targeting 
agents.59 Classical antioxidant molecules, like polyphenols and vitamins, especially 
vitamin E, were functionalized with TPP pendants to target mitochondria, but also some 
SOD mimicking catalysts, such as salen compounds were functionalized with TPP salts to 
selectively drive them into mitochondria (Figure 35).60  
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Figure 35:  Scheme of TPP salts synthesis from an alkyl bromide and triphenylphosphine (PPh3) and three 
examples of antioxidants conjugated with TPP: vitamin E, MitoQ and SOD-like Mn catalyst. 
 
A lot of other targeting agents exist, for example sulfonyl-urea compounds, anthracyclines, 
resveratrol and its analogues, some kind of porphyrins, curcumin and other lipophilic 
compounds (Figure 36).52  
 
 
Figure 36: Other examples of targeting antioxidant molecules, clockwise from upper left: two sulfonyl-urea 
derivatives, an anthracycline, curcumin and resveratrol molecules. 
 
Herein, the conjugation of the dinuclear manganese complex with rhodamine and TPP salts 
has been obtained exploiting the carboxylic bridging  ligand of the dinuclear complex 4. 
Two rhodamine B derivatives were thus synthetized with two semi-rigid spacers between a 
carboxylate and the aromatic region of the rhodamine. A TPP salts of bromovaleric acid 
was also used to synthetize a complex with a mitochondriotropic pendant. 
Rhodamine B was chosen because of its cheapness and good quantum yield (0.53 for 
cationic form).  
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The first step was the functionalization of rhodamine B base with a semi-rigid spacer, such 
as piperazine or trans-1,4-diaminocyclohexane amide.61 Rhodamine B Base can be easily 
synthetized starting from rhodamine B by basification. Lactone form is obtained in high 
yield (>90%). Both diamino-spacers react with the lactone in the presence of 
trimethylaluminium, in dry dichloromethane under nitrogen (Scheme 9). 
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Scheme 9: Synthesis of rhodamine trans-1,4-diaminocyclohexane amide(RhoD) and rhodmaine piperazine 
amide (RhoP)starting from rhodamine B Base.61 
 
In the next step, a carboxylic acid, required for Mn coordination, has to be introduced. So 
RhoP has been reacted with succinic anhydride forming amido bond and leaving an 
available carboxylic functionality (Scheme 10). 
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Scheme 10: Synthesis of  rhodamine 4-(3-carboxypropionyl)piperazine amide (RhoPS).61a 
 
Finally, it was possible to synthetize the catalyst 5 using RhoPS instead of benzoic acid 
(Scheme 11). The product did not crystalize but after the addition of trimethylamine a 
reddish-pink solid precipitated. Solid was abundantly washed with methanol an diethyl 
ether. The paramagnetic product 5 was characterized by FTIR, UV-Vis and MALDI-TOF 
MS. 
 
Scheme 11: Synthesis of 5. 
 
In particular, FTIR analysis (Figure 37) confirmed the formation of the complex, upon 
comparison of the region around 1100cm-1, with the comparison of typical bands of the 
catalyst, but also the reduction of carboxylate signals at about 1600-1700cm-1, expected 
after coordination to the manganese atoms. 
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Figure 37: FTIR spectra of tetradentate ligand L (upper spectrum, blue), rhodamine derivatives carboxylate 
RhoPS (below, dark blue) and final complex 5 (in the middle, red). 
 
Mass spectrum analysis confirmed the formation of the products, indeed with a MALDI-
TOF instrument the molecular peaks was clearly visible (m/z 1329 [M+]), together with 
other molecular fragments (m/z: 611-817-970-1161), due to spacer breaking at different 
points (Figure 38). Also ESI-MS confirmed the formation of the complex by molecular 
peaks double charged at about m/z 664.2. 
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Figure 38: MALDI-TOF spectra of compound 5. 
 
UV-Vis analysis of 5 showed that the rhodamine spectral features have been retained and 
catalyst bands are clearly visible at abut 250nm (Figure 39). Also the fluorescence of 
rhodamine is retained, with a decreased intensity of emission in ethanol. 
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Figure 39: UV-Vis spectra of original complex 4 (green), rhodamine ligand RhoPS (blue) and complex 5 
(red) 10-5M in EtOH. 
 
In the case of RhoD, 4-formylbenzoic acid was attached by reaction between aldehyde and 
amine of diamine cyclohexane. To increase the stability of the bonds to aqueous 
conditions, the resulting imino bond has been reduced in situ with sodium 
cyanoborohydride and the product RhoDIR was purified by a chromatographic column 
(Scheme 12). 
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Scheme 12:  Synthesis of rhodamine-trans-1,4-diminocyclohexane amide-4-carboxybenzyl (RhoDIR). 
 
As in the previous synthesis of 5, it was possible to synthetize the catalyst with the new 
rhodamine derivative. Product 6 is obtained after precipitation and washed with methanol 
and diethyl ether (Scheme 13).  
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Scheme 13: Synthesis of 6. 
 
Product 6 was characterized by FTIR, UV-Vis, ESI-MS and MALDI-TOF MS. Also in this 
case FTIR confirm the formation of the complex, indeed a band at about 1100cm-1 
appeared, but also some peaks at 1700cm-1 disappeared, due to carboxylate coordination 
(Figure 40). 
 
 
Figure 40: FTIR spectra of tetradentate ligand L (upper spectrum, blue), rhodamine derivatives carboxylate 
RhoDIR (below, dark violet) and final complex 6 (in the middle, red). 
 
Mass spectrum analysis confirms the formation of the products, indeed with a MALDI-
TOF instrument the molecular peaks was clearly visible (m/z 1390 [M+]), but also other 
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molecular fragments (m/z: 359-442-830-963), in which the carboxylate is broken at 
different point.  
 
The last compound with a mitochondriotropic function is a TPP-based carboxylate, 
obtained from reaction of commercially available bromovaleric acid with 
triphenylphosphine. 62 The carboxylate was then reacted with the ligand, in the presence of 
trimethylamine and manganese perchlorate. The white precipitate was washed with 
methanol and diethyl ether (Scheme 14). 
 
 
Scheme 14: Synthesis of triphenylphosphine derivative (TPPAcV) of valeric acid (upper reaction) and 
synthesis of catalyst 7. 
 
FTIR and mass analysis confirmed the structure of the complex. FTIR showing the shift of 
the carboxylate band from about 1750cm-1 to 1600cm-1 and the peak at 1100cm-1 typical of 
the complex (Figure 41). While ESI-MS analysis confirm the presence of the complex by 
its molecular peak at m/z 540.1 [M2+] and its fragmentation peaks  due to ligand, 
carboxylate and rupture of carboxylic acid (m/z 306.2, 363.2, 763.1).  
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Figure 41: FTIR spectra of tetradentate ligand L (upper spectrum, blue), TPP Valeric acid TPPAcV (below, 
orange) and final complex 7 (in the middle, red). 
 
Finally, the catalytic activity of these compounds to dismutate H2O2 was tested in borate 
buffer solution (BBS), that was found to be the best systems, at pH 7.8. It was also possible 
to evaluate the effect of the apical ligand on the initial rate of oxygen production. The 
kinetics are shown below (Figure 42). 
 
 
Figure 42: Kinetics trace of hydrogen peroxide dismutation by compound 5 (black line), 6 (red line) and 7 
(blue line). Kinetics were performed in the same condition used for the original compound 4, borate  buffer 
solution 50mM at pH 7.8 and H2O2 33mM. 
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How it is possible to see form kinetic traces piperazine compound 5, was the most reactive, 
with higher initial rate of dismutation of 52µMO2/s, while TPP complex was the less 
reactive with an initial rate of about 21µMO2/s and diaminociclohexane derivative had an 
intermediate value (33µMO2/s). This meaning that changing the apical ligand could 
influence initial rate of dismutation. However, despite the differences of R0, all of them 
reached complete dismutation in about one hour, the reactivity of initial complex was 
indeed retained. Further studies should be performed to better understand the effects of 
complex apical ligands, indeed while considering acetate, benzoate and 4-formylbenzoate, 
no differences occurred between the complexes, in the presence of carboxylate that 
contains positive charge, basic group or more hydrophobic group, some differences have 
appeared. Maybe with the optimization of the apical ligand it will be possible to further 
increase the initial rate of dismutation of the complex but also its activity at pH lower than 
7.8, to get closer to physiological pH. 
The last study to do is to check the effective entrance of these compound into 
mitochondria, in particular the rhodamine derivatives could be follow by fluorescence, 
while TPP compound entrance could be monitored on isolated mitochondria with a TPP 
ion selective electrode. 
 
 
 
 
2.6 Conclusions 
 
In conclusion to this part, two kind of manganese-containing catalysts that are able to 
mimic SOD and CAT enzymes have been studied. The mononuclear compounds are the 
first examples of  mononuclear complexes that are able to dismutate superoxide anion and 
hydrogen peroxide in aqueous solution, being their activity dependent on the heteroatoms 
on the ligands (S > O > N).  
Then a dinuclear complex of manganese was thoroughly studied as antiROS compound.  
Starting for literature knowledge of its reactivity for H2O2 dismutation, we deeply studied 
its activity, finding the best buffer solution (borate buffer near physiological pH) to 
perform catalytic test, then we obtained Michaelis-Menten parameter that allows us to 
compare the activity with other literature compounds. This catalyst is the best, till now, 
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that is able to eliminate hydrogen peroxide in aqueous solution, with complete conversion 
of the substrate without loss of reactivity, while most of the literature compounds work 
only few minutes. Stability was indeed confirmed by FTIR, mass analysis and recharging 
experiments. Toxicity studies on isolated mitochondria revealed no toxicity till 50µM 
concentrations and a possible interaction with ATPase and induction of anticipating  
permeability transition pore opening. Modification of apical bridging carboxylate with 
mitochondriotropic pendants like rhodamine derivatives and triphenylphosphonium salts 
was achieved, products were characterized and catalytic activity was confirmed to be 
maintained and similar to original compound. Unfortunately, no crystal structure of these 
compound was obtained. As perspective, the positive effects on cell protection against 
oxidative stress and selective delivery and also the toxicity will be studied. 
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 3.Manganese oxoclusters as 
artificial antioxidants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of the work described in this chapter was performed during a Short Term Scientific 
Mission within COST action 1203, in the laboratory of Prof. Wolfgang Schmitt, at the 
Trinity College Dublin in Ireland, from June 23rd to September 7th 2014. 
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3.1 Manganese oxoclusters, a brief overview 
 
The increase of  number of metal centers have been taken into account in order to amplify 
the activity of the artificial CAT/SOD mimicking systems. In this chapter, polynuclear 3d 
manganese oxoclusters have been considered as catalase and superoxide dismutase 
synzymes. Oxoclusters are a class of compound characterized by the presence of a 
multimetallic structure in which metals are linked by oxygen bridge and coordinated by 
organic polydentate ligands. Early transition metals clusters (e.g. Zr, Hf, Ti), mixed 
clusters (e.g. Ti-Zr, Ag-Zr, Ti-Y Cu-Y), lanthanide (e.g. La-Zn, Ba-Ce, Sm-Ti) and also 
middle transition metals clusters (Fe, Cr, Mn) have been synthetized during these years.1, 3 
They are usually discrete and globally neutral species, featuring different nuclearities (3-14 
metals), connectivity modes (corner, edge or face sharing of the polyhedra) and 
coordination number of metal atoms (depending on metal atom).2 The interest for these 
polynuclear 3d metal complexes is due  to various reasons: they might exhibit high-spin 
(S) ground states and magnetic anisotropy, thus working as nanoscale magnetic particles,3 
or they can be used as building blocks for hybrid inorganic-organic materials,4 and as 
precursors for the nucleation of nanostructured metal oxides or secondary building units 
(SBU) for MOFs (Metal organic frameworks).5 
There has been considerable interest in manganese complexes over the last 20 years mainly 
owing to their utility in the fields of bioinorganic chemistry and magnetic materials.6 Mn is 
an essential redox active metal, used by nature as catalyst in important biological reactions, 
it is also present in many enzyme active site.7 Manganese oxoclusters are of particular 
interest for two main reasons. They share some features with the natural catalase, in which 
two manganese atoms are bridged by two oxygens and a carboxylate, and with the oxygen 
evolving catalyst (OEC) of photosynthetic system, in which there are four manganese and 
a calcium ions linked by oxygen bridges (Mn4CaO5, Figure 43).8 Their magnetic properties 
as single-molecule magnets (SSM) are really interesting in material science,9 indeed 
SMMs are regarded as the elementary units in both ultimate high-density magnetic storage 
devices and for the design of quantum computers.10 In literature there are many examples 
of multi manganese oxoclusters that have been studied, mainly for their electronic and 
magnetic properties, that are very often related to their symmetry and nuclearity, but 
nothing about  their catalytic activity has been reported yet. 
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Figure 43: Catalytic center of photosynthetic OEC containing 4 Mn atoms (left) and Mn catalase of 
L.plantarum containing 2 Mn atoms. 
 
For all these motives, in the next section, the preparation of different multi-metallic 
compounds of Mn has been taken into account, trying to discover novel catalysts that have 
catalase and superoxide dismutase mimicking activity.  
 
 
3.2 Catalytic activity and stability of multi-manganese complexes (8-16) 
 
Mn-based oxoclusters containing 13 and 6 metal centers in different oxidation states have 
been prepared following literature procedures.11 These compound are usually made of 6-13 
manganese ions connected by oxygen and/or chloride atoms and coordinated by organic 
phosphonate ligands (tert-butyl-, phenyl- and benzyl-); metal centers are usually present as 
MnIII, but it is also possible to have MnII atoms. These compound show interesting 
magnetic properties and are stable in acetonitrile, DMF and DMSO. In a typical synthesis 
(more details can be found in the Experimental Part, chapter 6), an organic phosphonate 
ligand is dissolved in organic solvent, usually methanol or acetonitrile, in the presence of 
manganese (+II) and manganese (+VIII) salts, whose amount differs from cluster to 
cluster, and an organic base is added. After few hours the solution is filtered and left to 
crystallize at room temperature for 1-2 weeks. The oxoclusters synthetized are listed 
below. They are all characterized by high nuclearity, 6, 13 or 14 manganese atoms, organic 
phosphonate ligands, mainly tert-butylphosphonates and an organic base, like 
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trimethylamine or pyridine and derivatives, that sometimes could also coordinate the 
metals. A molybdate oxocluster, containing 6 manganese, was also prepared. 
 
-[MnIIMnIII12(µ4-O)8(µ4-Cl)(tert-butylPO3)8][MnII(CH3CN)6]Cl2·6CH3CN·5.25H2O (8) 
-(C5H7N2)3[MnII3MnIII10(µ4-O)6(µ3-O)(µ3-OH)(µ4-Cl)4(Cl)(tert-butylPO3H)(tert-butyl 
  PO3)9] ·3CH3CN·2H2O (9) 
-(C5H7N2)2[MnII3MnIII11(µ4-O)6(µ3-O)(µ3-OH)(µ2-OH)(µ4-Cl)4(tert-butyl-PO3H)(tert- 
  butyl-PO3)10(2-aminopyridine)]·3CH3CN·2H2O (10) 
-[(MnII0.5MnIII0.5)MnIII12(µ4-O)6(µ-OH)2(µ-CH3O)4(CH3OH)2(tert-butyl-PO3)10(4- 
  picoline)4]Cl0.5 ·1.5H2O (11) 
-[(MnII0.5MnIII0.5)MnIII12(µ4-O)6(µ-OH)2(µ-CH3O)4(CH3OH)2(tert-butylPO3)10 (4,4’TPD)2]  
  Cl0.5 ·8CH3OH  (4,4’-TPD = 4,4’-trimethylenedipyridine) (12) 
-[MnIII13(µ4-O)2(µ3-O)4(µ2-OH)2(µ2-CH3O)4(C6H5PO3)10(C5H5N)5Cl]·3H2O (13) 
-[MnIII13(µ4-O)2(µ3-O)4(µ2-OH)2(µ2-CH3O)4(C6H5CH2PO3)10(C5H5N)5Cl]·5H2O (14) 
-[MnIII13(µ4-O)2(µ3-O)4(µ2-OH)2(µ2-CH3O)4(C6H5CH2PO3)10(C6H5-C3H6-C5H4N)5Cl]  
  ·5H2O (15) 
-TBA2[Mn6IIMo10VI(O)12(µ3-O)4(tert-butylPO3)6(Ac)2(pyridine)2(H2O)6] (16) 
 
In figure 44 are reported all the structures of these clusters: it is interesting to notice the 
different spatial arrangement of manganese atoms in the structures, depending on the type 
of phosphonate used, the ratio of MnII/MnVII added, the presence of bases and the molar 
ratio of the ligands. Molybdate-based species are of particular interest, considering that 
they contain a more extended inorganic domain that can make the cluster more resistant to 
oxidative conditions, while the occurrence of many metal centers could support multi-
electronic reactions. 
Manganese oxoclusters as artificial antioxidants 
76 
 
 
Figure 44: Structure of the clusters sinthetized 8-16, in particular from the top left: compoound 8-9-10. In 
the middle from the left: 11-12-16. And lower from left: 13-14-15. Legend: in blue manganese atoms, in red 
oxygen atoms, light green (compound 16) molybdenum atoms, dark green chloride atoms and carbon atoms 
in black. 
 
Compounds 8-12 are formed by tert-butylphosphonates ligands and have 13-14 Mn atoms, 
the bases used are different and also the MnII content is different. Also compound 16 has 
tert-butylphosphonates ligands, but there are only 6 manganese atoms in the structure. The 
others oxoclusters, 13-15 are synthetized with phenyl and benzyl phosphonates with 
different bases but all are formed by 13 MnIII atoms. 
All these compound were tested as catalase mimics: interestingly for almost all of them,  
reactivity in acetonitrile falls down rapidly, while in aqueous solution they often reach the 
complete dismutation of H2O2 in few hours (Figure 45).  
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Figure 45: Example of differences in reactivity in acetonitrile (pink-red lines) and in water (blue-black lines) 
of two manganese oxoclusters with similar structure (11-12). 
 
This behavior is common for the compound with 13 manganese atoms, while molybdate 
compound (16), with only 6 MnII atoms, has still low activity in acetonitrile but is basically 
inactive in pure water. Compound 8-10 have similar structural features. Indeed, they are 
obtained lowering the molar ratio between chloride anion and phosphonate ligands, with 
respect to oxocluster 8, leading to less symmetric compounds (Figure 46). These changes 
slightly affect the reactivity, being the less symmetric compound the most reactive one 
(Figure 46 left). 
 
 
Figure 46: Schematic rappresentation of compounds 8 (left), 9 (middle) and 10 (right) in which manganese 
atoms cluster is in blue, while phophonate ligands are in pink. Dark blue is the “external” manganese portion 
of clusters 9 and 10.11a 
 
Compounds 13-15 contain hindered aromatic phosphonates. They are less reactive, with 
only a small difference between phenyl-based clusters (13) and benzyl-based clusters (14), 
probably due to phosphonate ligand,  being the former more reactive than the latter. For the 
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compound 15, the introduction of a different coordinating base (4-(3-
phenylpropyl)pyridine) is responsible for a better reactivity (Figure 47). Being the 
coordianation environment similar to that of compound 14, this effect may be due to a 
different aggregation state in solution. 
 
 
Figure 47:Kinetics trace of similar clusters, on the left compounds 8-9-10, on the right compounds 13-14-15. 
 
The mixed Mn/Mo cluster (16) shows an opposite behavior, with a very low activity for 
H2O2 dismutation in water, while in acetonitrile it is active, even if not so fast. The low 
reactivity, in this case, can be due to stabilization of Mn in a lower oxidation state (MnII, 
while previous clusters contain mainly MnIII atoms). Cluster reactivity are resumed in table 
12, highlighting that the compound 12 was the most active one, with an initial dismutation 
rate of 17.5µMO2/s in aqueous solution, Again, the use of different base (in 11), affects the 
reactivity of isostructural clusters. 
 
Table 12: Number of manganese atoms and initial rate of hydrogen peroxide dismutation in water of 
oxoclusters 8-16. 
Cluster N. N. Mn atoms R0 µMO2/sa
8 13 7.6 (-) 
9 13 9.7 (0.4) 
10 14 14.6 (1.2) 
11 13 12.3 (0.9) 
12 13 17.5 (1.7) 
13 13 7.5 (0.6) 
14 13 4.6 (-) 
15 13 9.5 (-) 
16 6 - (1.6) 
a: Initial rate in acetonitrile inside brackets. 
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The different coordination environment is particularly important if considering that, in 
concentrated aqueous solution, the oxoclusters have the tendency to precipitate after few 
hours. Solids were analyzed by FTIR and mass spectroscopy, upon re-dissolving them  in 
acetonitrile or DMF. IR spectra reveals some changes in the cluster structures, and suggest 
the loss of the coordinating base. 
The reactivity in buffered solution was also tested: in phosphate buffer solution (PBS), 
catalysts was much less efficient, probably because of the competition between 
phosphonate ligands and phosphate. Indeed, solids precipitated from phosphate buffer 
(50mM, pH 7.4) showed major changes in IR spectrum (Figure 48 reports the 
representative behavior of compound 13). Unfortunately, mass spectra did not give any 
information about structure changing or modification, while recrystallization attempts were 
not successful.  
 
 
Figure 48: Example of IR spectra of compound 13, a Mn13 cluster, before (blue line, middle) and after 
dissolution and precipitation in water (red line, top) and phosphate buffer (pink line, bottom). 
 
Finally, the SOD activity of these oxocluster was analyzed, using borate buffer at pH 7.8. 
Preliminary tests have shown a good activity against superoxide anion formation, with an 
IC50 lower than 1µM, with an hypothetic kinetic constant higher than 106 M-1s-1. The 
Mo/Mn mixed cluster was instead much less reactive.  
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3.3 Conclusions 
 
New multimetallic compounds have been prepared and used for hydrogen peroxide 
dismutation. The anti ROS activity of manganese oxoclusters, in aqueous solution, is 
herein demonstrated for the first time. From a comparison of reactivity, it is evident that 
Mn(III) is required to dismutate H2O2, while in the presence of only Mn(II), the activity is 
extremely reduced.  
Despite the high nuclearity, however, the clusters are slower that the dinuclear compound 
presented above. In addition, in water their structure changes and a major drawback is 
represented by the need to avoid  phosphate buffers. Further experiments should thus be 
performed to assess the nature of the active species, and to exclude manganese release 
from the cluster. To increase the solubility and stability in water, different synthetic 
procedures, involving different/hydrophilic ligands have already been considered, but this 
will require further experiments. Activity in other buffered solutions, containing Tris, 
Mops, Hepes, carbonate buffer will also be explored to optimize the reactivity.  
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4.1 Polyoxometalates: short description and applications in medicine 
 
Polyoxometalates (POMs) are interesting polynuclear multicharged oxyanionic compounds 
of variable sizes (from Ångstrom to tens of nanometers) that are easily synthesized in 
aqueous solution using early transition metals (V, Mo and W are the most common) in 
high oxidation state (d0-d1) in controlled pH, concentration and temperature conditions.1  
 
Two are the fundamental parameters to have these structures: 
1. Cationic radii able to host an octahedral coordination; 
2. Empty d orbitals able to form terminal double bond metal oxygen. 
Commonly they are formed by octahedral MO6 (sometimes petahedral MO5 or tetrahedral 
MO4) where one or at least two oxygen (Lipscomb’s principle2) form a double bond with 
the metal. Terminal oxygens are essential for the formation of discrete structure and avoid 
the formation of widespread structure like in metal oxides.  
Polyoxometalate could be divided in isopolyanion (A) or heteropolyanion (B) depending 
on chemical composition: 
A. [MmOy]p-  
B. [XxMmOy]q-  
Where M is the transition metal in high oxidation state and X is another d-group metal or a 
non-metal atom (P, Si, As, Sb, Bi). 
One of the most studied and famous class of these compounds are the α-Keggin, with a 
general formula [Xn+M12O40](8-n)- with M= MoVI or WVI and X= SiIV, GeIV, PV, AsV and 
SbV. The heteroatom is in the center of the structure with a tetrahedral coordination XO4 
surrounded by 12 octahedral metal centers MO6 of molybdenum or tungsten that are 
usually  divided in triplets M3O13 in which each octahedral unit shares the edge. These 
triplets are linked by the corner of octahedral units, the particular disposition gives a Td 
symmetry to the POM structure (Figure 49). 
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Figure 49: Polyhedric structure of α-Keggin polyanion [PW12O40]3-: Octahedra WO6 in blue and internal 
tetrahedral heteroatom P(orange). 
 
The structure described is the most stable and is labelled as α form, many isomers less 
stable, characterized by the rotation of 60° of one (β isomer), two (γ isomer), three (δ 
isomer) or four (ε isomer) triplets M3O13 around their symmetry axes.3 These compounds 
are called saturated because of their low anionic charge, high stability and high symmetry. 
It is possible to synthesize lacunary structures in which one or more tetrahedral units MO4+ 
are removed from the saturated structure, generating monovacant (XM11O39), divacant 
(XM10O36) and trivacant (XM9O34) structures (Figure 50).4   
 
 
Figure 50: Polyhedric representation of a trivacant polyanion [α-PW9O34]9-: Octahedra WO6 in blue and 
internal tetrahedral heteroatom P(orange). 
 
Exploiting  the nucleophilic oxygen of the lacuna it is possible to insert different 
functionalities, for example other metal centers such as   FeII/III, MnII/III, CoII/III, 
RuII/III/IV).5,6,7,8 These compound are synthesized starting from the lacunary POM and metal 
precursors (M'L). 
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Figure 51: Example of transition metal substituted polyoxometalates. 
 
The simplest case of TMSP is when a single metal M' is coordinated in the lacunary site of 
a monovacant POM (Figure 51, first structure on the top-left). The lacunary 
polyoxometalates can also act as a inorganic polydentate ligand coordinating more metal 
atoms usually stabilized by sandwich-like or dimeric/trimeric structures.9 The resulting 
transition metal substituted POMs display coordination analogies with porphyrins and 
enzymes, and in some cases, a biomimetic activity has also been recorded. This feature, 
coupled with high robustness to oxidative conditions is of great interest for catalytic 
applications.10  
Due to their redox properties, POMs can oxidize several organic substrates, including 
biological targets.11 This feature, coupled with the possibility to interact with positively 
charged domains of proteins and enzymes,12,13,14 makes POMs interesting inorganic 
nanodrugs candidates with antitumoral,15 antiviral,16 antibacterial17 activity. There are also 
evidences of POM containing Lewis acid sites acting as proteases, so they are able to cut 
and disassemble complex protein.18  
Some literature data have demonstrated that they are able to penetrate cell’s membranes, 
characterized by a negative surface, even if they are also negatively charged species. POM 
cytotoxicity depends on POM composition.19 Considering HeLa cells, one of the most used 
type, IC50 of 80-90µM were usually found, although Mn or V substituted POMs have an 
IC50 lower than 10µM. 
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A major disadvantage, that has hampered they clinical development, is the lack of 
hydrolytic stability, resulting in the formation of smaller toxic species.20 Nevertheless, a 
second generation of POMs (TMSP and POMs decorated with organic pendants) is 
nowadays well developed, and there are several examples of stable POMs with enhanced 
activity, which are promising for their antitumoral properties. Other problems are the high 
molecular weight of POMs and their inorganic composition, while usually drugs are 
organic and with low molecular weight. These characteristics can be a problem in the 
blood flux and  to cross the blood brain barrier (BBB).21 On the other hand, the use of 
cargo macromolecules, in particular starch,22 liposomes,23 chitosan24 or 
carboxymethylchitosan (CMC)25,26 has shown that is possible to improve cellular uptake 
and stability of POM, while reducing their toxicity.  
Concerning the interaction with proteins, the formation of adducts with  serum protein was 
extensively studied in the last years. In particular interaction with serum albumin, bovin 
(BSA) or human (HSA), was deeply studied, also because albumin is the most abundant 
protein in blood plasma (40mg/ml) where it is important for interception, transport and 
transfer of bioactive molecules, aminoacids, lipids, drugs and metal ions. Moreover 
albumin facilitate hematic flux to organs, especially to liver, intestine, kidney and brain. It 
is clear how the study of POM albumin interaction is important for their use in medicinal 
application.12 
Common techniques to study this interaction are fluorescence, circular dichroism (CD), 
calorimetry (ITC and DSC) an UV-Vis spectroscopy. Fluorescence is the preferred one, 
indeed quenching of tryptophan (but sometimes also quenching of tyrosine or 
phenylalanine) allows to obtain Stern-Volmer binding constant, which are mainly static, 
due to electrostatic interactions of POM with the protein. Different polyoxometalates were 
studied, Keggin, Wells-Dawson and also POM substituted with transition metals or 
lanthanides. In this last case, using europium POM, an increase of POM’s fluorescence (up 
to 5 times) in the presence of albumin was observed,  due to the favorable competition of 
albumin with water molecules on the lanthanide (Figure 52).13 Usually, the binding 
constant fall between value of 5·104 e 107 M-1, depending on POM’s structure, charge and 
pH of the solution (usually around 7.4). Similar results are obtained by means of 
isothermal titration calorimetry (ITC) from which thermodynamic parameter could be 
obtained. Circular dichroism is used to investigate changes in secondary structure of the 
protein, indeed interaction with the polyoxometalate could drastically alter the CD signal, 
meaning that the protein structure is strongly altered. 
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Figure 52: Interaction of HSA with europium polyoxometalate, albumin-POM adduct enhance POM 
intrinsic fluorescence.13 
 
Recent studies have shown that polyoxometalates can also interact with amyloid peptides 
and display antiamyloidogenic activity. This interaction was confirmed by fluorescence, 
dichroism and ITC methods. In particular, the aggregation of the peptide in fibrillary 
structures was monitored using fluorescent probes (for example thioflavin T, ThT) that 
increase their fluorescence intercalating the aggregated peptide (forming β-sheet secondary 
structure). CD analysis demonstrated the β-sheet breaker activity of POM. The interaction 
efficiency depend on POM charge, dimensions and on presence of other transition metals, 
which may allow to establish a specific coordination. This interaction is mainly 
electrostatic, in the Aβ40-42 domain, where positive charged residues such as lysine, 
histidine and arginine, are localized.27 
 
 
Figure 53: Two different POMs (H2W12O406- and NaP5W30O11014-), with different charge and shape, that 
interact with an amyloid peptide (Aβ1-40).27 
 
Recently a polyoxometalate containing a nickel atom was used as antiamyloidogenic 
compound, in order to avoid amyloid aggregation, thanks to electrostatic interaction with 
the peptide, but also coordination of nickel atom by histidine residues, showing also an 
indirect anti-ROS effect. Indeed, the coordination of amyloids to POM, avoid interaction 
of these peptide with iron haem, interaction that could increase ROS production. 
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Furthermore, studies of stability and blood brain barrier (BBB) penetrations, have 
demonstrated that POM could pass through BBB, remaining intact, and suggesting its 
extracellular distribution into the brain.28 
 
 
4.2 Catalytic activity and inhibition of Tetranuclear Ruthenium (IV) 
polyoxometalate Na10[Ru4O4(OH)2(H2O)4(γ-SiW10O36)2] (17) in 
water solution 
 
The polyoxometalate studied is a tetraruthenium substituted polyoxometalate, firstly 
synthetized in our research group in 2008, and known for its oxygenic activity: indeed it is 
able to oxidize water and also to dismutate hydrogen peroxide. Its molecular formula is 
Na10[Ru4O4(OH)2(H2O)4(γ-SiW10O36)2] (RuPOM, 17) and it is characterized by an 
adamantane-like tetraruthenium core that can perform multi-electronic reactions, stabilized 
by two dilacunary decatungstosilicate anions [SiW10O36]8- (Figure 54).29 
 
 
Figure 54: Structure of Na10[Ru4O4(OH)2(H2O)4(γ-SiW10O36)2] (RuPOM, 17), in evidence the tetraruthenium 
core. It is possible to see from the image the two [SiW10O36]8- polyoxometalate scaffolds. in red oxygen 
atoms, in blue tungsten atoms and in grey silicon atoms. Ruthenium atoms are in green (magenta in the 
scheme on the right). 
 
The oxidation state of ruthenium atoms in the core is RuIV, while during the catalytic cycle 
all ruthenium atoms are supposed to oxidation state +V.30 It has a high negative charge (-
10) and is resistant to oxidative and hydrolytic conditions. For the aim of this thesis, the 
H2O2 dismutation is an added value that characterize this POM. In particular, the high 
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charge could promote interaction with amyloid peptides, while the catalytic activity and 
robustness are attractive features in the field of ROS elimination. 
RuPOM can act as artificial catalase, in particular in phosphate buffer (50mM) it can reach 
a TON of 2200 with a bimolecular rate constant k of 36.8M-1s-1.31 An even higher catalytic 
activity can be observed at higher pH, as shown by the increasing initial rates, 
R0pH7.8>R0pH7.4>R0pH7.0 calculated from the kinetics curves (Table 13, Figure 55). 
 
Table 13: Initial rate of hydrogen peroxide dismutation at different pH, H2O2 33mM, 15µM RuPOM in 12ml 
PBS 50mM, µmolO2 are calculated after 1h of reaction. 
pH R0 µMO2/s  µmolO2
7.0 7.11 157 
7.4 11.87 164 
7.8 26.4 172 
 
 
Figure 55: Kinetics trace of H2O2 dismutation by RuPOM at different pH, red pH 7.8, green pH 7.4, blue pH 
7.0. No oxygen evolution was registered without catalyst. 
  
In addition, the initial rates of oxygen evolution were determined by setting up different 
H2O2 decomposition experiments in the presence of 15 µM RuPOM, and varying the initial 
H2O2 concentration in a wide range ([H2O2]0=8-165mM). All experiments were performed 
in phosphate buffer (50mM) at pH 7.0 and 25°C. 
Data were analyzed collecting values of oxygen evolution rate, R0 (µmolH2O2/s), for each 
[H2O2]0 conditions. Fitting these experimental values, according to the Michaelis-Menten 
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equation, results in a well-behaved saturation curve (Figure 56) from which the kinetic 
parameters as Rmax (µmolH2O2/s) kcat (s-1) KM (mM) and kcat/KM (s-1M-1) (Table 14) can be 
extracted. 
 
Figure 56: Michealis-Menten graph (R0 vs [H2O2]). 
 
Table 14: Kinetics parameter obtained by Michaelis-Menten equation. 
Rmax (µmol H2O2/s) 3.43
kcat (s-1) 19 
KM (mM) 590 
Kcat/KM (s-1M-1) 32 
 
In other buffered solution, the activity of RuPOM can change drastically, depending on the 
buffer nature (Figure 57). Indeed, if a coordinating buffer is used, such as Tris or Hepes, 
catalase activity could be quite inhibited. Mops, that has some similarity with Hepes, does 
not affect much the activity of RuPOM.  
 
Figure 57: Some buffer molecules commonly used in biological assay (Tris, Mops and Hepes) and an 
addictive to selectively remove calcium ions (EGTA). 
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The addition of salts can influence the kinetics, how shown before for dimanganese 
complex 4, but in the case of RuPOM the addition of salts seems to increase the activity of 
the compound. Indeed in Mops buffer solution containing EGTA the kinetic is faster, if 
also KCl and phosphate are added, the rate of dismutation further increases. Finally, if a 
physiological buffer with carbonate, sulfate, chloride, potassium, sodium, calcium and 
glucose is considered, (Krebs-Henseleit: pH 7.4, NaCl 118mM, NaHCO3 25mM, KCl 
4.7mM, KH2PO4 2.15mM, MgSO4 0.6mM, CaCl2 1.69mM and glucose 2gr/l), it is 
possible to see that the activity is fully maintained (Figure 58). 
 
 
Figure 58: Kinetic traces of H2O2 dismutation by RuPOM, in different buffer but at the same pH. KH stands 
for Krebs-Henseleit buffer solution. 
 
The inhibitory effects of some classical catalase inhibitors such as cyanide, azide and 
aminotriazole were also tested on RuPOM, in order to assess the possibility of using 
RuPOM to assist a deactivated native enzyme. Unfortunately, like natural catalase, all 
these compounds partially or completely inhibit the catalyst. Azide is the least efficient 
inhibitor but it is able to slow the dismutation about 8 times with a conversion of only 20% 
after one hour, while the most powerful azide and cyanide inhibit the dismutation about 42 
and 475 times respectively, with a conversion of 4% and 2% after one hour (Figure 59). 
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Figure 59: Kinetic traces of H2O2 dismutation by RuPOM in the presence of different catalase inhibitors: 
aminotriazole (ATZ in red), cyanide (KCN in green) and azide (NaN3 in blue) whose structure are shown on 
the right, compared with a non-inhibited kinetic (black line). 
 
A comparison of RuPOM with natural catalase was done, but natural catalase is much 
more efficient in terms of initial rate and also catalytic efficiency, even at a concentration 
10 time lower than that of RuPOM (Figure 60). 
 
Figure 60: Kinetic traces of H2O2 dismutation by 15µM RuPOM (in red) and by 1.5µM of commercially  
available natural  iron-catalase (in black), in phosphate buffer at pH 7.0 and 33mM H2O2.  
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In the following table 15, some values of initial rate and turnover number (TON after an 
hour), of RuPOM, in different buffer solution, are reported, to have a global vision of 
buffer, inhibitors and pH effects. 
 
Table 15: Initial rate, TON and buffers used for H2O2 (33mM) dismutation by RuPOM 15µM at different pH 
and in the presence of inhibitors (30mM). TON is calculated as mole of H2O2 reacted per mole of catalyst 
after 1h. Comparison with bovine liver Fe catalase 1.5µM. 
 Compound Buffer R0 uMO2/s Time TON 
pH
 7
 
Fe-Catalase PBS 549.96 250s 16670 
RuPOM PBS 7.11 1h 1744 
RuPOM Tris 0.35 1h 64 
RuPOM Mops 5.65 1h 1511 
RuPOM + KCN PBS 0.015 1h 311 
RuPOM + NaN3 PBS 0.93 1h 61 
RuPOM + ATZ PBS  0.17 1h 41 
pH
 7
.4
 
RuPOM Mops+KCl+EGTA+Pi 14.16 1h 1778 
RuPOM Tris 0.53 1h 86 
RuPOM Hepes 0.74 1h 211 
RuPOM Krebs-Henseleit 17.43 1h 1889 
pH
 
7.
8 
RuPOM PBS 26.40 1h 1911 
RuPOM BBS 15.78 1h 1822 
 
SOD-mimicking activity of the polyanion was then investigated, using NBT and 
Xanthine/Xanthine oxidase assay, as described before for monomanganese and 
dimanganese complexes. In the presence of RuPOM,  however there is a lower production 
of  oxidized NBT, due to a moderate superoxide dismutation activity of POM. IC50 is about 
11µM, and the kinetic constant is 5.4·105M-1s-1. Although the latter is four orders of 
magnitude lower than natural SOD, it is still meaningful for a catalase-like catalyst. 
 
 
4.3 Interaction with amyloid peptides 
 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease. It is 
characterized by protein deposits called amyloid plaques that consist of aggregates of the 
small amyloid β peptide (Aβ).32 Although there are many hypothesis about this pathology, 
the amyloid cascade hypothesis explains how amyloid peptides are produced and how they 
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accumulate generating plaques, in particular it seems that short amyloid peptides can 
aggregate in oligomeric forms that assembles into fibrillar structure and produce 
precipitation of tangles of protein.28,33 Fibrillogenesis of Aβ can be divided in two steps: 
nucleation and elongation. Proteins rearrange in anomalous way: the hydrophobic portions, 
normally not exposed, become accessible and available to form soluble oligomers packed 
as  layered β-sheets. During fibrillogenesis, β-sheets are perpendicularly aligned along 
fibril axis. Fibrils have a diameter of 6-10nm, and are composed by protofilaments made of 
polypeptide (Figure 61a-c).34 Then, through a cascade reaction, insoluble fibrils are formed 
and finally plaques deposit, with further neurological damages. 
 
 
a b
c d  
Figure 61:  a)Scheme of fibrillation of amyloid peptides, b)model of fibrils; c) TEM image of partially 
formed fibrils and d) image of amyloid plaque in brain tissue.35  
 
The oligomeric form seems to be more toxic than fibrils, since they can interact and 
permeabilize cellular and mitochondrial membranes, forming channels into membranes 
and disrupting cell or mitochondrial homeostasis.36 Total and mitochondrial-associated 
amyloid Aβ of various length increase with age.  
Although there is a link between mitochondrial dysfunction and plaques formation, the 
upstream cause is still unclear.37 In addition, amyloid peptide impact on mitochondrial 
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functions, inhibiting enzymes involved in the electron transport chain (complex I and 
IV),38 thus causing impairment of oxidative phosphorylation and anomalous ROS 
production.39,40  
Moreover, metal dysregulation play a key role in pathogenesis of Alzheimer, indeed metal 
ions, such Zn2+, Cu2+ and Fe3+,  foster amyloid aggregation and become, once coordinated 
by asparagines, methionine, tyrosine and histidine of Aβ, a primary font of reactive oxygen 
species (ROS) via Fenton reaction.41,42,43,44 Hydrogen peroxide treatment of neurons45 and 
deficiency of mitochondrial enzyme MnSOD were shown to increase Aβ production and 
deposition.46 Within this scenario, ROS production is involved in all phases of the 
disease.47,48 
Aβ peptides are made of 40-42 aminoacids, and contain an hydrophobic region with a 
KVLFF49 amino acidic motif (AA16-20), which is main responsible to foster β-sheet 
formation and the subsequent oligomerization and fibrillation. There are also four main 
aminoacids, three histidines and one aspartate, that can bind metal atoms. For the tests in 
solution, three peptides of different length are usually studied, 1-40, 1-28, and 1-16 
because of their good solubility and less tendency to aggregate, while amyloids 1-42 are 
mainly used for biological tests rather than chemical experiments because their aggregation 
is extremely fast (Figure 62).50 
 
 
Figure 62: Amino acid sequence of  most abundant amyloid peptides Aβ40 and Aβ42, and two most studied 
shorter fragments, Aβ28 and Aβ16 used for their higher solubility respect to longer peptides. Coordinating 
amino acids are colored, in red the four main coordinating.50 
 
In the last years, research has focused on the inhibition of peptide aggregation to prevent 
fibril deposit and then the related dysfunction. Crystallographic structures of amyloid-like 
fibrils suggest that steric zipper interface between highly ordered parallel and antiparallel 
beta sheet is an essential element of fibril formation, so that diverse beta-sheet breakers 
have been investigated.51 Examples include the use of short peptides and 
aromatic/hydrophobic  molecules. Among the molecules that have been tested as inhibitors 
of fibrillation, we find fullerene,52 quinones,53 isopeptide,54 or recently cucurbit[7]uril.55 
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Metal mediated aggregation represents another major contribution towards 
fibrillogenenesis. As confirmed by NMR studies, indeed three histidine residues (His6, 
His13 and His14) can interact with metal centers, which can, in turn, assist further 
aggregation between peptide chains.56 A competition with these binding site is thus another 
possible strategy to inhibit the aggregation. Being His present on the initial fragment, 
shorter Aβ fragments, such as 1-28 can also be used for studying the interaction with 
metals.57 In the last few years polyoxometalates were also tested as anti-amyloidogenic 
compounds, showing that they are able to prevent fibril formation, as confirmed by 
thioflavin assay, CD measurement, enzyme digestion, fluorimetric titration and ITC 
analysis.27,58 As for the interaction with other proteins and enzymes, the anti-fibrillation 
effect is mainly due to the ionic interaction with positively-charged aminoacids (mainly 
His13–Lys16 region, HHQK cluster), with a stoichiometry depending on charge and 
dimensions of the POM. PC12 cells incubated with Aβ and Dawson-POM mixtures 
(Aβ:POMs =5µM:10µM) were shown to increase their survival up to 90%, being POM 
cytotoxicity negligible at the same concentration.58a   
Moreover, transition metal substituted Dawson POMs ([P2MW17O61]8- with M=NiII or 
CoII) can selectively interact with histidines residues of amyloid peptide (HHQK),59 
showing a higher binding constant (up to 6.44 times) than non-substituted Dawson POM, 
with 1:1 stoichiometry. In this case the POMs were tested in vivo, and they were found to 
be beneficial for inhibiting the peroxidase activity of haem-binding β-Amyloid. In 
addition, the authors suggested that the POM could distribute extracellularly in the brain, 
where Aβ aggregates predominately exist, being able to cross the BBB and remaining 
intact.59 
The use of anti-aggregation agents, has shown to be only scarcely useful to limit 
neurodegenerative affects. Chelation therapy, used to scavenge redox active transition 
metals in the brain,60 or the administration of  antioxidant molecules (polyphenols) are also 
pivotal to limit ROS damages.53,61 As already demonstrated in the previous chapter, 
catalytic ROS scavenger would be more useful thanks to their prolonged activity. Within 
this scenario, multitask compounds represent a major goal. For example, salen Mn 
complexes with superoxide (SOD) activity were used as ROS scavenger and were also 
shown to inhibit lysozyme aggregation.62 
RuPOM has been studied to assess its dual activity, the ability to inhibit Aβ fibrillation 
and, at the same time, to reduce oxidative stress.63 
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First of all, the interaction of RuPOM with amyloid peptide 1-40 was studied exploiting 
the intrinsic fluorescence of tyrosine, exciting at 270nm and recording the fluorescence at 
305nm. Amyloids were titrated with RuPOM, and the fluorescence was corrected in order 
to take in account dilution and absorbance of POM. Plotting POM concentration vs F0/F 
(Initial fluorescence divided by observed fluorescence) allows to calculate Stern-Volmer 
constant of the static quenching occurring with the interaction (Figure 63). 
 
 
 Figure 63: Stern-Volmer graph of Aβ 1-40 titrated with RuPOM. λex = 270nm; λem = 306nm.  
 
The plot gives a Stren-Volmer binding constant value, KSV, of about 1.3·105 M-1, which is 
in agreement with the literature values found for other POMs, around 105-106 M-1 
depending on POM structure and charge.58 
After fluorescence studies, circular dichroism (CD) analysis was performed over time to 
evaluate the effect of RuPOM on β-sheet formation. It is know that Aβ forms beta sheet 
after incubation at 37°C for 1-2 weeks. As for other polyoxoanions, RuPOM incubated at 
37°C for 2 weeks is able to avoid the formation of beta sheet of amyloid 1-40 and also the 
formation of fibrillary species. Indeed while Aβ incubated at 37°C for 14 days, without 
POM shows the classical change of conformation from random coil to α-helix and finally 
to β-sheet secondary structure, that is responsible for oligomerization and fibril formation. 
In the presence of POM, instead, there is no formation of β-sheet, as it is possible to see 
from CD curves (Figure 64).  
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Figure 64: CD spectra of Aβ 1-40 with (yellow, after 14 days) and without RuPOM at t=0 (blue line), t=7 
days (green line) t=14 days (red line); RuPOM has no CD signal (not shown). 
 
Considering fragment 1-40 alone it is possible to observe the conformation change from 
t=0 random coil (blue line), to alpha helix (t=7 days, green line) and finally to beta sheet, 
(t=14 days, red line). In particular, the minimum moves from 200nm (random coil), to 
about 215nm, as expected for the typical β-sheet curve. Yellow line indicates amyloid 
incubated 14 days at 37°C in the presence of 1 equivalents of RuPOM. As expected, the 
dichroic signal was lower and during the incubation we did not see any change due to 
conformation evolution. 
 
A parallel TEM analysis of peptide incubated, confirms the inhibition of fibrillation, as it is 
possible to see after 14 day incubation with and without 1eq of RuPOM. Amyloid 1-40 
alone, after 14 days incubation, shows quite long and ordered fibrillar structures with 
length up to 2µm and pre-fibrillar aggregates are also visible (Figure 65 left), instead 
amyloid 1-40 incubated in the presence of POM shows disordered aggregates (Figure 65 
right).  
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Figure 65: TEM micrographs of Aβ 1-40 (80µM) without (left) and with 1eq. of RuPOM (right). 
 
So RuPOM has good anti-fibrillar properties and also the capability to avoid formation of 
beta-sheet from random coil peptide. The common ThioflavinT (ThT) experiments, based 
on ThT fluorescence increase during the aggregation of β-sheet structures, could not be 
performed, because RuPOM interaction with ThT and competitive absorbance do not 
permit to follow the increase of fluorescence during amyloid incubation. So it was 
impossible to track the kinetics of fibril formation with this technique. As said before, 
Aβ42 shows an even higher tendency to fibrillogenesis, so it is quite  difficult to follow 
fibrillation kinetic. After four days of incubation of Aβ42 (80µM), treated with 
hexafluoropropanol to disaggregate the peptide, it is possible to see the variation of the 
dichroic signal at 220nm, that become more negative, and also at about 200nm, that 
become bigger. In the presence of 0.1eq. (8µM) of RuPOM, the band at 220nm keeps, 
more or less, the same intensity, while there is a significant change in the region <200nm, 
where the Cotton effect becomes negative after 4 days incubation with POM (Figure 66). 
This experiment proofs the capability of RuPOM to avoid or to slow the production of beta 
sheet ad so the fibrillation of these peptides. 
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Figure 66: CD spectra of Aβ1-42 (Amy, 80µM) incubated without RuPOM (black line t=0, orange line after 
4 days)  and with 8µM RuPOM (red line RuPOM alone, blue line t=0 and green line after 4 days). 
 
To better understand the nature of this interaction with amyloidogenic peptides, an 1H-
NMR study was made on a shorter peptide. Due to the low solubility and extremely high 
tendency of the Aβ 1-40 and 1-42 to aggregate, the 1-28 peptide chain has been initially 
chosen as a model fragment to establish the interactions between the POM and the peptide 
chain. As shown before, this fragment has the following aminoacidic sequence, 
DAEFRHDSGYEVHHQKLVFFAEDVGSNK, and it contains three His residues that 
could be important for metal coordination. In addition, it is more stable in water and 
display a lower propensity to aggregate in solution. The 1H-NMR spectrum of Aβ28 
(200µM) was recorded, than 0.2 equivalent of RuPOM were added from a concentrated 
stock solution. The first effect observed was a general broadening of all signals, even if 
with sub-stoichiometric RuPOM. Interestingly, the same broadening effect is reported in 
the literature for the addition of 0.2 equivalents of zinc or cadmium solution suggesting the 
occurrence of equilibria involving proton exchange.64 We have focused our attention on 
the signals above 6.7 ppm, where aromatic residues display well resolved signals: 7.78-
7.73 ppm and 6.88-6.96 ppm for histidine (His), 7.01 and 6.73 ppm for tyrosine (Tyr), 7.12 
ppm for phenylalanine (Phe). In particular, His signals have a much lower intensity or 
disappear, already after addition of 0.2 RuPOM equivalents, thus suggesting the 
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occurrence of a strong interaction between His and RuPOM (Figure 67). With 0.4 
equivalents of RuPOM added, the broadening of the spectrum becomes even more 
pronounced, with disappearance of most of the signals (not shown). 
 
 
Figure 67: Aromatic region 1H-NMR spectra of Aβ 1-28 with (top) and without (bottom) RuPOM. 
 
NMR experiment confirms the interaction of RuPOM with the amyloid peptide. Beside 
histidine residues of Aβ28, also acidic residues like aspartic or glutamic acids could 
coordinate. In addition, the general broadening could be due to electrostatic interaction 
between the positive residues of peptide and the negative charge of POM. Future 
investigations will be performed with longer peptide 1-40 to have a more complete idea on 
the coordination mode. 
To achieve the goal of the dual activity, RuPOM should retain its activity once coordinated 
to Aβ. So, the effect of amyloid on the CAT  activity was tested, using the same fragment 
1-28. Oxygen evolution was monitored at 1:1 and 1:2 ratio of RuPOM and Aβ28 (Aβ 
concentration was fixed at 10µM, while RuPOM concentration was 5 and 10µM). The 
corresponding experiments without amyloids were also performed. Although coordination 
of peptide to catalytic active site reduces the reactivity of POM (Figure 68), a complete 
H2O2 dismutation can still be achieved, so that anti-ROS properties of RuPOM are partially 
maintained, especially with 1:1 amyloid/POM ratio. 
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Figure 68: Kinetics trace of H2O2 evolution in the absence and in the presence of amyloid 1-28 (10µM) and 
in the presence of 5-10µM of RuPOM. 
 
In Table 16, kinetic data have been collected. Entries 2 and 4 show that the initial rate in 
the presence of amyloid peptides are about 50% lower, that the complete conversion of 
hydrogen peroxide to oxygen and water is achieved in a longer time, especially at lower 
catalyst concentration. The turnover number (TON) remains high, while obviously TOF 
values decrease because of lowering of the reaction rates. 
 
Table 16: Initial rate, TON, TOF and yield of H2O2 disproportion by RuPOM at different concentration 
alone and in the presence of Aβ28. 
# RuPOM Aβ 1-28 R0 µmolO2/s TON (2h) TOF s-1 (2h) Yield (Time) 
1 5µM - 0.01435 5333 0.74 >99(4.5h) 
2 5µM 10 µM 0.00689 933 0.13 80 (25h) 
3 10µM - 0.03033 3300 0.46 >99 (2h) 
4 10µM 10 µM 0.01482 2766 0.38 >99 (4.5h) 
 
 
Furthermore, we have studied the anti-ROS effect of RuPOM, using 2’,7’-
dichlorofluorescein diacetate (H2DCF) a molecular probe commonly used to monitor 
oxidative stress in vitro. Once the diacetate form enters into the cell it is cleaved by 
esterase enzyme, being thus trapped within the cell. When ROS are present, the non-
fluorescent H2DCF is oxidized to DCF, becoming fluorescent (Scheme 15).65 
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Scheme 15: Scheme of oxidation of 2’,7’-dichlorofluorescein (H2DCF) in the presence of ROS with the 
formation of the fluorescent form (DCF) (λex: 490nm, λem: 525nm). 
 
In a typical experiment, H2DCF (5µM) and H2O2 (50µM) were mixed, in the presence of 
POM. In this case we used RuPOM and a nickel containing POM ([P2NiW17O61]8-
NiPOM), known in literature to have antiamyloidogenic properties and some indirect 
effects that limit ROS production thanks to Aβ coordination, however it has not anti-ROS 
activity (CAT-like) as RuPOM. The activity of RuPOM in limiting the production of DCF 
was compared with NiPOM (and with a blank experiment) following the increase of 
fluorescence at 525nm (Figure 69, λex: 490nm).  
 
 
Figure 69: Increasing of DCF (5µM) fluorescence in the presence of H2O2 (50µM): alone (black line), with  
8µM RuPOM (red line) or NiPOM (blue line). Inset: histogram of normalized intensity after 1400s. 
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In the presence of RuPOM, the increase of fluorescence due to DCF formation is slower, 
meaning that part of hydrogen peroxide was scavenged by RuPOM before forming radical 
species. Instead, in the presence of NiPOM there is a continuous increase of fluorescence, 
as for the POM-free experiment. Increase of DFC fluorescence, using different H2O2 
concentration was also performed, with a plate reader, with and without RuPOM and 
NiPOM for a longer time (20h). While with 5-50µM of H2O2 (1-10eq.) there are little 
differences with respect to blank experiment (no H2O2), in the presence of 500µM (100eq.) 
of H2O2 it is possible to obtain a strong fluorescence enhancement (Figure 70, left). Such 
H2O2 concentration was thus chosen to evaluate RuPOM effect. Indeed, the extent of DCF 
oxidation can be decreased of about 80% with respect to either POM-free or Ni-POM 
experiments (Figure 70, right).  
 
 
Figure 70: 5µ DCF oxidation in the presence of  5-500µM H2O2 (left) and in the presence of 500µM H2O2 
and 8µM of POM (right). 
 
These experiments confirm protective effect of RuPOM against reactive oxygen species. In 
the next chapter cytotoxicity studies will be presented, including the DCF experiment in 
vitro. 
 
 
4.4 Toxicity in cell and protective effects in the presence of amyloids 
 
In collaboration with Dr. Loredana de Bartolo and Dr. Sabrina Morelli (ITM-CNR Rende, 
CS) some biological tests were performed on neuronal cells culture. Since the aim of this 
part of thesis work is to use RuPOM against Alzheimer’s disease, toxic effect of POM and 
its anti-ROS/anti-amyloidogenic effects in the presence of amyloid peptides were 
0 2 4 6 8 10 12 14 16 18 20
0
50
100
150
200
250
300
350
I (
a.
u.
)
Time (h)
 DCF 5uM
 DCF 5uM H2O2 5uM
 DCF 5uM H2O2 50uM
 DCF 5uM H2O2 500uM
0 2 4 6 8 10 12 14 16 18 20
0
50
100
150
200
250
300
350
400
I (
a.
u.
)
Time (h)
 DCF 5uM H2O2 500uM
 DCF 5uM H2O2 500uM RuPOM 8uM
 DCF 5uM H2O2 500uM NiPOM 8uM
Polyoxometalate against degenerative disease 
107 
 
evaluated. So all the tests have been done in the presence of amyloid 1-42, Aβ42, checking 
the toxicity of this peptide alone and comparing the results in the presence of RuPOM. 
Neuronal cells were growth on polycaprolactone-polyurethane (PCL-PU) membranes to 
recreate a neuronal  bio-artificial system. 
First of all, toxicity of RuPOM on neuronal cells was evaluated, monitoring cell viability in 
the presence of different concentrations of compound (Figure 71). 
 
 
Figure 71: Viability of neuronal cells in PCL membrane system after 24 hrs of treatment with various 
concentrations of RuPOM (colorimetric MTT assay). 
 
How it is possible to see, RuPOM has no toxicity on neuronal cells culture and viability of 
cells remains near control values at concentration as high as 100µM. A further study was 
performed monitoring the overall activity of endogenous enzymes as an indirect method to 
evaluate cell viability. In particular, specific fluorimetric  assays allows to evaluate natural 
catalase (CAT) and glutathione peroxidase (GPx) activity. Although these should eliminate 
ROS from cellular environment, in case of sever oxidative stress their activity is not 
enough to prevent cellular damages, resulting, in turn, in a generally lower cellular activity.  
While in control experiments, without H2O2, enzymes have quite high activity, in the 
presence of hydrogen peroxide there is a reduction of their reactivity. The reference 
NiPOM shows no effects on such behavior. On the contrary, RuPOM is able to protect the 
enzymes against ROS induced damages (Figure 72). 
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Figure 72: Quantitative determination of antioxidant enzyme activities: (left) catalase (CAT) and (right) 
Gluthatione peroxidase (GPx) in cells under oxidative stress with and without POMs. 
 
From these experiments, it is clear that there RuPOM could be a great help in the ROS 
detoxification in cells under high oxidative stress conditions. 
Then, the effects of POM on neuronal cells treated with Aβ42 were studied. So, viability of 
cells treated with amyloid peptides, incubated alone or in the presence of RuPOM at 
different concentration, was evaluated with an MTT assay (see Experimental Part), 
showing the protective activity of RuPOM against amyloid cytotoxicity (Figure 73 left) 
and confirming the non-toxicity of RuPOM. Furthermore, antioxidant properties were 
evaluated using DCF as probe of ROS production in the presence of Aβ. Neuronal cell 
incubated with Aβ42, without and in the presence of three different RuPOM concentration, 
were analyzed by Laser Scanning Confocal Microscopy (LSCM), exploiting the 
fluorescence of oxidized DCF. In the presence of amyloid peptide there is a great 
fluorescence increase, meaning that there is an high ROS production (Figure 73 right), 
with RuPOM, fluorescence intensity is lower, near to control values, meaning that it has a 
protective effect against A-mediated oxidative stress. 
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Figure 73: Aβ42 (5µM) incubated with or without RuPOM added to neuronal cells; the cell viability was 
measured using MTT assays (left). Quantitative analysis of fluorescence intensity of DCF produced in 
neuronal cells incubated with Aβ42 (5µM ) alone or with a mixture of Aβ42 and RuPOM for 24h (right). 
 
Cytotoxicity of amyloids, and protective effects of RuPOM were also evaluated checking 
apoptotic cells by monitoring fluorescence signals due to activation of caspase 3 (Casp3) 
and phosphorylated Jun protein kinase (p-JNK).§ The percentage of apoptotic cells was 
calculated by the ratio of apoptotic nuclei (caspase-3 positive nuclei and p-JNK positive 
nuclei) over total nuclei (DAPI-stained nuclei) counted at different culture conditions 
(Figure 74). 
 
 
Figure 74: Confocal laser micrographs of neuronal cells without treatment (left), incubated for 24h with Aβ 
5µM) alone (middle) and co-treated with Aβ and RuPOM 10µM (right). Cells were stained for p-JNK (red), 
caspase-3 (green) and nuclei (blue). 
                                                          
§ The apoptosis of cells was determined by analysis of active N-terminal c-Jun protein kinase (p-JNK) and 
Caspase-3, expressed in dead cells. Since p-JNK and Caspase-3 are involved in the apoptotic process, it is 
possible exploit their production to calculate the percentages of apoptotic cells in a culture. Using two 
different fluorimetric assays, the presence of Caspase-3 and p-JNK could be evaluated in cells incubated in 
the presence of β-amyloid peptide and with or without POM. 
Polyoxometalate against degenerative disease 
110 
 
How it is possible to see from histogram, obtained by fluorescence measurements in figure 
75, in the presence of only amyloid peptide, percentage of apoptotic cells revealed by 
Casp3/JNK is very high. Instead if RuPOM is present, activation and cleavage of these two 
proteins, that are involved in the apoptotic process, is much lower, similar to control 
experiment, meaning that there is a protective effect of RuPOM on cell apoptosis induced 
by amyloid peptides. 
 
 
Figure 75: Quantitative analysis of p-JNK (full bar) and Caspase-3 (empty bar) activity. The percentage of 
apoptotic cells was calculated by the ratio of apoptotic nuclei (caspase-3 positive nuclei and p-JNK positive 
nuclei) over total nuclei (DAPI-stained nuclei) counted at different culture conditions. 
 
Finally mitochondrial function in cells was evaluated measuring mitochondrial membrane 
potential (MMP), using a potential-sensing fluorescence probe, in the presence of amyloids 
and amyloids and RuPOM. It is clear from the graph (Figure 76) that in the presence of 
amyloid peptides MMP decrease, meaning that mitochondria are damaged by Aβ. On the 
contrary if RuPOM is present, MMP returns at normal values also in the presence of 
amyloids. So another protective effects of POM is proved. In the next chapter, considering 
the importance of mitochondria in ROS production the study will focus on the effects of 
RuPOM on isolated mitochondria. 
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Figure 76: Mitochondrial membrane potential in neuronal cells measured with potential-sensing fluorescent 
probe, JC-1(λex:514nm, λem:529nm). The fluorescence intensity of both mitochondrial JC-1 monomers and 
aggregates λex:585 nm, λem:590 nm) in the presence of Aβ alone or in a mixture with RuPOM at different 
concentrations. 
 
 
 
4.5 Mitochondrial toxicity test 
 
Likewise dimanganese complex 4, it was not possible to evaluate a positive effect of 
RuPOM on isolated mitochondria, whose respiration was artificially blocked by selected 
inhibitors. So, the toxic effects of the polyanion was studied, as discussed above, analyzing 
the respiration of mitochondria, as oxygen consumption rate, in the presence of different 
concentrations of RuPOM.  
Respiration of isolated mitochondria at different RuPOM concentrations was analyzed 
using Mops buffer (20mM) at pH 7.4, containing potassium chloride (120mM), EGTA 
(10µM), phosphate (1mM), an example of experiments is shown in figure 77. 
RuPOM effects starts already at 5µM and become more evident at ≥10µM, and can be 
summarized as follows: 
(i) The rate of oxygen consumption during phosphorylation process (State3/St3), is 
lowered, suggesting a small inhibitory effect on mitochondrial respiration  
(ii) There is an increase of basal respiration (State2/St2 or State4/St4, after 
phosphorylation), suggesting a slight uncoupling effect of RuPOM (meaning 
that it disrupts a little bit the protonic gradient of the mitochondria) 
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(iii) RuPOM seems to inhibit phosphorylation rate (State3 rate), indeed oxygen 
consumption decreases increasing RuPOM concentration. 
(iv) Considering Respiratory Control Ratio (RCR, ratio between State3 and State2, 
St3/St2), it is possible to notice that already at 5µM there is a decrease of the 
value, meaning that mitochondria are not in good conditions.  
  
 
Figure 77: Graph of mitochondrial respiration in the presence of different RuPOM concentration (2.5-
30µM), effects of RuPOM can be seen at ≥10µM (blue line). 
 
At concentration of 30µM it is almost impossible to discriminate between the different 
respiration states and at 100µM there is no differences in oxygen consumption (Table 17). 
 
Table 17: Table of oxygen consumption rates (nmolO2·mg protein-1·ml-1) with different RuPOM 
concentrations (average value and standard deviation on three measurements). 
RuPOM µM 0 5 10 30 100 
St 2 4.17±0.09 5.19±1.01 4.44±0.51 4.61±0.53 3.50±0.02 
St 3 13.48±6.66 6.09±1.70 9.65±3.13 4.69±0.67 3.50±0.02 
St 4 4.76±1.82 5.77±1.18 5.21±1.42 4.61±0.53 3.50±0.02 
St Un 14.44±3.16 2.26±0.93 7.81±2.93 4.43±0.22 3.50±0.02 
St 3/St 2 3.22±1.51 1.24±0.52 2.14±0.43 1.02±0.03 1.00±0.00 
St Un/St 2 3.04±0.07 0.42±0.09 1.73±0.45 0.95±0.06 1.00±0.00 
 
To better understand the effects of the RuPOM transmission electron microscopy analysis 
(TEM) of isolated mitochondria, incubated 5 and 50 minutes with RuPOM 5µM (also 
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without for control experiment) was performed. Mitochondria incubated with RuPOM 
seem to be swelled and there are much more mitochondria broken after 50 minutes 
incubation with RuPOM. However, also mitochondria incubated alone, after 50 minutes, 
were not completely intact (Figure 78). Staining of samples with uranyl acetate was 
necessary to mark and define the mitochondria for TEM analysis, but this treatment 
strongly interferes with the recognition of RuPOM. However TEM images suggest that 
probably RuPOM could act on mitochondrial pores, leading to organelle’s rupture. 
 
 
Figure 78:TEM of isolated mitochondrial after control incubation of 5 minutes(a) and 50 minutes(b) without 
POM and mitochondria incubated in the presence of 5µM RuPOM for 5 minutes(c) and 50 minutes(d). 
 
Calcium Retention Capacity (CRC) analysis have been  performed to evaluate the effects 
of RuPOM on the mitochondrial permeability pores and confirm some swelling effects. 
CRC analysis were done in the absence and in the presence of RuPOM at different 
concentrations, also with cyclosporin A that postpones pore opening. Effectively RuPOM 
anticipates pore opening already at 2.5µM concentration, at 10µM concentration of 
RuPOM pore opens at half calcium concentration with respect to the control (Figure 79). 
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An interesting observation is that these pores are in the inner mitochondrial membrane, so 
that this could be an indication of POM entering also in mitochondria, despite their 
negative charge. With cyclosporin A, the pores opening occurs at higher calcium 
concentrations, and in the presence of RuPOM and cyclosporin A the pores opening is 
postponed to [Ca2+] of 85µM instead of 40µM that is however lower than the control 
experiment without RuPOM (180µM) (Figure 80). 
 
 
Figure 79: CRC graph of isolated mitochondria in the absence (black line) and in the presence of different 
concentrations of RuPOM: 10µM (orange line), 5µM (red line), 2.5µM (blue line) and 1.25µM (green 
line).The arrows indicate the additions of calcium chloride and the total concentration added. 
 
 
Figure 80: CRC graph of isolated mitochondria in the presence of cyclosporin A with/without RuPOM (blue 
and orange lines) compared  with blank experiment without cyclosporin A (red and black lines). 
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In the following table 18 are resumed the concentration of calcium chloride added until 
there is the opening of the pores. 
 
Table 18: Calcium concentrations at which there is pores opening in the presence of different RuPOM 
concentrations and in the presence of cyclosporin A (on the right). 
 Without Cyclosporin A With Cyclosporin A (1µM) 
RuPOM 0 µM 1.25 µM 2.5 µM 5 µM 10 µM 0 µM  5 µM 
Opening, µM di Ca2+ 70 70 60 40 30 180 85 
 
 
 
 
4.6 Encapsulation 
 
In this final part, the engineering of a suitable carrier system for POM delivery into cells 
was investigated, with the aim to enable tissue targeting and controlled POM release. 
 
In collaboration with Dr.ssa L.L. del Mercato (NLL, Lecce) RuPOM was encapsulated into 
biocompatible polymeric multilayer capsules (PMC). These microcapsules were prepared 
by a layer-by-layer deposition of charged polymer on a templating core of calcium 
carbonate, formed in situ around a dextran core. After removal of the template CaCO3 by 
EDTA treatment, these capsules display a typical “core-shell” structure. The core dictates 
the volume of the capsule and is the place where macromolecules or nanoparticles can be 
encapsulated. The shell is stable after the removal of the template and its function is to 
temporary protect the core and its content, but it could also be modified with molecules for 
biological targeting or loaded with ionic species to be sandwiched between the layers.66 
In more complex systems, core and shell could be loaded with different molecular 
functions, including fluorescent probes, to enable their localization. The layers are 
permeable to small molecules, and designed to permit the release of the encapsulated 
species, better if after an external stimulus (change of pH or radiations) or after 
biodegradation. 25,67 
For RuPOM delivery capsules were prepared as follows (Scheme 16): 
1) Dextran labelled with fluoresceine isothiocyanate (FITC) was settled in the core. 
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2) Alternated layers of negative polystyrene sulfonate (PSS) and positive  
polyallylammonium (PAH) were used to build up the shell.  
3) A single layer of RuPOM is usually introduced  in the middle of the shell, after a 
positive polymer (PAH) and before a layer of negative polymer (PSS) that saturates 
the positive sites.  
 
 
Scheme 16: Synthetic steps for capsule formation. 
 
In the first case capsules with dextran (labelled with fluorescein isothiocyanate) in the core 
were synthesized, and RuPOM was embedded between two double layer of polymers with 
the following composition (PSS/PAH)2RuPOM(PSS/PAH)2. These capsules, as observed 
by optical/fluorescence microscopy a diameter near 3µm (Figure 81). 
 
      
Figure 81: Images of multilayer microcapsules at optical microscope and at fluorescence microscope (with a 
filter at 488nm), with a core of FITC-dextran and with different polymeric coating, with PSS and PAH (on 
the left) and with dex-S and pArg (one the right).  
 
The uptake of RuPOM can be easily  calculated from UV-Vis measurement, measuring the 
absorbance (λ:270nm, ε270:74846M-1cm-1) of the POM solution before encapsulation, and 
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of the supernatant solution and washing solutions after encapsulation. The spectrum of 
capsules confirms the uptake of RuPOM (Figure 82). 
 
Figure 82: Absorption spectra of RuPOM alone (top left), polymers Dex-S and pArg alone(top right) and 
capsules Dex-FTIC(Dex-S/pArg)2RuPOM(Dex-S/pArg)2 (bottom). 
 
ESEM, TEM and EDAX analysis confirm both the dimensions and the RuPOM presence 
into the capsules, as it is possible to see from the mapping of the heavy elements 
distribution within the capsule outer shells. This is highlighted by the bright contour 
profiles of EDAX/ESEM superimposable images  indicating that the tungsten sites of the 
POM catalyst are localized at the peripheral rim of the spherical micro-structure, with an 
even distribution and in agreement with the fabrication planning (Figure 83). 
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Figure 83: a) Fluorescence microscopy image of capsules, b) TEM image of a capsule, c) EDAX 
microanalysis and d) image and W maps obtained by ESEM/EDAX. 
 
ICP-MS measurements confirmed RuPOM concentration, equal to 0.046% (w/w), obtained 
by UV-Vis analysis. The W/Ru ratio found, 4.5±0.7, corresponding to about 0.6 fmol per 
capsule, (calculated value W/Ru=4). FTIR analysis of capsules (Figure 84) confirms POM 
encapsulation, indeed typical W-O-W stretching (780-800cm-1) and Si-O stretching  
(940cm-1) of RuPOM are clearly visible in the spectrum, while they are not present in 
blank capsules without RuPOM.  
Polyoxometalate against degenerative disease 
119 
 
 
Figure 84: FTIR spectra of blank capsules (green), RuPOM containing capsules (red) and RuPOM alone 
(blue).  
 
So, the confinement of the RuPOM cargo is assessed by three lines of evidence: FTIR 
spectra,  inductively coupled plasma mass spectrometry (ICP-MS) and  environmental 
scanning electronic microscopy (ESEM), coupled with energy dispersive X-ray (EDAX) 
analyses. 
RuPOM containing capsules retain the catalytic activity for hydrogen peroxide 
dismutation, however the reaction is much slower than the homogenous one, this is 
probably due to coverage of POM by the polymers, that although it is permeable, slow 
down the dismutation process. Furthermore there is a inhibitory effect of 
polyallylammonium (PAH), as it is possible to see from kinetics experiments carried out 
with RuPOM in the presence of different PAH concentrations (0.2 and 0.02mg/ml). The 
higher is the PAH concentration, the higher is the inhibitory effect of the polymer.  
It was possible to estimate a POM activity into capsules, that resulted to be equal to 7% 
compared to free POM solution, at the same nominal concentration, 3.6µM, considering 
the initial rate. While in the presence of homogeneous POM and PAH 0.02mg/ml and 
0.2mg/ml the POM activity was respectively 48% and 5% of initial rate. 
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Figure 85: Kinetics of H2O2 (0.1M) dismutation by RuPOM capsules (blue) and by an homogenous 
equimolar solution of RuPOM (3.6µM, in red). Comparison with homogenous solutions of RuPOM 
containing 0.2-0.02mg/ml PAH (green-violet).  
 
FTIR analysis of capsules after the dismutation reaction, separated by centrifugation and 
washed with water, confirm the stability of the capsules and the maintenance of RuPOM 
into the system (Figure 86). 
 
 
Figure 86: Zoom of FTIR analysis of blank capsules (blue), RuPOM containing capsules (red) and RuPOM 
containing capsules after the reaction with H2O2 (green). 
 
Preliminary tests in HeLa cells have confirmed the uptake of the capsules into the cellular  
membrane. Analogue capsules, whose shell was build up using negative dextran sulfonate 
(Dex-S) and positive polyarginine (pArg) are currently under investigation to evaluate the 
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possibility to achieve a controlled release in an oxidative environment. In the future, 
indeed, these systems will be tested in vitro, within cells under oxidative stress.  
 
 
4.7 Conclusions 
 
In conclusion of this part, a completely inorganic compound, a polyoxotungstate, 
containing a tetraruthenium core, has been studied as artificial catalase with possible 
application in Alzheimer’s disease. Indeed, exploiting its high negative charge and the 
presence of exchangeable water ligands coordinating the Ru ions, amyloid peptides interact 
with the POM without starting the fibrillogenesis. The antiamyloidogenic activity was 
demonstrated using fluorimetric techniques, circular dichroism and TEM analysis. A NMR 
analysis has confirmed that coordination of ruthenium with histidine may play a crucial 
role in limit amyloid toxicity, not only for the reduced aggregation, but also because the 
coordination of ruthenium avoid coordination of reactive metal centers like iron or copper, 
able to give enhanced ROS production once coordinated. Catalase activity has been studied 
in different buffered solution and has been compared with other complexes known in 
literature. The anti-ROS activity of RuPOM has been checked also in the presence of 
amyloids, and despite the lowered rate of dismutation, complete elimination of hydrogen 
peroxide could be reached. Biological experiments have confirmed the positive effect of 
POM also in cellular culture, showing low toxicity and great effects against amyloid 
cytotoxicity oxidative stress. Toxicity on isolated mitochondria is more relevant, and only 
very low concentrations of RuPOM are admissible, however it should be considered that 
the experiment  was done on isolated organelles, not in a real condition. Furthermore 
measurements seem to confirm that RuPOM is able to enter in mitochondria, that have an 
high negative charge of their outer membrane and maybe also interact with ATPase and 
other inner membrane proteins. Finally, encapsulation of RuPOM into multilayered 
polymeric capsules has been considered for addressing the delivery issue. 
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In conclusion, in this dissertation, some synthetic compounds, based on transition 
metals (Mn and Ru), have been evaluated as promising artificial catalase (CAT) and 
superoxide dismutase (SOD) mimicking, for their possible application as ROS 
scavengers in biological environment. In particular, the following metal complexes and 
nanosystems were investigated: 
I. Mononuclear manganese complexes bearing a tris-pyridyl pentadentate ligand 
with a NXNXN binding motif (X=N,O or S, Table 19, entry 1). With respect to 
existing mononuclear Mn compounds, we found (for X=S) an interesting yield 
and initial rate, with an unprecedent dual CAT/SOD reactivity and excellent 
stability, also in aqueous solution. 
II. Dinuclear manganese complexes with general formula [Mn2L2X] (Table 19, entry 
2). In this case a comparison with other literature compounds was performed by 
analyzing enzymatic Michaelis-Menten parameters. In aqueous solution, they 
result to be the best dinuclear complexes (not only of Mn) in terms of catalase 
reactivity, and they are also active in superoxide dismutation. Toxicity tests, 
performed on isolated mitochondria, revealed no toxicity till 50µM concentrations. 
Modification of apical bridging carboxylate with mitochondriotropic 
functionalities was taken in account: rhodamine derivatives and 
triphenylphosphonium salts were synthetized and characterized.  
III. Multinuclear manganese oxoclusters (Table 19, entry 3). The clusters have been 
tested for the first time, as catalyst for H2O2 dismutation, showing an interesting 
reactivity in non-buffered water. Preliminary test as SOD mimics were also 
performed. However, the clusters precipitate from the reaction mixture and are 
deactivated by phosphate buffer. In this case, further experiments will be required 
to assess the nature of the active species and to increase their solubility/stability.  
IV. A fully inorganic tetraruthenium substituted polyoxotungstate (Table 19, entry 
4). This POM, with known catalase activity has been successfully used to contrast 
molecular events involved in Alzheimer’s disease. Indeed, thanks to its negative 
charge and to the presence of exchangeable water ligands on ruthenium atoms, β-
amyloid can coordinate on the POM surface, resulting in a decreased 
fibrillogenesis. In addition, catalase activity was maintained in the presence of 
these peptides, allowing reduction of Aβ-induced oxidative stress within model 
neuronal cells. Experiments on isolated mitochondria suggest that probably 
RuPOM, despite its high negative charge, could enter in mitochondria and maybe 
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can interact with inner membrane proteins. Finally, the ruthenium polyoxometalate 
was encapsulated into multilayered polymeric capsules for future delivery 
application.  
 
Among these compounds, the most promising ones are the dinuclear manganese 
complexes, that are very active, in buffered solution, toward hydrogen peroxide 
dismutation. The possibility of tuning dismutation efficiency and the insertion of targeting 
functionalities, modifying only carboxylate ligand, makes this complex even more 
appealing. Ruthenium polyoxometalate is another promising compound, in particular as 
anti-amyloidogenic and catalytic antioxidant.  
Both species are definitely worth of further investigations, to confirm their reduced 
toxicity, the positive effects on cell protection against oxidative stress, and to enable their 
selective cell delivery.  
 
Table 19: Collection of relevant results, obtained for the molecular metal complexes and nanosystems, 
described in this thesis. 
Entry Compound Structure N. Active Atoms 
SOD CAT 
kMcCF 
(M-1s-1) 
R0 (µMO2/s), 
(Yield (%)) 
1 1-3 (MonoMn) 1 2-8·106 8-128 (0.6-14) 
2 4-7 (DiMn) 2 3.3·10
7 12-93 (50->99) 
3 8-16 (PolyMn) 6-13-14 >106 5-17 (>90) 
4 17 (RuPOM) 4 5.5·105 7-25 (>99) 
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6.1 Materials and methods 
 
All commercially available reagents and solvents were used without further purifications. 
MilliQ-deionized water (Millipore) was used for the reactions, buffers preparation and for 
spectrometric measurements. 
Solvents and deuterated (d) solvents:  
- diethyl ether, hexane, methanol, ethanol, chloroform, dichloromethane, acetonitrile, 
chloroform-d, acetonitrile-d3, methanol-d4, DMF-d7, DMSO-d6, D2O, 
dichloromethane-d2 (Sigma-Aldrich); 
- DMSO (Lab Scan); 
- 1,2-dichloroethane, pyridine (Carlo Erba). 
Reagents: 
- Na2WO4·2H2O, KBr, Na2SiO3, RuCl3·xH2O, Mn(ClO4)2·xH2O, MnCl2·2H2O, 
Ni(NO3)2·6H2O, NaBH4, NaBH(OAc)3, NaBH3CN, KMnO4, CuCl2·2H2O, NaOH, 
NaHCO3, HCl (37%), HNO3 (70%), H3PO4 (85%) NaN3, 3-amino-1,2,4-triazole 
(ATZ), P2O5, CuSO4·5H2O, Na2C4H4O6·2H2O, tert-butylphosphonic acid, 
phenylphosphonic acid, di-2-pyridylketone, salicylaldehyde, rhodamine B, 
rhodamine B Base, trans-1,4-diaminecyclohexane, piperazine, succinic anhydride, 
zinc (powder), Al(CH3)3 2M (heptane solution), triphenylphosphine, bromovaleric 
acid, acetic acid, Tris, Hepes, Mops, EGTA, (CH3)2AsO2Na, ADP, FCCP, 
glutaraldehyde, cyclosporine A, antimycin A from Streptomyces sp., 2-
aminopyridine, 4-picoline, cytochrome c,  tetrabutylammoniumchloride/bromide 
(TBAX), isonicotinic acid, 4,4’-trimethylenedipyridine (4,4’-TDP), 4-(3-
phenylpropyl)pyridine, Mn(acac)3, Xanthine, Xanthine Oxidase, Cytochrome c, 
Nitro Blue Tetrazolium chloride (NBT), Catalase from bovine liver, 
polystyrenesulfonate (PSS), polyallylammonium (PAH), polyarginine (pArg), 
dextran sulfonate (Dex-S), dextran, dextra-FITC, dextran-RITC, hydrogen peroxide 
(30%), thioflavinT (ThT), Amberlite, Sephadex-G50™, Sephadex-G15™, 2’,7’-
dichlorofluorescin diacetate (DCF), (Sigma-Aldrich); 
- NH4OAc, NaCl, KCl, K2CO3, CaCl2, MgSO4·xH2O, Na2SO4·xH2O, 
Na2HPO4·xH2O, NaH2PO4·xH2O, H3BO3, Na2B4O7·xH2O, benzoic acid, 4-
carboxybenzaldehyde, sucrose, glucose, trimethylamine (Carlo Erba) 
- Calcium Green N6 (Molecular Probe); 
- Amyloid peptide 1-40, Amyloid peptide 1-42, Amyloid peptide 1-28 (Genscript). 
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6.2 Instruments 
 
1H-NMR spectra were recorded with a Bruker Avance-DAX 200 spectrometer operating at 
200 MHz. Chemical shift were determined using Si(CH3)4 as reference (δ 1H-NMR=0 
ppm). For the protonic spectra, the following symbols have been used: s: singlet, d: 
doublet, t: triplet, q: quartet, m: multiplet. 
 
1H-NMR analysis of amyloid peptide was performed on a Bruker Avance 600 MHz. 
 
FTIR spectra were recorded with a Nicolet 5700-Thermo Electron Corporation instrument. 
For FTIR spectra following symbols have been used: w: weak signal, m: medium signal, s: 
strong signal, b: broad signal. 
 
UV-Vis spectra were recorded with a Varian Cary 50Bio spectrophotometer.  
 
Fluorescence measurements were performed with a Perkin Elmer LS50B instrument with a 
cell length of 1cm. 
 
ESI-MS spectra have been obtained with a Agilent LC/MSD Trap SL spectrometer, by 
using a capillary potential of 1500V. Solvent used: MeOH, ACN, H2O 
 
MALDI-MS spectra were recorded with a MALDI TOF/TOF 4800 AB SCIEX instrument. 
 
ICP-MS analysis were performed with a ICP-MS Agilent Technologies 7700xx instrument 
operating at 1550 W plasma power. Samples were diluted in 4 mL of HCl/HNO3 3:1 and 
mineralized in the Microwave Digestion System (CEM Explorer SP-D plus). The solution 
was then diluted in 100 mL of 5% aqua regia and analyzed. The instrument was calibrated 
by using Ru and W standard solutions diluted in 5% aqua regia. 
 
Circular Dichroism (CD) spectra were recorded with a Jasco J-715 spectropolarimeter. 
Signal was mediated for 6 measure, 2mm cuvettes and a scan rate of 50nm/min were used. 
 
Transmission electron microscopy (TEM) measurements were obtained using a FEI Tecnai 
G2 transmission electron microscope at Biology Department of University of Padova. 
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For catalytic experiments of hydrogen peroxide dismutation an home-made pressure 
transducer, with a septum for sample injection was used.   
 
pH measurement was performed with a pH-meter HI 223 Hanna Instrument with a glass 
electrode. Calibration was carried out with Sigma-Aldrich buffers (pH 4-7-10). 
  
 
6.3 Synthetic procedures 
 
-Seven coordinates complexes (1-3) 
Synthesis of ligands and seven-coordinated complexes has been reported in Michaela 
Grau’s PhD thesis, Imperial College, 2013.1 Here is briefly reported the general synthesis 
for the metal complexes [Mn(L)(OTf)2] used. 
The relevant ligand L and 1 molar equivalent of [Mn(MeCN)(OTf)2] were placed in 
different Schlenk flasks and dissolved in absolute tetrahydrofuran. After adding the 
solution of the ligand to the suspension of the metal precursor, the reaction mixture was 
stirred overnight at room temperature. The resulting solution was concentrated to one third 
of the initial volume. Diethyl ether was added to precipitate the product, which was dried 
under vacuum. If the complex already precipitated from the tetrahydrofuran solution 
during the reaction, the solvent was removed by filtration and the solid dried under 
vacuum. 
 
-Synthesis of: di-2-pyridy-ketoxime2 
 
Di-2-pyridyl ketone (1.72g, 9.24mmol) and hydroxylamine hydrochloride (1.35g, 
19.1mmol) were dissolved in 5ml of pyridine and heated at 110°C for 4-5 hours. After 
cooling to 0°C, 10ml of water were added and  a white precipitate appeared (if not, scratch 
with a glass rod help the precipitation). Product was filtered on a gootch and washed 
abundantly with water and dried under vacuum. Yield: 1.84g (9.23mmol, 99%). 
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FTIR (KBr, cm-1): 3395 (s, br), 2996 (s, br), 2801 (s, br), 1621 (w), 1593 (s), 1566 (s), 
1475 (s), 1432 (s), 1337 (m),1282 (m), 1153 (m), 1096 (m), 1050 (w), 1017 (s), 999 (s), 
949 (s), 904 (w), 791 (s),758 (m), 690 (m), 659 (m), 622 (m), 580 (m), 495 (w). 
1H-NMR (200MHz, MeOD) δ: 7.34-7.49 (m, 2H), 7.62 (d, J: 7.9Hz 1 H,), 7.80-7.99 (m, 
3H), 8.43 (d, J: 4.8Hz, 1H), 8.60 (d, J: 4.3Hz, 1H) ppm. 
 
-Synthesis of: di-2-pyridyl-methylamine3 
 
Di-2-pyridyl-ketoxime (1.8g, 9.0mmol) was dissolved in a mixture of 17ml of ethanol, 
10ml of water and 11ml of 28% aqueous NH3. NH4OAc (1.73g, 22.5mmol) was added and 
solution was heated to 80°C. Zinc powder (2.95g, 45.0mmol) was added in 30 minutes, 
then reaction was left refluxed for 4.5 hours. Solution was then filtered on paper, to remove 
residual solid, and concentrated under vacuum, until a white-yellow precipitate appeared. 
The resulting aqueous solution (~5ml) was basified with NaOH 10M, solid disappeared 
and solution turned to yellow color. Basification continued until solution turned reddish-
pink and  a with precipitate appeared, then it was extracted with dichloromethane (5ml X 
3). Organic fraction was washed with  brine (5ml X 3) and water (5ml X 3), dried with 
MgSO4 and solvent was evaporated under reduced pressure. A yellowish oil was obtained. 
Yield: 1.25g (6.75mmol, 75%) 
1H-NMR (200MHz, CDCl3) δ: 2.40 (br. s, 2H), 5.31 (s, 1H), 7.13 (ddd, J: 7.5-4.9-1.1 Hz, 2 
H, 2-H), 7.38 (d, J: 7.9Hz, 2H), 7.62 (dt, J: 7.7-1.8Hz, 2H), 8.56 (ddd, J: 4.9-1.5-0.8Hz, 
2H) ppm. 
 
-Synthesis of:  2-({[Di(2-pyridyl)methyl]imino}methyl)phenol4 
 
N
NH2
NN
N
N
OH
EtOH/H2O/NH3aq, 80°C
NH4OAc, Zn
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To a stirred solution of di-2-pyridyl-methylamine (1.25g, 6.75mmol) in 5 mL of methanol 
was added neat salicylaldehyde (0.84g, 6.8mmol). The solution immediately turned 
yellow. After stirring for about 5 min a yellow crystalline material appeared. The reaction 
mixture was cooled to 0ºC and stirred for other 30 minutes. The solids were isolated by 
vacuum filtration, washed with ice-cold methanol and dried under vacuum. A yellow 
powder was obtained. Yield: 1.7g (5.9 mmol, 87%).  
FTIR (KBr, cm-1): 3441 (w, br), 3046 (w), 3009 (w), 1626 (s), 1585 (s), 1498 (m), 1463 
(s), 1431 (s), 1382 (w), 1312 (w), 1280 (s), 1216 (w), 1201 (w), 1152 (m), 1058 (m), 988 
(m), 876 (w), 857 (w), 775 (s), 760 (s), 666 (w),610 (m), 541 (m), 464 (m), 436 (w). 
1H-NMR (200MHz, CDCl3) δ: 5.93 (s, 1H), 6.83-7.99 (m, 2H), 7.14-7.20 (m, 2H), 7.27-
7.36 (m, 2H), 7.44 (dd, J: 7.8-0.5, 2H), 7.67 (dt, J: 7.7-1.7Hz, 2H), 8.49-8.61 (m, 2H), 8.63 
(s, 1H) ppm.  
 
-Synthesis of:  2-({[Di(2-pyridyl)methyl]amino}methyl)phenol4 
 
To a stirred solution of 2-({[di(2pyridyl)methyl]imino}methyl)phenol (1.7g, 5.9mmol) in 
15 ml methanol at 0ºC NaBH4 (227mg, 6.0mmol) was added in 3 portions during 15 min. 
The reaction mixture was stirred for 4 h. The mixture was then  acidified with 2 M aq. HCl 
to pH 1 and stirred for 15 min. Subsequently the reaction was neutralized with 2 M aq. 
NH3 and 30 ml water was added (pH ~8), methanol was removed under reduced pressure 
and the mixture extracted with ethyl acetate (5ml X 3). The combined organic layers were 
dried with Na2SO4 filtered and solvent was removed under vacuum to yield a reddish oil (it 
turned into a glass after several weeks). Yield: 1.61g (5.53mmol, 94%). 
1H-NMR (200MHz, CDCl3) δ: 3.95 (s, 2H), 5.15 (s, 1H),6.72-6.93 (m, 3H), 7.13-7.21 (m, 
3H ), 7.31-7.35 (m, 2H), 7.65 (dt, 2H, J: 7.7-1.7Hz, 2H), 8.58-8.60 (m, 2H) ppm.  
 
 
 
N
NH
N
OH
N
N
N
OH
NaBH4, MeOH, 0°C
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-Synthesis of: 2-{[[Di(2-pyridyl)methyl](methyl)amino]methyl}phenol4 
 
To a solution of 2-({[di(2-pyridyl)methyl]amino}methyl)phenol (1.61g, 5.53mmol) in 
25mL of ClCH2CH2Cl was added aqueous 30% formaldehyde (650µl, 11.0mmol) and after 
15 min of stirring NaBH(OAc)3 (2.54g, 11.0mmol) was added in small portions during 20 
minutes. Subsequently the reaction was vigorously stirred overnight. Dichloromethane
 
(20 
mL) was added and the organic layer was washed consecutively with 2 M aq. NH3 (10ml 
X 2), and twice with water (10ml X 2). After drying with MgSO4, filtration and 
evaporation of the solvents under reduced pressure, the product was obtained as a sticky oil 
which was purified by chromatography on silica using diethyl ether. A white solid material 
was obtained. Yield: 1.38g, (4.46mmol, 81%).  
FTIR (KBr, cm-1): 3048 (m), 3007 (m), 2970 (m), 2924 (m), 2849 (m), 2712 (m), 1607 
(m), 1586 (s), 1490 (m), 1466 (s), 1432 (s), 1379 (w), 1330 (m), 1287 (m), 1257 (s), 1199 
(m), 1149 (m), 1120 (m), 1102 (w), 1025 (m), 993 (m), 931 (m), 869 (w), 857 (w), 785 
(m), 748 (s), 722 (m), 679 (w),617 (m), 540 (w), 448 (w). 
 
1H-NMR (200 MHz, CDCl3) δ: 2.22 (s, 3H), 3.67 (s, 2H), 4.98 (s, 1H), 6.71-6.98 (m, 3H), 
7.14-7.23 (m, 3H), 7.53-7.57 (m, 2H), 7.66 (dt, J. 7.7-1.7Hz, 2H), 8.61 - 8.63 (m, 2H) ppm.  
 
-Synthesis of: Rhodamine B Base5 
 
Rhodamine B (2.59g, 5.4mmol) was dissolved and partitioned between 1M NaOH  
aqueous solution (20ml, ~20mmol) and ethyl acetate. After isolation of organic layer, 
N
N
N
OH
N
NH
N
OH
1.CH2O
2.NaBH(OAc)3
ClCH2CH2Cl
Overnight, Tamb
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aqueous part was washed with ethyl acetate (10ml X 2). The combined organic solution 
was washed with NaOH solution (10ml X 2), brine (10ml X 2) and water (10ml X 2), then 
dried with Na2SO4, filtered and concetrated under reduced pressure. A pink solid was 
obtained. Yield: 2.1g (4.75mmol, 88%). 
1H-NMR (200 MHz, MeOD) δ: 2.22 (s, 3H), 3.67 (s, 2H), 4.98 (s, 1H), 6.71-6.98 (m, 3H), 
7.14-7.23 (m, 3H), 7.53-7.57 (m, 2H), 7.66 (dt, J. 7.7-1.7Hz, 2H), 8.61 - 8.63 (m, 2H) ppm.  
 
-Synthesis of Rhodamine B piperazine amide (RhoP)5 
 
Al(CH3)3 (8ml, 2M in heptane, 16.0mmol) was slowly added dropwise to a solution of 
piperazine (2.34 g, 27.1mmol) in 10ml of dry CH2Cl2 under nitrogen. After 1 hour of 
stirring a white precipitate appeared. A solution of rhodamine B Base (3.0g, 6.8mmol) in 
7ml of dichloromethane was added dropwise. Gas evolution was observed during the 
addition. After stirring  at reflux for 24 hours, 0.1M aqueous HCl was added dropwise until 
gas evolution ceased. The heterogeneous solution was filtered and the solid was rinsed 
with dichloromethane and a 4:1 mixture of  CH2Cl2/MeOH. The combined filtrate was 
concentrated and the residue was dissolved in dichloromethane, filtered again and solvent 
was evaporated under reduced pressure. Solid was partitioned between ethyl acetate and 
aqueous NaHCO3 solution (0.1M). The aqueous layer was washed with ethyl acetate (10ml 
X 3), saturated with NaCl, acidified with 1M aqueous HCl and finally extracted with 2:1 
mixture of i-propanol/dichloromethane (10ml X 5). The organic layer was dried with 
Na2SO4, filtered and solvent was evaporated under reduced pressure, obtaining a dark 
purple solid. Yield. 2.6g (4.9mmol, 72%) 
FTIR (KBr, cm-1): 3422 (w, br), 2972 (w), 2713 (w, br), 1714 (w), 1647 (m), 1625 (m), 
1588 (s), 1528 (w), 1467 (s), 1412 (s), 1337 (s), 1273 (m), 1245 (m), 1181 (s), 1132 (m), 
1074 (m), 1009 (w), 974 (w), 921 (w), 819 (w), 682 (w), 577 (w). 
1H-NMR (200 MHz, MeOD) δ: 1.30 (t, J: 7.0Hz, 12H), 3.13 (br s, 4H), 3.55-3.79 (m, 
12H), 6.96-8.35 (m, 10H) ppm. 
ESI-MS (m/z): 511.4 [M]+ 
O
O
O
N N
1.Al(CH3)3, CH2Cl2, N2
2. Piperazine
3.Aqueous HCl
O
O
N
N N
NH
RhoP
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-Synthesis of Rhodamine B 4-(3carboxypropionyl)piperazine amide (RhoPS)5 
 
Triethylamine (0.56ml, 4.0mmol) was added to a stirred solution of rhodamine B 
piperazine amide (1.7g, 3.2mmol), succinic anhydride ( 0.35g, 3.5mmol) and DMAP 
(DiMethylAminoPiperazine, 0.41g, 3.4mmol) in 12ml of dichloromethane. Mixture was 
stirred 24 hour at room temperature then partitioned between ethyl acetate and 1M aqueous 
K2CO3 solution. The aqueous layer was washed with 3 additional portion of ethyl acetate 
(10ml X 3), then saturated with NaCl and extracted with 2:1 mixture of i-
propanol/dichloromethane (10ml X 5). The organic layer was dried with Na2SO4, filtered 
and concentrated under reduced pressure. The resulting solid was dissolved in chloroform 
and filtered again. Solvent was evaporated, obtaining a dark solid. Yield: 1.27g (2.1mmol, 
66%) 
FTIR (KBr, cm-1): 3426 (m, br), 2968 (w), 2726 (w, br), 1751 (w), 1634 (s), 1588 (s), 1510 
(w), 1467 (s), 1413 (s), 1336 (s), 1273 (m), 1247 (m), 1179 (s), 1128 (m), 1072 (m), 1005 
(m), 920 (w), 820 (w), 682 (w). 
1H-NMR (200 MHz, MeOD) δ: 1.31 (t, J: 7.0Hz, 12H), 2.38-2.44 (m, 2H), 5.51-2.59 (m, 
2H), 3.31-3.43 (m, 8H), 3.69 (q, J: 7.0Hz, 8H), 6.82-8.01 (m, 10H). 
ESI-MS (m/z): 611.4 [M]+ 
 
 
-Synthesis of: Rhodamine B-trans-1,4-diaminocyclohexane amide (RhoD)6 
 
 
O
O
N
N N
NH
O
O
N
N N
N
O
OH
OO O
TEA, DMAP
CH2Cl2, 24h
RhoPS
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Al(CH3)3 (8ml, 2M in heptane, 16.0mmol) was slowly added to trans-1,4-
diaminocyclohexane (3.1g, 27.1mmol) in 10ml of dry CH2Cl2  under nitrogen. The mixture 
was stirred for 30 minutes than Rhodamine B (3.0g, 6,8mmol) in 7ml of CH2Cl2 was added 
in one portion. Solution was refluxed for a minimum of 24 hours. After cooling to room 
temperature, 0.1M HCl was added dropwise in 20 minutes until effervescence ceased. 
Mixture was filtered and washed with CH2Cl2 (100ml). Solution was concentrated under 
reduced pressure and the obtained solid was washed with 0.01M HCl, saturated with NaCl 
and extracted with a 4:1 mixture of i-propanol/dicholormethane (10ml X 3). The organic 
layer was dried with Na2SO4, filtered and solvents evaporated under reduced pressure. 
Product was purified by chromatography on silica using CH2Cl2/MeOH/TEA mixture 
(95/5/1), giving a pale pink solid. Yield: 1.2g (2.24mmol, 33%). 
FTIR (KBr, cm-1): 3407 (s, br), 2940 (s, br), 2616 (s, br), 2458 (m, br), 1695 (s), 1613 (s), 
1496 (s), 1470 (s), 1406 (s), 1359 (m), 1315 (s), 1270 (w), 1246 (m), 1174 (w), 1152 (w), 
1115 (w), 1076 (w), 1056 (w), 1014 (m), 986 (m), 922 (w), 836 (w),  807 (w), 763 (m),  
693 (w), 627 (w), 538 (w), 489 (w). 
1H-NMR (200 MHz, CDCl3) δ: 0.80-2.00 (m, 20H), 2.26 (s, 2H), 3.08-3.18 (m, 1H), 3.61-
3.80 (m, 8H), 4.02-4.13 (m, 1H), 7.12-7.38 (m, 5H), 7.73-7.83 (m, 4H), 8.00-8.09 (m, 1H) 
ppm. 
ESI-MS (m/z): 539 [M+] 
 
-Synthesis of: Rhodamine B-trans-1,4-diaminocyclohexane amide-4-carboxybenzyl 
(RhoDIR) 
 
Rhodamine B-trans-1,4-diaminocyclohexane amide (1.1g, 2.0mmol) was dissolved in 10ml 
of a mixture 1:1 methanol/dichloromethane. Triethylamine (0.835ml, 6.0mmol) and 4-
carboxybenaldehyde (0.306g, 2mmol) were added. After 10 minutes of stirring, NaBH3CN 
(0.65g, 10.0mmol) was added and solution was stirred at room temperature. After 24 hours 
0.1M aqueous HCl was added until effervescence stop (final pH ~2). The organic layer 
O
O
H
N
N N
N
H
O OH
RhoDIR
O
O
H
N
N N
NH2
O O
OH
1.
2.NaBH3CN
3.HCl
MeOH/CH2Cl2
24 h, rt
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was separated and washed with 0.01M aqueous HCl. The combined aqueous solution was 
saturated with NaCl and extracted with a mixture 4:1 dichloromethane/i-propanol, dried 
with Na2SO4, filtered and concentrated. The obtained solid was dissolved in few ml (1-2) 
of methanol and filtered again to eliminate residues, then solvent was evaporated under 
reduced pressure. A pink solid was obtained. Yield: 1.0g (1.4mmol, 70%) 
FTIR (KBr, cm-1): 3419 (s, br), 2979 (s, br), 2620 (s, br), 2457 (m, br), 2362 (m), 2339 
(m), 1697 (s), 1685 (s), 1614 (s), 1590 (m), 1496 (s), 1471 (s), 1455 (s), 1408 (s), 1362 
(m), 1328 (m), 1273 (w), 1247 (m), 1180 (m), 1152 (m), 1113 (m), 1076 (w), 1014 (m), 
985 (m), 921 (w), 837 (w),  791 (w), 762 (m),  694 (w), 667 (w), 635 (w), 503 (w). 
1H-NMR (200 MHz, CDCl3) δ: 1.27 (t, J: 7.0Hz, 12H), 2.28-2.69 (m, 4H), 3.38 (br s, 7H), 
3.52-3.80 (m, 9H), 6.68-6.77 (m, 2H), 6.86-7.21 (m, 4H), 7.64-7.98 (m, 4H) ppm. 
ESI-MS (m/z): 673.3 [M+] – 337.1 [M2+] 
 
 
-Synthesis of: (4-Carboxybutyl)triphenylphosphonium bromide (TPPAcV)7 
 
To a solution of 5-bromovaleric acid (1.0g, 5.5mmol) in 10ml of acetonitrile, 
triphenylphosphine (1.6g, 6.1mmol) was added. The mixture was stirred at 80°C for 24 
hours and then concentrated. The white residues was washed abundantly with benzene, 
hexane and finally diethyl ether. If there were still some reagent, the solid would be 
dissolved in 1-2ml of dichloromethane and precipitated with diethyl ether. The 
precipitation was repeated until the product wass clean. Yield:  1.8g (5.0mmol, 92%) 
FTIR (KBr, cm-1): 3428 (w, br), 2958 (m, br), 2902 (m), 2870 (w), 2590 (w, br), 2447 (w), 
1990 (w), 1918 (w), 1838 (w), 1755 (s), 1712 (m), 1586 (m), 1484 (m), 1447 (s), 1437 (s), 
1407 8w), 1370 (m), 1354 (m), 1306 (m), 1212 (m), 1189 (m), 1110 (s), 1044 (w), 995 
(m), 944 (m), 855 (w), 818 (w), 757 (s), 737 (s), 687 (s). 
1H-NMR (200 MHz, CDCl3) δ: 1.62-1.80 (m, 2H), 1.86-1.97 (m, 2H), 2.62 (t, J: 6.8Hz,  
2H), 3.54-3.69 (m, 2H), 7.69-7.82 (m, 15H) ppm. 
ESI-MS(m/z): 363.2  [M+] 
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-Synthesis of: General synthesis of compounds 4-7 
Ligand 2-{[[Di(2-pyridyl)methyl](methyl)amino]methyl}phenol (0.2g, 0.66mmol) was 
dissolved in about 5ml of dry methanol in a 50ml round bottom flask under N2 and stirring. 
Then Mn(ClO)4·6H2O (0.24g, 0.66mmol) and apical carboxylate ligand (0.33mmol) were 
added to the solution. After complete dissolution of all solids trimethylamine (0.14ml, 
0.99mmol) was added. Suddenly a precipitate appeared, and after 5 minutes of stirring, 
solution was heated to boiling and acetonitrile was added dropwise until solution became 
clear. Solution was left cool down slowly overnight and, in the case of acetate and 
benzoate, crystals appeared after few days. In the case of rhodamine derivatives, TPP and 
formylbenzoate, no crystals were obtained, the solids were filtered and washed abundantly 
with cold methanol and diethyl ether. Yield: 100-300mg (0.1-0.23mmol, 30-70% 
depending on carboxylate ligand. 
FTIR 4 Formylbenzoate (KBr, cm-1): 3443 (w, br), 3062 (w), 3012 (w), 2933 (w), 2814 
(w), 1701 (m), 1597 (s), 1559 (s), 1481 (s), 1447 (s), 1408 (s), 1279 (s), 1202 (w), 1152 
(w), 1086 (s), 1008 (m), 886 (m), 809 (w), 785 (m), 759 (s), 729 (w), 682 (w), 587 (w), 
561 (w),530 (m), 470 (w). 
ESI-MS (m/z) 4 Formylbenzoate: 867.1 [M]+, 763.2 [L2Mn2(O2CH)]+, 306.2 [L]+ 
FTIR 4 Benzoate (KBr, cm-1): 3428 (w, br), 3066 (w), 3012 (w), 2978 (w), 2931 (w), 2889 
(w), 2854 (w), 2815 (w), 1597 (s), 1561 (s), 1481 (s), 1446 (s), 1412 (s), 1289 (s), 1280 (s), 
1201 (w), 1153 (w), 1090 (s), 1012 (m), 889 (m), 791 (m), 762 (s), 736 (m), 697 (w), 676 
(w). 
ESI-MS (m/z) 4 Benzoate: 839.1[L2Mn2Bz]+, 763.2 [L2Mn2(O2CH)]+, 306.2 [L]+. 
FTIR 4 Acetate (KBr, cm-1): 3430 (w, br), 3063 (w), 3006 (w), 2976 (w), 2936 (w), 2881 
(w), 2846 (w), 2806 (w), 1593 (s), 1574 (s), 1563 (s) 1479 (s), 1451 (s), 1421 (s), 1369 
(w), 1291 (s), 1279 (s), 1235 (w), 1151 (w), 1096 (s), 1000 (m), 884 (m), 790 (m), 763 (s), 
730 (w), 682 (w), 623 (m), 589 (w), 557 (w),530 (m), 473 (w). 
ESI-MS (m/z) 4 Acetate: 777.3 [M]+, 763.2 [L2Mn2(O2CH)]+, 306.2 [L]+. 
FTIR 5 (KBr, cm-1): 3440 (m, br), 3061 (w), 2971 (m), 2868 (w), 1683 (m), 1634 (m), 
1615 (s), 1599 (s), 1548 (m), 1514 (m), 1480(s), 1444 (s), 1402 (s), 1332 (m), 1289 (m), 
1275 (m), 1232 (w), 1218 (w), 1181 (w), 1153 (w), 1116 (s), 1014 (m), 886 (m), 819 (w),  
787 (m), 758 (m),  702 (w), 623 (m), 557 (w), 531 (w). 
ESI-MS (m/z) 5: 664.2 [M]2+, 763.1 [L2Mn2(O2CH)]+, 611.3 [RhoPS]+, 359.1 [M-
RhoDR]2+, 306.2 [L]+. 
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FTIR 6 (KBr, cm-1): 3432 (m, br), 3061 (w), 2973 (w), 2930 (w), 1647 (m), 1589 (s), 1528 
(w), 1480(s), 1467 (m), 1452 (m), 1412 (m), 1336 (m), 1274 (m), 1246 (m), 1198 (w), 
1181 (m), 1157 (w), 1084 (s), 1007 (m), 921 (w), 885 (w), 822 (w),  787 (w), 757 (m),  727 
(w), 683 (m), 622 (m), 559 (w), 529 (w). 
ESI-MS (m/z) 6: 867.1 [M-(C34H42N3O2)]+, 763.1 [L2Mn2(O2CH)]+, 673.3 [RhoDIR]+, 
443.2 [RhoDIR-(C14H17NO2)]+, 359.1 [M-RhoDIR]2+, 306.2 [L]+. 
FTIR 7 (KBr, cm-1): 3619 (w), 3335 (w, br), 3073 (w), 2995 (w), 2972 (w), 2949 (w), 2854 
(w), 2802 (w), 1598 (s), 1568 (m), 1480 (s), 1452 (s), 1444 (s), 1420 (m), 1286 (s), 1273 
(s), 1252 (w), 1151 (w), 1015 (w), 997 (m), 885 (m), 784 (m), 771 (m), 756 (s), 733 (w), 
683 (w). 
ESI-MS (m/z) 7: 540.1 [M]2+, 763.2 [L2Mn2(O2CH)]+, 363.3 [TPPAcV]+, 306.2 [L]+. 
 
-Synthesis of: [MnIIMnIII12(µ4-O)8(µ4-Cl)(tert-butyl-PO3)8][MnII(CH3CN)6]Cl2·6CH3CN    
 ·5.25H2O (8) 
MnCl2·2H2O (324mg, 2mmol), tert-butylphosphonic acid (138mg, 1mmol), isonicotinic 
acid (123mg, 1mmol), KMnO4 (33mg, 0.2mmol) and triethylamine (65µl, 0.5mmol) were 
dissolved in 25ml of CH3CN and stirred for 3h. After addition of CuCl2·2H2O (166mg, 
1mmol), solution was stirred for other 2h, then it was filtered and left to evaporate at room 
temperature. 
FTIR (KBr, cm-1): 3404 (m, br), 2975 (w), 1626 (m), 1480 (m), 1461 (w), 1396 (w), 1365 
(w), 1026 (m), 986 (m), 924 (s), 830 (m), 670 (w). 
 
-Synthesis of: (C5H7N2)3[MnII3MnIII10(µ4-O)6(µ3-O)(µ3-OH)(µ4-Cl)4(Cl)(tert-butyl-PO3H)  
 (tert-butyl-PO3)9] ·3CH3CN·2H2O (9) 
MnCl2·2H2O (162mg, 1mmol), tert-butylphosphonic acid (69mg, 0.5mmol), 2-
aminopyridine (96mg, 1mmol) and KMnO4 (16mg, 0.1mmol) were dissolved in 20ml of 
CH3CN and stirred for 5h at room temperature. Solution was then filtered and left to 
slowly evaporate. 
FTIR (KBr, cm-1): 3395 (m, br), 3188 (m), 2972 (m), 2870 (w), 1666 (s), 1626 (m), 1479 
(m), 1459 (w), 1393 (w), 1363 (w), 1326 (w), 1099 (m), 936 (s), 830 (m), 769 (m), 723 
(w). 
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-Synthesis of: (C5H7N2)2[MnII3MnIII11(µ4-O)6(µ3-O)(µ3-OH)(µ2-OH)(µ4-Cl)4 
 (tert-butylPO3H)(tert-butyl-PO3)10(2-aminopyridine)]·3CH3CN·2H2O (10) 
MnCl2·2H2O (162mg, 1mmol), tert-butylphosphonic acid (69mg, 0.5mmol), 2-
aminopyridine (191mg, 2mmol) and KMnO4 (16mg, 0.1mmol) were dissolved in 20ml of 
CH3CN and stirred for 5h at room temperature. Solution was then filtered and left to 
slowly evaporate at room temperature. 
FTIR (KBr, cm-1): 2971 (w), 1665 (m), 1617 (w), 1478 (m), 1452 (w), 1392 (w), 1362 (w), 
1327 (w), 1095 (m), 938 (s), 831 (m), 771 (m). 
 
-Synthesis of: [(MnII0.5 MnIII0.5)MnIII12(µ4-O)6(µ-OH)2(µ-CH3O)4(CH3OH)2 
  (tert-butylPO3)10(4-picoline)4]Cl0.5·1.5H2O (11) 
MnCl2·2H2O (162mg, 1mmol), tert-butylphosphonic acid (69mg, 0.5mmol), 4-picoline 
(200µl, 2mmol) and KMnO4 (16mg, 0.1mmol) were dissolved in 20ml of CH3OH and 
stirred for 5h at room temperature. The solution was filtered and left to evaporate at room 
temperature. 
FTIR (KBr, cm-1): 2949 (m), 2923 (m), 1618 (m), 1477 (m), 1456 (w), 1392 (w), 1361 (w), 
1116 (s), 1054 (s), 998 (s), 978 (s), 833 (s), 806 (s), 723 (w), 667 (m). 
-Synthesis of: [(MnII0.5 MnIII0.5)MnIII12(µ4-O)6(µ-OH)2(µ-CH3O)4(CH3OH)2 
 (tert-butylPO3)10(4,4’-TPD)2]Cl0.5·8CH3OH (12)  
(4,4’-TDP = 4,4’-trimethylenedipyridine) 
MnCl2·2H2O (162mg, 1mmol), tert-butylphosphonic acid (140mg, 1mmol), 
4,4’trimethylenedipyridine (303mg, 1.5mmol) and KMnO4 (34mg, 0.2mmol) were 
dissolved in 40ml of CH3OH and stirred for 5h at room temperature. Solution was then 
filtered and left to evaporate at room temperature. 
FTIR (KBr, cm-1): 2949 (m), 1614 (m), 1477 (m), 1458 (w), 1424 (w), 1392 (w), 1361 (w), 
1117 (s), 1065 (s), 978 (s), 832 (s), 808 (w), 754 (w), 666 (s). 
 
-Synthesis of: [MnIII13(µ4-O)2(µ3-O)4(µ2-OH)2(µ2-CH3O)4(C6H5PO3)10(C5H5N)5Cl]·3H2O   
 (13) 
MnCl2·2H2O (162mg, 1mmol), phenylphosphonic acid (94mg, 0.6mmol) and KMnO4 
(39mg, 0.25mmol) were dissolved in 10ml of CH3OH(5ml)/CH3CN(5ml) mixture, the 
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1.2ml of pyridine were added and the solution was stirred for 5h. After filtration, solution 
was left to crystallize. 
FTIR (KBr, cm-1): 3503 (w, br), 3055 (w), 1601 (w), 1485 (w), 1438 (m), 1139 (m), 1120 
(s), 1084 (s), 1066 (s), 1032 (s), 1003 (s), 971 (s), 753 (s), 721 (m), 695 (s). 
 
-Synthesis of: [MnIII13(µ4-O)2(µ3-O)4(µ2-OH)2(µ2-CH3O)4(C6H5CH2PO3)10(C5H5N)5Cl]   
 ·5H2O (14) 
MnCl2·2H2O (162mg, 1mmol), benzylphosphonic acid (102mg, 0.6mmol) and KMnO4 
(39mg, 0.25mmol) were dissolved in 10ml of CH3OH(5ml)/CH3CN(5ml) mixture, the 
0.5ml of pyridine were added and the solution was stirred for 5h. After filtration, solution 
was left to crystallize. 
FTIR (KBr, cm-1): 3423 (w, br), 3028 (w), 2918 (w), 2815 (w), 1601 (m), 1495 (m), 1446 
(m), 1409 (w), 1240 (w), 1192 (w), 1132 (m), 1116 (s), 1080 (s), 1066 (s), 982 (s), 830 
(m), 788 (m), 758 (w), 730 (w), 693 (s). 
 
-Synthesis of: [MnIII13(µ4-O)2(µ3-O)4(µ2-OH)2(µ2-CH3O)4(C6H5CH2PO3)10 
 (C6H5C3H6C5H4N)5Cl]·5H2O (15) 
MnCl2·2H2O (162mg, 1mmol), benzylphosphonic acid (102mg, 0.6mmol) and KMnO4 
(39mg, 0.25mmol) were dissolved in 20ml of CH3OH, then 4-(3-phenylpropyl)pyridine 
(1ml, 5mmol) was added and solution was stirred for 5h. After filtration, solution was left 
to crystallize at room temperature. 
FTIR (KBr, cm-1): 3471 (w, br), 3060 (w), 3026 (w), 2921 (w), 2813 (w), 1615 (m), 1602 
(m), 1558 (w), 1495 (m), 1453 (m), 1426 (w), 1240 (w), 1193 (w), 1133 (m), 1118 (s), 
1082 (s), 1067 (s), 984 (s), 828 (m), 789 (m), 730 (w), 695 (s). 
 
-Synthesis of: TBA2[Mn6IIMo10VI(O)12(µ3-O)4(tert-Butyl-PO3)6(Ac)2(pyridine)2(H2O)6]  
 (16) 
Manganese(III) acetylacetonate (177mg, 0.5mmol), TBA2Mo6O19 (138mg, 0.1mmol), tert-
butylphosphonic acid (71mg, 0.5mmol), TBABr (323mg, 1.0mmol) and pyridine (80µl) 
were dissolved in 25 ml of CH3CN and stirred at room temperature for 5h. Solution was 
the filtered and left to crystallize. 
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FTIR (KBr, cm-1): 3444 (w, br), 2964 (m), 2872 (m), 1737 (w), 1660 (m), 1599 (w), 1563 
(m), 1478 (m), 1443 (m), 1364 (w), 1311 (w), 1217 (w), 1101 (s), 1027 (w), 1003 (w), 972 
(s), 945 (s), 892 (s), 832 (m), 795 (m), 764 (s), 700 (s), 659 (s). 
 
-Synthesis of: α2-K8P2W17O61(Ni2+·OH2)·17H2O (NiPOM)8 
 
In a 50ml round bottom flask, α2-K10P2W17O61·15H2O* (2.0g, 0.42mmol) was dissolved in 
5ml of water at 90°C. A solution of Ni(NO3)2·6H2O (0.138g, 0.47mmol) in 1ml of water 
was added under vigorous stirring, the solution turned pale green. After 15 minutes of 
stirring heating was stopped and solution was slowly cooled to 5°C for 5 hours. Light 
green crystals were collected by filtration, washed with water (10ml X 2) and dried under 
vacuum. Yield: 1.5g (0.31mmol, 74%). 
FTIR (KBr, cm-1): 3543 (s, br), 1613 (s), 1085 (s), 945 (s), 915 (s), 779 (s), 526 (m). 
UV-Vis: ε680: 10cm-1M-1  
 
-Synthesis of: K8[β-SiW10O36] 
 
Sodium metasilicate (3.0g, 24,7mmol) was dissolved in 50ml of water. In a separated 
beaker sodium tungstate dehydrate (90.9g, 0.276mol) was dissolved in about 150ml of 
water and immersed in an ice/water bath at 5°C. to this solution 40ml of 4.1M HCl 
(0.16mmol) were added dropwise in about 40 minutes under vigorous stirring, in order to 
dissolve tungstic acid. When the solution returned to room temperature, metasilicate 
solution was added and pH was adjusted at 5.5 with 4.1M HCl. The pH was maintained by 
small addition of 4.1M HCl for 100 minutes than solid KCl (44.2g, 0.6mol) was added. 
After 15 minutes of stirring the white precipitate was collected by filtration through a 
sintered glass filter. Product was dissolved in 420ml of water filtered and precipitated 
again with KCl (39.4g, 0.5mol), filtered and washed with 2M KCl solution (15ml X 2) and 
dried under vacuum. Yield: 34.0g (11.4mmol, 46%) 
FTIR (KBr, cm-1): 3423 (s, br), 1611 (s), 991 (s), 947 (s), 878 (s), 809 (s), 713 (s), 535 (m). 
 
 
 
                                                          
* α2-K10P2W17O61·15H2O was synthetized according to literature procedure (see ref.8). 
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-Synthesis of: K8[γ-SiW10O36] 
 
This synthesis required an accurate control of the pH. 
The fresh prepared potassium salt K8[β-SiW10O36] (34.0g, 11.4mmol) was dissolved in 
530ml of water and filtered to eliminate impurities. The pH of the solution was quickly 
adjusted to 9.1 by addition of 2M aqueous K2CO3 solution and kept stable for 16 minutes. 
KCl (91.0g, 1.2mol) was then added to precipitate the potassium salt of γ-decatungstate. 
Solution was stirred for 10 minutes maintaining the pH at 9.1 by addition K2CO3 solution. 
The solid was filtered, washed with 1M KCl solution and dried under vacuum.  
Yield: 20.0g (7.6mmol, 66%) 
FTIR (KBr, cm-1): 3461 (s, br), 1635 (m), 989 (m), 942 (s), 863 (s), 813 (s), 742 (s), 658 
(m), 532 (w). 
 
-Synthesis of: Na10[Ru4O4(OH)2(H2O)4(γ-SiW10O36)2] (RuPOM, 17)9 
 
In a round bottom flask, K8[γ-SiW10O36]·12H2O (1.0g,  0.38mmol) was dissolved in 16ml 
of water, then RuCl3·xH2O (0.153g, 0.74mmol) was added and solution was heated at 
70°C for 1 hour (pH drop to 1.6). After cooling excess of CsCl (4.4g, 25mmol) was added 
to precipitate the cesium salt. Product was recovered by centrifugation and washed three 
time with cold water, then it was dissolved in about 100ml of water to prepare the sodium 
salt after cation exchange by eluting it through a cation exchange resin, charged with Na+. 
Solvent was evaporated under reduced pressure and the black solid was dissolved in 5ml of 
water. Product was purified on a size exclusion column charged with Sephadex-G50® resin 
(10g). Solvent was evaporated and the purified sodium salt was obtained as a black solid. 
Yield: 0.8g (0.28mmol, 74%). 
FTIR (KBr, cm-1): 3434 (s, br), 2923 (w), 2853 (w), 1622 (m), 1044 (w), 999 (w), 950 (s), 
876 (s), 804 (s), 539 (w). 
UV-Vis: ε278: 69601cm-1M-1, ε453: 19116cm-1M-1. 
 
-Synthesis of capsules 
Calcium carbonate (CaCO3) porous microparticles with size distribution around 2-3 µm 
were obtained by mixing in a glass vial (6 mL) equal volumes (3.075ml) of aqueous 
solutions of CaCl2 (0.33 M) and Na2CO3 (0.33 M) with 3.85ml of AM-dextran solution 
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conjugated to rhodamine (dextran-RITC) or fluorescein (dextran-FTIC) (fluorophore 
concentration ~50 µM). The solution was left stirring for 30 s. Subsequently, the 
precipitate was separated from the supernatant by centrifugation (4500 rpm for 5 s) and 
washed three times with 1 mL of MilliQ water to remove unreacted species.  
Particles were resuspended in 5 ml of 0.5 M NaCl solution containing the polyanion PSS 
(p-DexS) (2 mg/ml, pH = 6.5). The dispersion was initially left for 2 min in a sonication 
bath and was subsequently continuously shaken for 10 min to avoid precipitation and 
aggregation of the particles on the bottom of the tube. The excess polyanion was removed 
by three centrifugation/washing steps with 1 ml of MilliQ water (4500 rpm for 5 s). 
Subsequently 5 mL of a 0.5 M NaCl solution containing the polycation PAH (p-Arg) (2 mg 
/ml, pH = 6.5) was added to the particles and the dispersion was mixed as described above, 
followed again by three centrifugation/washing steps with 1 ml of MilliQ H2O (4500 rpm 
for 5 s). The particles were then incubated for 10 minutes in 5 ml of RuPOM solution 
(H2O, pH = 5.0, 2 mg/ml, 0.35 mM). The unbound molecules were removed by three 
centrifugation/washing steps with 1 mL of MilliQ water (4500 rpm for 5 s). As expected, 
the colour of the pellet changed to brown. Some other bi-layers of polymers were then 
adsorbed to complete the multilayer walls. 
The CaCO3 compartments were finally removed by complexation with EDTA buffer. To 
this aim coated CaCO3 particles were shaken for 2 minutes with 5 ml of EDTA solution 
(0.2 M, pH = 7.0) followed by gentle centrifugation at 1200 rpm for 10 minutes in order to 
settle down the template-free capsules. After that, the supernatant was removed and the 
capsules were washed three times with 1ml MilliQ water by intermediate centrifugation 
steps at 1200 rpm for 8 min. 
Finally, the capsules were stored as suspension in 500 µL of MilliQ water at 4 °C. The 
capsule number per volume was determined by direct counting by a haemocytometer under 
a microscope. A drop of a diluted solution of capsules was added onto the chamber and the 
number of capsules in the volume defined by the haemocytometer was counted by using a 
20X objective in phase contrast channel.  
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6.4 Catalytic measurements 
 
-Hydrogen peroxide dismutation 
In a typical experiment 12ml (or 6ml) of buffer solution (phosphate, borate, Tris, Mops, 
Hepes, pure water or organic solvent) were placed in a thermostated reaction vessel. 
Mother commercially available H2O2 solution (30%) was added to reach 33mM 
concentration (for Michaelis-Menten analysis, different H2O2 concentrations were used). 
After 2 minutes of signal stabilization (not shown into kinetic traces), mother solution of 
catalyst was added through a septum to reach a final concentration of usually 15µM or 
60µM. The head-space of the reactor for mole of oxygen calculation was 14,6ml (or 
20,6ml). Ideal gas law was used to calculate the mole of oxygen produced at 25°C.  
 
-SOD-test 
SOD-like activity of complexes was measured by inhibition of superoxide-dependent 
reduction of NBT (or cytochrome c) on a Cary 50 UV-Vis spectrophotometer. The 
superoxide radical anions, generated enzymatically by the xanthine/xanthine oxidase 
system, in phosphate buffer at pH 7.8, were detected at 550 nm measuring the reduction of 
NBT to blue formazan. Reaction mixture contained 50µM xanthine, 100µM NBT, 50 mM 
phosphate buffer and xanthine oxidase 0,0053 U/ml. 
In the presence of a SOD mimic, the absorbance values of the blue formazan decrease with 
increasing concentration of complex, this is because the SOD mimic will compete with the 
NBT to scavenge the O2‾•, this then allows the SOD activity of the complex to be 
calculated. The indirect method assumes that there are no side reactions occurring and that 
only the catalytic superoxide dismutase reaction is taking place.10 Mother catalyst solutions 
were prepared 2-0.2mM in water (or DMSO, not acetonitrile) and addiction of 10, 20, 30 
µL of prepared solution were done. Conditions were optimized to be close to IC50. Change 
in absorbance slope compared to the X/XO solution were determined in order to calculate 
the parameters. From IC50 value it is possible to calculate kinetic constant of the catalyst 
for superoxide elimination (kMcCF = kindicator[Indicator]/IC50). 
The calculated rates are more appropriate for a comparison of results with literature values, 
as IC50 values will be smaller where a lower [NBT] has been used and the calculated rate is 
independent of both the nature and concentration of detector used. 
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-Aggregation of Aβ40-42 
Amyloid peptide was dissolved in 1,1,13,3,3-Hexafluoro-2-propanol (HFIP) at a 
concentration of 1mg/ml and stirred 2 hours at 4°C. Solvent was evaporated with a gentle 
stream of N2 and the peptide was re-dissolved in 10mM phosphate buffer a t pH 7.4. Stock 
solution was divided in Eppendorf tube at concentration of 100µM, with or without 
RuPOM for CD and TEM measurement, and incubated at 37°C, for fixed time intervals.  
 
-1H-NMR of Aβ28 
Amyloid 1-28 were dissolved in phosphate buffer solution (10 mM, pH 7.4, H2O with 10% 
D2O) at 200 µM concentration. NMR spectra were recorded before and after addition of  
0.2-0.4 equivalents of RuPOM (stock solution 0.005 M in the same buffer.  
 
-Amyloid Fluorescence 
Quenching of tyrosine emission was followed at 305 nm, with excitation at 270nm and 
5nm slit.   
 
 
 
6.5 Biological tests 
 
-Mitochondria preparation 
Fresh livers (1-3) from CD1 mice, grown in the biological department of University of 
Padova, have been extracted thanks to collaboration of Dr. Mauro Ghidotti. 
Organs were put into a buffer solution (RLM: 250mM sucrose, 10mM Tris, 0.1mM EGTA, 
pH 7.4) and cut in small pieces, than homogenized. The homogenized was centrifuged at 
700g for 4 minutes at 4°C. Supernatant was recovered and centrifuged at 7000g for 10 
minutes, in order to separate mitochondria. Supernatant was eliminated and mitochondria 
pellet was washed with buffer solution, then was centrifuged again at 10000g for 5 
minutes. After the elimination of supernatant, mitochondria were dispersed in few µl of 
buffer solution. Quantification of mitochondria concentration was assessed with Biuret 
method (20µl mitochondria in 1.5 ml biuret, 1ml H2O MilliQ and 500µl of 1% 
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deoxycholate solution (DOC); after heating of 2 minutes at 80°C, absorbance at 540nm is 
registered).† Mitochondria are to be used in the day. 
 
-Mitochondrial respiration measurement 
Mitochondrial respiration was measured using a Clark-type electrode in the group of Prof. 
Paolo Bernardi, with the supervision Dr. Valeria Petronilli, in the Biology Department of 
University of Padova. Measurement were performed in a 2ml vessel containing the 
following buffer solution: 120mM KCl, MOPS 20mM, EGTA 10µM, Pi 1mM at pH 7.4. 
Before each experiment the following solution were added by a syringe, to reach the 
concentration in the bracket: glutamate/malate (5/2.5mM) or succinate (5mM) and catalyst 
(2.5-100µM). Registration was started and after about 100s, fresh prepared mitochondria 
(1-2mg/ml) were added. ADP solution was added after 200s to reach 100µM 
concentration. When phosphorylation was finished FCCP (50nM) was added, at about 
500s after registration started. Finally at about  650s antimycin A (0.5µM) and inhibitors 
(30mM) were added. Depending on mitochondrial respiration, addition could be done at 
different times. In the case of incubated mitochondria, they were incubated with and 
without RuPOM for 5 and 50 minutes then were injected into the vessel or prepared for 
TEM analysis. TEM samples were centrifuged for 5 minutes at 8000g, mitochondrial pellet 
was re-suspended in sodium cacodilato 0.1M at pH 7.3, with 1% of glutaraldehyde. 
Samples treated were further prepared for TEM by Dr. Caicci, Dr. Boldrin and Dr.ssa 
Moschin of Biology department of University of Padova. 
 
-Calcium Retention Capacity (CRC) measurement 
Mitochondria were incubated in a buffered medium (120mM KCl, 20mM Mops, 20µM 
EGTA, 1mM Pi, 5mM/2.5mM glutamate/malate, pH 7.4) at a concentration of 0.5mg/ml. 
Catalysts (RuPOM or [Mn2L2]) at different concentration were added before measurement 
was started. Calcium Green-5N (CaG, Molecular Probes: λex:505nm, λem:535nm) was also 
added before starting at a concentration of 1µM. CaG is impermeable to the membrane and 
becomes fluorescent when complexes Ca2+ ions (with a KD of 14µM). So it allows to 
monitor extra-mitochondrial calcium and follow release or accumulation of Ca2+. 
                                                          
† Biuret test allows to calculate mitochondria concentration, it is a mixture of strong base (usually NaOH),  
  copper sulfate (CuSO4·6H2O) and sodium tartrate. In the presence of proteins, Cu2+ is reduced to Cu+ with  
  an increase of absorbance at 540nm, that is proportional to mitochondrial concentration, obtained by a  
  calibration curves with bovine serum albumin (BSA). 
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Fluorescence was measured by a Perkin-Elmer LS50B instrument at controlled 
temperature of 25°C and under magnetic stirring. Calcium chloride 2.5µM (mother 
solution 1mM) was added every minute until pore opening. 
 
-Cell viability 
The cell viability was measured by using the quantitative colorimetric MTT assay, 
showing the mitochondrial activity of living cells. Cells were incubated at 37°C under 5% 
CO2 humidified air incubator for 72 h. After the first day of culture, the SH-SY5Y cells 
were treated with various concentrations (0–80µM) of POM. After treatment the medium 
was removed and 400µl of medium, containing 40µl of MTT solution (5 mg·ml-1 in PBS), 
were added to each well and the cells were incubated at 37 °C. After 2 h of incubation at 
37 °C, the reaction was stopped by adding 400µl of lysis buffer (10% SDS, 0.6% acetic 
acid in DMSO, pH 4.7). The quantity of formazan product was directly proportional to the 
number of metabolically active living cells. The optical density of each well was 
spectrophotometrically measured at 570nm. Results were expressed as the percentage of 
the control without treatment. 
 
-Apoptosis detection 
The apoptosis of cells was investigated by Annexin V-Apoptosis detection kit (Santa Cruz 
Biotechnology) and by investigating the expression of Caspase-3 by using Laser Scanning 
Confocal Microscope (LSCM). Normal viable cells in culture are negative for Annexin V-
FITC and negative for PI. Cells that are induced to undergo apoptosis are positive for 
Annexin V FITC and negative for PI. Both cells in the later stages of apoptosis and 
necrotic cells are positive for Annexin V-FITC and PI. Controls and treated samples 
treated were rinsed and washed once with 500µl of 1× Assay Buffer per well. Following 
100µl of Assay Buffer was added to each well, containing 1µg of Annexin V-FITC and 
10µl of propidium iodide. After the incubation of cells for 15 min at room temperature in 
the dark, the fluorescence intensity of Annexin V-FITC and of propidium iodide was 
evaluated with LSCM. Data were analyzed and expressed as a percentage of the control. 
For the analysis of active N-terminal c-Jun protein kinase (p-JNK) and caspase-3 
expression neuronal cells were rinsed with PBS, fixed for 15 min with paraformaldehyde 
(4%), permeabilized for 10 min with 0.25% Triton X-100 and subsequently blocked for 30 
min with 1% BSA at room temperature. p-JNK expression was detected using anti-mouse 
monoclonal p-JNK antibody (1:250; Santa Cruz Biotechnology, CA) over night at 4 °C 
Experimental Part 
154 
 
and anti-mouse IgG Cy3-conjugated (1:400; Jackson Immunoresearch) for 60 min at room 
temperature. Caspase-3 expression was detected using rabbit anti-caspase-3 antibody 
(1:250; BD, Milan, Italy) over night at 4 °C and goat anti-rabbit IgG FITC conjugated 
(1:100; Invitrogen) for 60 min at room temperature. Nucleic acids were counterstained 
with DAPI30 (200ng/ml; Sigma, Milan Italy). Images were taken by using LSCM. 
Mitochondrial membrane potential (MMP) in cells was measured using a fluorescent 
probe, JC-1 (5,5′,6,6′-tetrachloro- 1,1′,3,3′-tetraethylbenzimidazolyl-carbocyanine iodide). 
Controls and cells treated with Aβ alone or a mixture of Aβ and POM at different 
concentrations were incubated with JC-1 staining solution (5 g/ml) for 20 min at 37 °C. 
The fluorescence intensity of both mitochondrial JC-1 monomers (λex:514 nm, λem:529 nm) 
and aggregates (λex:585 nm, λem:590 nm) were detected by using LSCM. The MMP of 
cells, for each treatment, was calculated as the fluorescence ratio of red to green. 
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Natural aminoacids: name, three letter and one letter symbols  
Name Symbol One-Letter Name Symbol One-Letter 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic Acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamine Gln Q Serine Ser S 
Glutamic Acid Glu E Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine Ile I Valine Val V 
 
 
FTIR, NMR and UV-Vis spectra. 
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-2-({[Di(2-pyridyl)methyl]amino}methyl)phenol 
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-Rhodamine B Piperazine Amide 
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-Rhodamine B 4-(3carboxypropionyl)piperazine Amide 
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-Rhodamine B trans-1,4-diaminocyclohexane Amide  
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-Rhodamine B trans-1,4-diaminocyclohexane Amide-4-carboxybenzyl 
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-(4-carboxybutyl)triphenylphosphonium bromide 
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-Compound 1-3 
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